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ABSTRACT 
Conducted within the hospice setting, this unique study assessed the prevalence of altered 
taste perception and its potential relationship with nutritional status in a group of 56 
advanced cancer patients who had not received any recent radiotherapy or chemotherapy, 
compared to 46 age matched healthy controls. An assessment was made of the impact of 
altered taste perception on quality of life in this group of cancer patients. Taste perception 
was objectively measured using the International standard for sensory appraisal (lSOI991) 
and nutritional status assessed using upper arm anthropometry, bioelectrical impedance 
analysis, weight and hand grip dynanometry. A 3-day weighed intake technique was used 
to estimate dietary intake, and quality of life assessment was based on the Hospital Anxiety 
and Depression scale (Zigmund and Snaith, 1983). Results indicate that cancer patients 
exhibited lower 'bitter' thresholds (increase bitter taste sensitivity) compared to age 
matched controls an effect which was not related to tumour type. Results of this study also 
highlight the impact that changes in taste perception have on quality of life, which is 
pivotal in the appropriate management of altered taste perception in palliative care. 
',-
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Heightened olfactory perception was also evident in cancer patients exhibiting heightened 
gustatory perception. Biochemical analysis suggests that Tumour Necrosis Factor a and 
associated acute phase response may be associated with increased bitter taste sensitivity. 
Within the cancer group, heightened bitter perception was associated with a reduced 
protein intake. These results have demonstrated that in a terminally ill group, dietary 
management should focus on altered taste perception, aiming to maximise quality of life. 
Based on these results, a 4-week intervention was undertaken using omega 3 fatty acid 
(fish oil capsules) in a subsequent group of advanced cancer patients, aimed at 
manipulating the acute phase response and lNFa production. This demonstrated no 
changes in taste perception. However, the intervention was ~~sociated with attenuation 'of 
i 
weight loss and an alteration in fatty acid composition of lipid membrane. These 
preliminary results suggest the value of further studies to investigate the effects of omega 3 
fatty acids on taste perception and other associated symptoms in cancer patients. Moreover, 
the challenges to recruitment and retention of patient in studies in the terminally ill are 
highlighted. 
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1.1 Introduction 
In recent years the management of patients with advanced cancer has seen a shift from care in 
the acute setting to the hospice where quality of life (QOL) is of prime concern (Cohen and 
Mount, 1992). Palliative care focuses on the management of disease associated symptoms, 
aiming to maximise QOL of patients (Bruera, 1992). To achieve this aim, nutritional support is 
an important component of the multidisciplinary approach used in the palliative management 
of malignant disease (Bruera and Fainsinger in Doyle et ai, 1993). 
Conducting research in a dying population is an activity, which in itself has the potential to 
impinge on the QOL of patients. Indeed, several researchers are of the opinion that patients 
with advanced disease, should share remaining time with family and/or friends without the 
intrusion of new treatment modalities (Scanlon and Fleming, 1989). A balance between 
research objectives and medical challenges in this clinical setting is required. In addition, 
there is the QOL of researchers working in an emotionally stressful environment that may also 
require support. 
In recent years, the majority of clinical research conducted in hospices have been retrospective 
in nature and are limited due to ethical considerations and difficulties in recruiting patients 
who are terminally ill. However, without prospective studies being performed, advances in 
care in improving QOL can not be assessed following intervention. A limited number of 
prospective longitudinal studies have been performed in palliative care and as a result there is 
limited information regarding possible recruitment and retention difficulties encountered in 
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these studies for example, a patient's condition may deteriorate or change and new symptoms 
may present within a short period. This in tum may necessitate alterations in treatment 
regimens that may exclude patients from participating in a study (McQuay and Moore, 1994). 
Despite these difficulties, it is important to acknowledge that research in this area can add a 
positive dimension to palliative care, for example, patients may gain comfort from the 
knowledge that others in the future may benefit from research studies (MacDonald, 1995). 
Palliative care involves the management of symptoms of advanced cancer such as cachexia, 
which is present in the majority of end-stage cancer patients. However, many research trials 
have failed in reversing cachexia weight loss mainly due to the lack of effective treatment 
strategies. However, the complex mechanisms of weight loss in cancer may explain why there 
are such difficulties in dietary intervention programmes. Symptoms of the cachexia syndrome 
include altered chemosensory function, altered food preferences and associated with altered 
metabolism (DeWys 1974; Shaw 1992). 
The identification of factors that contribute to nutritional related symptoms are clearly 
important because of the negative impact that the resulting anorexia and malnutrition have on 
QOL and social interaction (Tchekmedyian et aI, 1990). In patients with advanced cancer, 
who may already be nutritionally compromised by the presence of disease, an alteration in 
food intake may disproportionately affect QOL. Malnutrition and associated apathy and 
depression have been associated with a negative effect on appetite (Tait and Aisner, 1989). 
However, alteration in taste perception has received little attention regarding its impact on 
QOL and on the nutritional status of patients with advanced cancer. The effect of altered taste 
2 
perception on food intake and acceptance may impinge on the involvement in food related 
activities in a social context and this has not been fully investigated. 
The following chapter will introduce taste perception and other symptoms associated with 
cachexia in patients with advanced cancer. Focusing on the causes of altered taste perception, 
the following sections examine the prevalence and causes of this symptom in a group of cancer 
patients receiving palliative care. Whilst patient may associate this with chemotherapy, there 
is evidence to suggest that alterations in taste perception occur in patients not receiving or who 
have never received any active treatment (Grosvenor t!t ai, 1984). The exact mechanisms of 
altered taste perception in patients not receiving any treatment are unknown. Particular 
emphasis is given to the impact of this symptom on QOL and the nutritional status of patients 
with advanced cancer. 
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1.2 Cancer cachexia syndrome 
In response to injury or trauma, a physiological protective mechanism response is triggered. 
Initially this local inflammatory response encompasses compensatory mechanisms such as the 
production of cytokines. In small quantities, cytokines serve to promote would healing but 
chronic production of cytokines, such as in malignancy, results in an imbalance of homeostasis 
(Grimble 1996, Noguchi et ai, 1996). With growing tumours, cytokines have systemic effects 
on host organs and may directly exacerbate cachexia (Cederholm et ai, 1997). 
Cachexia, derived from the Greek Kakos (bad) and Hexis (body habitus) is a common 
manifestation of neoplastic disease, characterised by a number of metabolic abnormalities, 
resulting in overt changes in body composition (Mercandante, 1996). Clinical manifestations 
of cachexia may be divided into two categories: 1) physical symptoms that include lean and fat 
tissue atrophy, anorexia, and lethargy, and 2) biochemical alterations such as anaemia, hypo-
albuminaemia and glucose intolerance (Kern and Norton, 1988). The production of cytokines, 
mediators of the inflammatory response to neoplastic disease, has been implicated in the 
metabolic alterations associated with cachexia. This suggests that circulating cytokines 
produced in response to a tumour may cause a significant component of the weight loss. A 
closer insight into the pathophysiology of cancer weight loss and associated symptoms may 
therefore enhance the efficacy of specific treatments and may have a positive impact on QOL 
as well as other clinical outcomes. 
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1.2.1 Symptoms associated with cachexia 
A loss of appetite is particularly apparent in malignant disease (OeWys, 1978; Cohn et aI, 
1981). The presence of pain, lack of sense of well-being, anxiety, and hospitalisation can all 
predispose to anorexia (Padilla, 1986). This is clearly illustrated in a study by Feuz and Rapin 
(1994) who noted that in over one hundred elderly patients with advanced cancer, dietary 
intake increased following successful pain control. The presence of anorexia is clearly 
illustrated in a study by Giacosa and colleagues (1996) who examined the dietary intake of 281 
patients with cancer using food diaries completed for three days. Mean energy intake of this 
group was 1207 ± 372s.d. kcaVday (17 ± 6s.d.% protein, 38 ± 19s.d % carbohydrate and 
38+16s.d % fat). Patients who were weight losing had a lower energy intake than weight 
stable patients. 
In a study by Grosvenor and colleagues in 1989, when energy intake was expressed in relation 
to body weight, no differences were noted between the weight losing patients (n 170, 31.4 ± 
1.5 sem kcal/kg weightlday) compared to the weight stable patients (n 84, 30.5 ± 2.2 sem kcal 
/ kg weight / day). Conversely, when energy intake was expressed relative to pre-illness body 
weight, weight losing patients consumed less energy (28.9 ± 1.2 sem kcaV kg pre-illness 
weightl day) than their weight stable counterparts (33.5 + 2.2 sem kcal/ kg pre-illness weightl 
day). Whilst this illustrates the presence of anorexia in weight losing cancer patients, the 
mechanism responsible for this component of cachexia in cancer patients remains poorly 
understood. 
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Many symptoms associated with advanced cancer and its palliative treatment contribute to a 
reduction in appetite (Trant et at, 1982; deConno et at, 1989, Mercandante, 1996). Grosvenor 
and colleagues (1989), examined symptoms associated with anorexia in 254 patients with a 
variety of unresectable tumours (n=93, colon n=50, prostate n=23, oropharyngeal n=18, breast 
n=15, gastrointestinal n=13 and others n=42) which included 39 patients who had received no 
previous chemotherapy or radiotherapy. Symptoms identified by multivariate analysis as 
occurring more frequently in patients with weight loss during their disease included early 
satiety, vomiting, dry mouth and the presence of taste changes. 
1.2.2 Clinical impact of weight loss in cancer 
Weight loss and reduced appetite are often the primary reason for patients seeking medical 
attention before diagnosis. Weight loss is one of the most frequent and serious problems 
confronting clinicians in the management of cancer (Theologides, 1972). Moreover, the size 
of the tumour does not appear to influence the amount of weight loss which suggests that 
circulating factors perhaps influence the overt weight loss (Tisdale, 1991). De Wys and 
colleagues in 1980 found that in a group of patients (28% malignant colorectal cancer and 14% 
breast cancer) had lost more than 5% of their usual body weight in a period of six months prior 
to diagnosis. Whilst these symptoms are troublesome and distressing for patients, clinical 
outcomes may be affected by significant amounts of weight loss (Fearon and Preston, 1990; 
Maltoni, 1995; et aI, 1993). 
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The clinical impact and prognostic effect of severe weight loss have been studied extensively. 
A 40% loss of lean body mass is regarded as incompatible with life and it is estimated that up 
to 40% of all cancer patients die solely from malnutrition associated with the cachexia 
syndrome (Grant, 1990). Weight loss also leads to a loss of muscle mass contributing to 
reduced muscle strength and decreased mobility (Kern and Norton, 1988) which may also have 
psychological impact on QOL. 
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1.3. Mechanisms of cachexia 
1.3.1 Altered metabolism in cancer weight loss 
Although an inadequate energy intake is considered a major factor in contributing to weight 
loss in cachectic patients, the effect of altered energy expenditure undoubtedly plays a role. 
Studies in this area are conflicting, suggesting that cancer patients are either hypermetabolic, 
hypometabolic or have normal energy metabolism (Dempsey et aI, 1983). Variations in energy 
expenditure may in part be due to biological differences as well as differences in the types of 
cancers studied, body composition (accounting for the amount of metabolically active lean 
body mass), stage of the disease and different methodologies used to measure energy 
expenditure. However, the consensus would appear to be that cancer patients have increased 
energy expenditure coupled with an ongoing inflammatory response (Kern and Norton, 1988; 
Keller, 1993a). 
Staal-van den Brekel and colleagues (1995) noted that hypermetabolism and weight loss 
(>10% pre-illness weight loss) in patients with non-small cell lung cancer were associated 
with a systemic inflammatory response demonstrated by elevated levels of inflammatory 
cytokine mediators (lnterleukin-l~, Tumour Necrosis Factor a. and Interleukin-6) and acute 
phase proteins such as C-Reactive Protein. Over 25 years ago, Theologides (1972) suggested 
that increased energy expenditure may be due to the growth of malignant tissue imposing 
greater energy expenditure than normal tissue. However, it is generally thought that the 
amount of tumour tissue present may be too small to account for the increased oxygen 
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consumption observed and that other factors are therefore involved (Kern and Norton, 1988). 
Weight loss in cachexia differs from that of weight loss due to simple starvation. In the latter, 
there is relative sparing of lean tissue with preferential use of endogenous fat stores. In 
prolonged starvation, glycogen stores become depleted at about 36-72 hours following 
cessation of eating and the brain adapts to using ketone bodies, products of fatty acid 
breakdown, to supply glucose as an energy source. In response to the production of acute 
phase reactants associated with the cancer state, there is an accelerated mobilisation of host 
protein stores (Espat et ai, 1994). Following nutrient deprivation in cancer, stores of glycogen 
and fat are broken down by glycolysis and lipolysis respectively to produce life-threatening 
skeletal muscle depletion (Lundholm et ai, 1976). The full extent of weight loss may often go 
unrecognised due to an expansion of the extra-cellular water space (Heber and Tchemedyian, 
1992) which masks any visual reduction in weight. 
In cancer cachexia, derangements of metabolic pathways lead to abnormalities of host 
carbohydrate, protein and fat metabolism, despite adequate nutritional intake (Keller, 1993a). 
One reason why increased carbohydrate metabolism is a significant contributor to the 
redistribution and depletion of body protein muscle stores is the energy drain on the host due 
to increased hepatic gluconeogenesis (Kern and Norton, 1988). As previously described, 
cancer patients appear to exhibit an increased rate of proteolysis, a reduced ability to oxidise 
exogenous glucose, and an increased rate of lactate production. Lactate production, 
anaerobically oxidised is a more expensive energy producing cycle. Increased glucose and 
glycerol turnover rate could in part account for the increased oxygen consumption and energy 
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expenditure associated with weight loss in cancer cachexia. In addition, the tumour may have 
an effect on glucose metabolism in the liver (Burt et ai, 1983). There also appears to be a 
maladaptive response resulting in fat mobilisation rather than fat storage. Alterations in fat 
metabolism, resulting in hyperlipidaemia and fat tissue loss may occur due to a defect in the 
enzyme activity of lipoprotein lipase, responsible for the clearance of lipids from blood. 
Weight losing cancer patients have demonstrated increased rates of glycerol and free fatty acid 
turnover compared with patients not exhibiting weight loss (Shaw, 1987). 
1.3.2 Mediators of cachexia 
Studies have focused on the identification of mediators that may be implicated in the tissue 
wasting of advanced cancer patients. A strategy to reverse or minimise the effects of such 
mediators may permit successful treatment modalities to improve symptom control and 
maximise QOL. 
As part of the inflammatory response to the presence of a tumour growth, the host produces 
small molecular weight proteins called cytokines (Cooper et ai, 1993), exhibiting a range of 
biological activities (Goh, 1990). Disease-induced changes in cytokine production result in 
several metabolic changes in cancer patients that can adversely affect nutritional status. 
Advances in molecular biology research in cancer indicate that cachexia weight loss may result 
from excess production of cytokines (Moldawer et ai, 1992; Cangiano et ai, 1996). 
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Cytokines are aptly described as mediators of defence and mediators of disease (Meydani and 
Dinarello, 1993). In defence, cytokines play an important role in normal T-cell response, 
tumour killing, non-specific resistance and anti-inflammatory processes. Changes designed to 
destroy the pathogen are characterised by fever, proteolysis in peripheral tissue and 
enhancement of the activity of the immune system (McNamara et ai, 1992). In inflammation, 
cytokines significantly alter the metabolic processes of the liver, which responds by producing 
acute phase proteins, such as C-Reactive Protein (CRP; Banks et ai, 1995). Cytokines act by 
mobilising nutrients from peripheral sites to provide nutrients for the synthesis of acute phase 
proteins (Kern and Norton, 1988) which are produced in preference to other plasma transport 
proteins such as albumin and transferrin (Falconer et ai, 1995). When produced in large 
numbers, cytokines spill over into the circulation and act systemically. Persistent secretion 
results in depletion of host muscle mass and mobilisation of peripheral tissue, contributing to 
cachexia weight loss (Heber et ai, 1992; Fong et ai, 1989). 
The effects of pro-inflammatory cytokines interleukin-l~ (IL-l~), interleukin 6 (IL-6) and 
Tumour Necrosis Factor ex (TNFex) in particular play important roles in the metabolic changes 
observed in cachexia (Kern and Norton, 1988, Moldawer et ai, 1992). Following tissue 
damage, cytokines initiate a cascade of effects, which include an acute phase response, and the 
activation of inflammatory cells through secondary release of haemopoietic growth factors. 
The cascade illustrates a network of interactions whereby macrophages signal fibroblasts as 
well as immunocompetent T and B cells. Cytokines induce an acute phase response in the 
liver, which results in an alteration in hepatic protein synthesis and alteration in plasma protein 
composition. 
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Acute phase protein response 
The presence of an acute phase protein response has been demonstrated as the most significant 
independent predictor of survival in patients with unresectable pancreatic cancer (Falconer et 
ai, 1995). This group found that the mean survival of patients with an acute phase response 
(CRP>lOmgIL) was reduced (66 days) when compared to patients not mounting this response 
(222 days). McMillan and colleagues in 1995 noted a higher recurrence of metastatic disease 
in colorectal cancer patients with an acute phase response (11 out of 15 patients) compared to 
those with no response (2 out of 21 patients). In a study by Gough and colleagues (1996), 
clinical outcomes were studied in a group of 13 patients with metastatic cancer and 7 healthy 
volunteers. These clinical outcomes included the acute phase response, TNFa production, 
phytohaemaglutin response and survival status. The acute phase response, measured by an 
elevated CRP, correlated with survival (r=O.69, p<O.05) and albumin (r=O.65, p<O.05) only. 
TNFa did however, correlate with impaired lymphocyte function in patients (r=O.56, p<O.05) 
which suggested that impaired lymphocyte function may influence TNFa production and 
metabolic disturbances in cancer cachexia. 
Based on in vitro studies, Banks and colleagues (1995) demonstrated that IL-1B, IL-6 and 
TNFa are key mediators of the acute phase response. In animals treated with ll....-6, the fastest 
response was observed for the acute phase proteins, CRP and amyloid A. ll....-6 induced 
changes in the majority of the acute phase proteins in vivo but, as the authors suggest, TNFa 
and IL-l ~ (which were not measured) may have also synergistically contributed to the effects 
observed with ll-6. 
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Tumour Necrosis Factor a 
TNFa 'cachectin' has been suggested to be the central mediator of the metabolic response to 
the presence of a tumour (McCall et aI, 1991; Gelin et aI, 1991). TNFa stimulates the 
synthesis of acute phase response and induces IL-l ~ release from endothelial cells and 
macrophages. The net effect of TNFa appears to encourage mobilisation of peripheral energy 
substrates required by the liver to meet the increasing demands of an activated host defence 
system (Tracey et aI, 1989). The association between increased TNFa production and weight 
loss has been clearly demonstrated in a study of breast cancer patients (Knapp et aI, 1991). 
Animal studies have demonstrated that TNFa production induces cachectic symptoms such as 
anorexia, weight loss, anaemia and depletion of whole-body proteins and lipids (Mahony and 
Tisdale, 1989). In one study, Llovera et al (1994) demonstrated that 4 days after the chronic 
administration of TNFa, increased circulating levels of urea concentrations and elevated 
urinary levels of 3-methylhistidine, an indicator of muscle protein catabolism were noted. 
Production of Prostaglandin PGE2 was enhanced in response to chronic administration of 
TNFa, which suggested that the anorectic effect of TNFa may be mediated by a prostaglandin 
intermediate. Weight loss and reduced food intake appeared to be cytokine-dose related and 
occurred within the first 24 hours. 
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Interleukin - 1 f3 
Interleukin l~ (IL-l~), the predominant form of interleukin 1 series, is an important mediator 
of local and systemic responses in inflammation. In particular, IL-1 ~ plays a role in mediating 
the production of acute phase proteins perhaps as a result of the inability of IL-1 ~ to induce 
prostaglandin synthesis. The rate limiting step in prostaglandin synthesis is the release of fatty 
acids from membrane phospholipids, some of which undergo lipohydrogenation, which alters 
immune cell function (Dinerallo et aI, 1990). 
In a study by Opara and colleagues (1995), the amount of IL-1 ~ in cerebral spinal fluid 
collected in anorectic tumour-bearing rats and healthy controls was measured. Daily dietary 
intake was significantly lower in tumour-bearing animals as compared to controls 
(7.1±1.1g/day vs 12.0 ± 1.1g/day, p<0.005). Moreover, lower dietary intakes were coupled 
with an increased amounts of IL-1 ~ detected in cerebral spinal fluid. IL-l ~ was detected in 8 
out of 13 of the tumour-bearing animals compared to none of the healthy animals. Further 
animal work by this research group has shown that anorexia may be caused by an indirect 
increase in ILl ~ production stimulated by hypothalamic serotonin activity. The ventromedial 
hypothalamus (VMH) appears to be the central site for the depressive effects on food intake of 
IL1~. Subdiaphragmatic vagotomy attenuated the reduction in food-motivated behaviour of 
animals induced by IL-l ~ (Watkins et aI, 1995) which indicated that a peripheral neural signal 
may also be involved in the action of IL-1~. Several other animal studies have examined the 
effects of IL-1 ~ to explore the exact mechanism of action of this cytokine. Laviano and 
colleagues (1995) suggested that cancer anorexia in an animal model involves the direct action 
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of ll...-IP on the VMH. The injection of a VMH ll...-IP antagonist correlated with an 
improvement in food intake. Further work by this group demonstrated that, following 
peripherally infused ll...-1 p, food intake was reduced (Debonis et at, 1995). Earlier work in 
humans by Mrosovosky et al (1989) suggested that D-IP lowers a set point for body weight 
and key findings by Yang and Meguid (1995) suggest that D-Ip induces anorexia centrally. 
Furthermore, in a study by Gelm and Klundholm (1992) blockade of prostaglandin 2 activity, 
a mediator of cytokine activity, resulted in attenuation of anorexia in rats. The role of ll...-l p in 
the alteration of neural signalling may have important implications in taste sensation that is 
controlled by similar signalling messages. 
Other cytokines mediating changes in nutrient metabolism 
Interleukin 1 cytokines are mediators in a broad spectrum of biological activities that includes 
the inflammatory response. Ling and colleagues (1996) demonstrated that acute and 
continuous infusion of ll...-la for 6 days to rats, resulted in reduced food intake and weight 
loss. This was coupled with an increased production of the acute phase response, loss of 
muscle protein and reduced circulating plasma zinc levels. D-la exerts a variety of 
physiological effects either alone or in combination with TNFa and ll...-6. Oldenburg et at 
(1993) observed an association between ll...-la receptor blockade and a reduced plasma ll...-6 
response, suggesting that the benefits achieved by ll...-1 a blockade are mediated by reduced 
systemic ll...6 production. 
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To summarise, the cytokines, TNFa, ll-l ~ and IL-6 appear to have a role in altering metabolic 
processes in cancer patients. More recent research demonstrated that the effects of the pro-
inflammatory cytokines, often in combination, are mediated via the production of acute phase 
proteins and indirectly through modulation of neuronal activity. Due to the known metabolic 
and nutritional derangements that occur in the host mediated by TNFa, IL-l ~ and IL-6, this 
study concentrates on these cytokines. 
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1.4 Nutritional management of cachexia syndrome 
1.4.1 Use of novel substrates to manipulate cachexia 
To minimise anorexia, the development of strategies that concentrate on correcting metabolic 
derangements, which may prevent effective utilisation of nutrients, is of prime importance. 
Our understanding of the effects of malnutrition on host immune defences is well known and 
provides the basis of the treatment of cancer. However, nutrition is only one of the many 
factors that modulate host defence mechanisms. The benefits of traditional aggressive 
nutritional support in providing adequate energy to meet anabolic demands have proved futile 
(Chlebowski et at, 1996). The focus of current research is the role of specific nutrients as 
regulators of the anticancer host defence mechanism and the control of nitrogen metabolism 
and tumour growth (Heys et aI, 1996). 
The amino acids arginine and glutamine, used as metabolic fuels in times of stress, have in 
particular received much attention. Diets supplemented with these amino acid have been 
shown to reduce post-operative morbidity in patients with cancer and to reduce bacterial 
translocation and improve nitrogen retention. Important effects on host defence such as 
increasing phagocytic activity in macrophages have been noted in patients supplemented with 
both amino acids (Barbul, 1986; Kirk and Barbul, 1990). In one particular study (Daly et aI, 
1992), patients with gastrointestinal cancer prior to surgery were randomised to either receive 
glutamine supplemented feed via jejunostomy or a standard jejunostomy feed. The 
supplemented feed provided more nitrogen (15.6g1day vs 9.0glday) and these recipients were 
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less in negative nitrogen balance (-2.2g1day vs -6.6g1day, p<0.05). Although the results are 
limited due to small number of patients, the supplemented diet group had significantly lower 
rates of pneumonia and wound complications. Animal studies appear to confirm this thought 
as oral glutamine supplementation may reduce tumour growth by enhancing natural killer cell 
activity (Fahr et ai, 1994). 
1.4.2. Fatty acid manipulation of cytokine action 
In more recent years, the use of the 0)-3 (omega 3) fatty acids has received much interest in 
nutritional support. Marine oils are a rich source of the fatty acids, eicosapentaenoic acid 
(EPA, 20:5 0)-3) and docosahexaenoic acid (DHA, 22:6 0)-3). High intakes of these 
polyunsaturated acids appear to have pharmacological properties including inhibition of anti-
inflammatory, anti-thrombotic effects and altered lipoprotein metabolism. The incidence of 
many inflammatory diseases including coronary heart disease and psoriasis are lower in 
Eskimos who ingest diets rich in n-3 fatty acids compared with healthy European controls 
(Sanders, 1993). In relation to the anti-inflammatory effects of n-3 fatty acids, EPA has been 
implicated in the amelioration of the acute phase response. Few studies have investigated the 
effect of fatty acid supplementation on the acute phase response in vivo. Cooper and 
colleagues (1993) investigated the effects of diets of healthy 18-36 year old male and females 
supplemented with 4.5g fish oil daily for 6-8 weeks (1.15g EPA and 1.56g DHA / day). 
Following 6-8 weeks, fish oil supplementation was associated with a reduction of in vitro 
production of pro-inflammatory cytokines. 
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Previous work by Endres and colleagues (1989) measured in vitro stimulation of peripheral 
blood mononuclear cells following the addition of endotoxin as a stimulus for cytokine 
production. In healthy subjects who had supplemented their diet with 18g fish oil daily for 6 
weeks, cytokine synthesis (IL1~, ILIa. and TNFa.) was suppressed (p<O.05). Moreover, a 
62% cytokine reduction was noted 10 weeks after ingestion. More recently, Tisdale (1996) in 
experimental animal models demonstrated the effects of diets supplemented with fish oil. 
Most strikingly, host weight loss was inhibited by this intervention and occurred without an 
alteration in either total energy or nitrogen intake. EPA was found to directly inhibit tumour-
induced lipolysis and protein degradation of skeletal muscle in cachexia. The authors 
postulated that this may be due to an inhibition of the rise in muscle prostaglandin E2 in 
response to EPA. This study demonstrated the properties of EPA, in altering the mechanism 
of action of tumour-produced catabolic factors. Billar and colleagues in 1988 observed a 
significant decrease in the in vitro ll.r 1 ~ production by Kupffer cells in an animal diet 
containing 15% energy as fish oil for 6 weeks as compared to diets containing 15% energy as 
corn oil. More recently, Kenler and colleagues (1996) examined the outcomes of fish oil 
supplemented jejunal feeding. In a group of post-operative gastrointestinal cancer patients, a 
reduction in gastrointestinal complications and infections were noted in patients receiving an 
omega 3 fatty acid enriched jejunal formula compared to patients receiving an iso-
nitrogeneous jejunal feed. This finding was coupled with a significant incorporation of EPA 
into the plasma and erythroycte phospholipids and modulation of urinary prostaglandin levels. 
Encouraging results from animal studies have paved the way for human studies. For example 
Endres and colleagues (1989) measured IL-l~ and TNFa production by peripheral blood 
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mononuclear cells in diets supplemented with 2.7g EPA and 1.85g DHA daily. IL1~ 
production was significantly reduced after 6 weeks supplementation where stimulated cells 
produced a 42% reduction in ILl~ (4.2 nglml) from pre-supplementation level (7.4 nglml 
ILl~; p<0.005). Ten weeks following supplementation, ILl~ production further decreased by 
60% (2.9ng/ml, p<0.OO5) and returned to pre-supplementation levels 20 weeks after cessation 
of supplementation. Changes in ILIa and TNFa were similar to that demonstrated by n-l~. 
Meydani and colleagues (1991) investigated age differences in the effects of 0>-3 fatty acids. 
Six young women (23-33 years) and 6 older women (51-68 years) were given 2Ag/day 0>-3 
fatty acid for a period of 3 months. Supplementation with 0>-3 fatty acids reduced IL-l ~ 
synthesis two-fold in the younger group and 10 fold in older group (p<0.05). In addition, 
TNFa was reduced by 58% and 70% in the younger and older (p<0.05) groups respectively 
and IL6 was reduced by 30% and 60% in the younger and older groups respectively (p<0.05). 
Reduction of cytokine levels associated with an anti-inflammatory effect, appeared more 
dramatic in the older group compared to younger group. 
In patients with unresectable carcinoma of the pancreas, Wigmore and colleagues (1995) 
demonstrated beneficial effects following daily supplementation of l2g fish oil (18% w/w 
EPA). Weight loss was reversed or halted accompanied by a significant decrease in the acute 
phase response (CRP) in the EPA supplemented group. All patients at baseline were losing 
weight (mean weight loss=2.9kg/month). However, the mean post supplementation weight 
gain of O.3kg was significantly different from baseline measurements (p<0.005). Eleven out 
of eighteen patients had gained weight, whereas three patients remained stable and four 
continued to lose weight but at a reduced rate. There was no difference in upper arm 
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anthropometric measurements and energy expenditure (measured by indirect calorimetry) after 
the supplementation period. Coupled with these weight changes, the concentration of EPA in 
plasma phospholipids increased from the pre-supplementation level to a median of 5.3% of 
total fatty acids following supplementation. This was paralleled with a reduction in 
arachidonic acid from 13.2% of total fatty acid pre-supplementation to 7.1% post 
supplementation. Dose escalation studies using high purity EPA in 22 pancreatic cancer 
patients showed a reduction in the rate of weight loss in the majority of patients (Wigmore et 
aI, 1996). Isolation of EPA indicated that this omega 3 fatty acid was responsible for the 
attenuation of weight loss. Purasir et al (1994) examined the effects of EPA and DHA 
supplementation (4.8g1day) on cytokines IL-l~, ll-6 and TNFa in colorectal cancer patients. 
For the first 2 months, no significant changes in plasma cytokine production were noted. 
However, after 6 months, ILl~ production was reduced by 61%, IL6 by 86% and TNPa by 
73%. Three months following cessation of supplementation (wash-out period), plasma levels 
returned to normal. 
The use of EPA supplementation in weight-losing patients is not unique to malignancy states. 
Diets of weight-losing patients with autoimmune deficiency syndrome (mean weight loss 
during illness 13.7kg) supplemented with 18g fish oil supplements (18% w/w EPA) did not 
result in changes in weight after a 10 week supplementation period (Hellerstein et ai, 1996). 
In addition, no change in dietary intake throughout the supplementation period was noted. 
These patients were already immuno-compromised due to their HN infection and therefore. 
the mechanism in cancer patients may not be the same. 
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Many of these studies have demonstrated that EPA has the potential to down-regulate the 
acute phase response in patients with cancer and that it is likely to involve suppression of the 
cytokines mediating this response. This correction of the pathological mechanism responsible 
for anorexia remains the goal of treatment for cancer anorexia. 
1.4.3. Mechanism of the manipulation of cytokine action by fatty acids 
Fatty acids have important structural roles in cells and also act as precursors for numerous 
bioactive metabolites such as eicosanoids. Eicosanoids such as leukotrienes, prostaglandins 
and thromboxanes have been implicated as contributing to the development of inflammatory 
and atherosclerotic disease. The presence of omega 3 fatty acids leads to a change in the 
profile of prostaglandins and leukotrienes produced during stress and sepsis. Many studies 
have suggested that dietary fats influence eicosanoid and prostaglandin metabolism, following 
incorporation of eicosapentanoic acid (20:5, 0>-3) into membrane phospholipids. 
Prostaglandins appear to modulate the production of cytokines that playa role in the mediation 
of fever and the associated increase in energy expenditure. 
Arachidonic acid is a main component of membrane phospholipids and a precursor in 
mammalian cells in the production of prostaglandin 2 series synthesis via the cyclooxygenase 
pathway (Dinarello et aZ1990). More recently, Caughey and colleagues (1996) investigated the 
mechanism of action involving eicosanoid mediators. Prostaglandin E2 (PGE2) production has 
been shown to be inhibited by fish oils. This process is important as it has been shown that 
one mechanism by which IL-I ~ induces anorexia appears to require cyc100xygenase 
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metabolites, such as PGE2• EPA (20:5 ro-3) also acts as a substrate for eicosanoid production 
and yields prostaglandins of the 3 series, which have lower biological activity which compete 
for binding sites that can reduce the production of arachidonic acid (Willis, 1981; Meuller and 
Talbert, 1988). The supply of fatty acids for eicosanoid synthesis is directly related to fatty 
acid composition of membrane phospholipids and influenced by dietary fat intake (Willis, 
1981). 
Arachidonic acid metabolism is known to mediate the biological activity of IL-l ~ in 
lymphocyte, neutrophils and muscle cells (Hellerstein et aI, 1989). Studies have shown that 
dietary ro-3 fatty acid modify the endogenous eicosanoid synthesis by competitive inhibition 
of arachiodonic ro-6 fatty acid uptake into cell membranes (Meydani and Dinarello, 1993). 
This involves competition with arachidonic acid, a precursor for eicosanoid synthesis, as a 
substrate for the cyclo-oxygenase enzymes. In addition, ro-3 fatty acids may reduce cytokine 
induced expression of endothelial lecuocytes and reduce secretion of mediators of 
inflammation (de Caterina et aI, 1994; Meuller and Talbert, 1988). 
The main effects of EPA include reduced formation of arachidonic acid metabolites of the 
prostaglandin 2 series, modification of the activity of cyclooxygenase and lipooxygenase and 
therefore the nature and the biological activity of the eicosanoids formed by these enzymes. 
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1.5. Outcomes of nutritional management in advanced cancer 
1.5.1 Clinical outcomes of nutritional support 
The use of nutritional support in preventing or controlling the symptoms of cachexia has 
received much attention in recent years. The difficulty in defining efficacy is in identifying 
appropriate outcomes. A study by Daly and colleagues (1986) failed to demonstrate any 
improved outcomes with the use of aggressive nutritional support in patients following general 
surgery. This suggested that despite improving intake, derangements in nutrient metabolism 
persist uncorrected. Nutritional support (both enteral and parenteral) may not always be 
effective in improving the nutritional status of undernourished cancer patients due to 
continuous changes in host metabolism (Laviano and Meguid, 1996). Aggressive nutritional 
support may only in the short term, improve nutritional status, increase tolerance to therapy 
and improve response to non-operative treatment (Detsky et aI, 1987; Torosian and Daly, 
1986). 
Many ethical issues surround the use of nutritional support in patients with advanced cancer 
(Dunlop et aI, 1995 Taylor et aI, 1989). A multi-centered study, involving experienced 
nursing staff examined the concepts involved in the decision to provide aggressive nutritional 
support to patients with advanced terminal cancer (Davidson et aI, 1990). A dilemma in the 
ethical justifications regarding the use of nutritional support in palliative care focused on the 
uncertain benefits of nutritional support in terms of survival and QOL in patients with terminal 
disease. 
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Traditionally, objective indices of the outcomes of cancer treatment and the relief of symptoms 
have focused on tumour response and survival, whereas hospice care focuses on patients QOL. 
The World Health Organisation's definition of QOL is 'a state of complete physical, mental 
and social well-being and not merely the absence of disease and infirmity' . Similarly Twycross 
(1987) eloquently described a good QOL to exist when "the hopes of an individual are 
matched and fulfilled by experience". This subjective parameter may alter over time due to 
perceptions of the impact of the disease and circumstances (Caiman, 1984; Schipper, 1992). 
The benefits of nutritional support for end-stage cancer patients may not be simply improving 
nutritional status but may provide benefits in terms of QOL (Shike, 1996; Ottery, 1995). 
Overt changes in nutritional status which occur within this patient group may have a 
considerable effect on QOL of patients. In a study of over 120 cancer patients by Padilla and 
colleagues in 1983, a good appetite and the physical ability to eat were important factors 
contributing to the patients QOL. In a more recent review of health-related QOL assessment 
tools, Padilla (1992) highlighted symptoms such as the ability to eat, appetite, a concern for 
weight changes and the pleasurable aspect of eating such as taste perception as key dimensions 
of QOL. However, Kaasa (1992) reiterates that the importance of each dimension may differ 
between many individual factors dependent on treatment, age and stage of disease. 
Quality of life assessments are important clinical outcomes of treatments, assessing the 
balance between possible risks, burdens and benefits of any treatment regimens (Gough et aI, 
1983). One such example of clinical research was in the use of an anabolic steroid that has a 
25 
stimulating effect on appetite, megesterol acetate but, no improvement in QOL was observed, 
despite increase in appetite (Chlebowski et ai, 1996). This suggested that objectively 
measured changes of increased appetite did not influence any QOL parameters. Beck and 
Tisdale (1990) demonstrated that megesterol acetate was effective in preventing weight loss 
and improving appetite in patients with a good dietary intake. 
A unique study by Larsson and colleagues (1995) explored the relationship between 
undernutrition and QOL, hypothesising that malnutrition was associated with a lower QOL. In 
almost 200 patients induding those with malignancy, under-nutrition was identified when the 
criteria for 3 or more parameters of undernutrition were met (% recent weight loss, triceps 
skin fold thickness, arm muscle circumference, pre-albumin and albumin). In this study by 
Larsson, an assessment of QOL was made based on a tool developed and tailored for this study 
popUlation. Thirty nine per cent of patients with malignancy identified as under-nourished 
showed significant impairment in many of the domains of QOL studied. In particular, weight 
loss >10% and low pre-albumin were associated with deteriorated well-being. This study has 
important implications for end-stage cancer patients, demonstrating a relationship between 
nutritional status and QOL. 
1.5.2 Nutritional assessment 
Patients with advanced cancer are often elderly, under-nourished with multi-system failure. 
These patients are characterised by a dynamic state in which the nature and intensity of 
symptoms and response to treatment are continuously changing. An assessment of nutritional 
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status may be used to assess the impact of symptoms of cachexia on the nutritional status of 
patients with cancer and subsequently the impact of any nutritional intervention. Shike and 
Brennan (1989) outlined the importance of nutritional assessment supplementing the 
information regarding symptoms obtained in a medical history. The effects of disease 
symptoms on mood, function and other QOL dimensions are essential for studies in the 
palliative care setting (Donnelly and Walsh, 1996). 
Two main components of the nutritional assessment of patients include determining body 
composition and dietary intake. Within clinical research, an accurate objective assessment and 
appropriate interpretation of data is required to detect significant changes in the nutritional 
status of patients. 
Body weight comprises of lean body mass (LBM) consisting of actively-metabolising tissues 
of the body but excluding extra-cellular protein; fat mass (FM), comprising subcutaenous but 
not cellular lipo-protein; and total body water with intra and extra-cellular components 
(Lohman, 1981; Heymsfield et aI, 1989). FM has been demonstrated to account for the 
majority of weight loss seen in cancer patients (Cohn et aI, 1981). However, in an advanced 
stage of malignancy, loss of LBM has also been demonstrated. Body cell mass (BCM) 
represents the total mass of all the cellular elements in the body and therefore the 
metabolically active component of the body (Moore et aI, 1963). It is an index of metabolic 
activity including oxygen consumption, carbon dioxide production, energy and protein 
requirements. Water balance can fluctuate due to an increased production of acute phase 
proteins in preference to albumin, resulting in reduced albumin levels. 
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Although, nutritional assessment provides an objective insight into nutritional status of cancer 
patients, many of the reference tools of assessment have practical and theoretical limitations 
for use in this population (Bistrian, 1986; MacFie and Burkinshaw, 1987). Body composition 
determination relies on accurate observer techniques and the use of appropriate tools within 
particular patient settings. Errors due to this measurement may be propagated in subsequent 
calculations of body composition and contribute to differences in the predictive value of this 
assessment (Fuller et ai, 1991). However, Reilly and colleagues (1993) suggest that the errors 
incurred with each choice of method have little impact when making comparison within a 
group. 
Reference techniques for the assessment of body composition include isotopes, body density, 
total body potassium and dual energy X-ray absorptiometry. However, the use of these 
procedures are often limited due to the time taken to complete the assessment, availability of 
equipment, specialist knowledge for operation and non-portable equipment. Whole body 
density involves weighing the patient when fully submerged in water (Jebb and Elia, 1993) 
and is therefore not a technique suitable for the assessment in immobile subjects or even in 
terminally ill patients. Total body potassium is performed in a whole body counter of which 
only a few centres of research have such equipment. The measurement usually takes more than 
one hour to perform and for practical purposes, as it requires patients to remain still for a 
period of time, is therefore not suitable for terminally ill patients. 
28 
1.5.3. Bedside techniques for measurements of nutritional status in patients with 
advanced cancer 
The assessment of body composition in patients with advanced cancer requires non-invasive, 
bedside techniques. Some of the most commonly used 'bedside' techniques for nutritional 
assessment will now be discussed in relation to their use in the hospice setting and validation 
against the reference techniques. 
Body weight 
Weight assessment is often limited in non-ambulatory patients and in patients with advanced 
cancer where acute fluid balance changes may influence the interpretation of data. Body 
weight may be compared with 'ideal' sex and age specific weight tables (Lehmann et a11991) 
or compared with 'ideal' weight for height tables (Metropolitan Life Insurance Tables). 
However, methods of expressing body weight often fail to consider the importance of pre-
illness weight loss, a useful marker of changes in protein energy status. Weight loss reported 
by patients is a more useful indicator of changes in body composition and hence reflective of 
nutritional status. 
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Body Mass Index 
The measurement of height when used in relation to weight, is a useful indicator of body mass 
index (BMI) widely used in the clinical setting as a frame of reference. BMI (mass in kg 
divided by height in meters squared) is the most commonly used ratio in younger adults. 
However, it is not an appropriate measure in the elderly as it does not take account of age-
associated changes in height or stature. Sex specific indices, demiquet (mass kg I demispan 
m2) and mindex (mass kg I demispan m) have been developed using the assessment of 
demispan. 
Triceps Skin/old Thickness 
Approximately 50% of body fat is located subcutaneously (Lukaski, 1987). Skinfold 
measurements provide an indication of the size of the subcutaneous fat layer and are of great 
clinical use in the estimation of energy reserves. Skinfold thickness measurements can be 
taken at one or more sites (triceps, biceps, subscapular and suprailiac) and the sum used to 
derive total endogenous fat reserves (Durnin and Wormseley, 1974). Two principle 
assumptions are made relating to the use of skinfold thickness: 1) the subcutaneous fat is 
proportional to total body fat and 2) the chosen site is representative of the average skinfold 
thickness across the surface of the whole body (Gurney and Jeliffe, 1973). Due to other fat 
deposits in the body such as inter-muscular, intra-muscular, surrounding the major organs and 
lipids in bone marrow there is considerable chance for biological variation in the relationship 
of measures of subcutaneous fat with total endogenous fat stores (Lohman, 1981). However, 
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in view of the errors and limitations in the assessment of fat mass, there are considerable 
merits in comparing skinfold data against reference percentiles (Norgan, 1991). However, in 
an elderly group with reduced mobility, the use of triceps skinfold thickness (TSF) 
measurement alone may be more appropriate. The triceps site is more accessible and less 
prone to the influence of oedema compared to the other sites. Measurements may then be 
compared with standard age and sex specific reference values, which are based on data from 
an assessment of 1600 healthy elderly subjects (Burr and Philips, 1983). 
The use of TSF as part of nutritional assessment provides a simple, quick, cheap, readily 
available and non-invasive method of estimating the body's fat reserve. In a study by Fuller 
and colleagues in 1992, 28 healthy adults (BMI 20-28 kglm2) were assessed using the 
reference techniques, Dual Energy X-Ray Absorptiometry, deuterium dilution and potassium 
counting and also the bed-side techniques namely skinfold thickness, impedance analysis 
(BIA), BMI and near infra red interactance. TSF was found to be as good a predictor of fat 
mass as the reference techniques in a group of subjects. 
Errors in the measurement of TSF have been acknowledged in previous studies (Hall et ai, 
1980, Harris et alI984). It is estimated that errors occur with either skinfold thickness greater 
than 15 nun or less than 5 mm which may arise due to difficulty differentiating between 
muscle and fat compartments in the mid-arm. Walker and Kindlen (1988) repeated TSF 
measurements on 5 occasions in 18 subjects by a trained and untrained observer and found 
significant error in estimating body fat by skinfolds thickness introduced by an inexperienced 
observer. However, the authors suggested that this error may be reduced by a relatively short 
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period of practice highlighted the importance of consistency in measurements by a single 
trained observer. Fuller et at (1991) examined inter-observer variation using a variety of 
bedside tools by 6 observers in 12 healthy adults. Variation as expected was greatest for 
skinfold measurements in assessing % body fat at 4 sites (coefficient of variation 11-18% 
individual skinfolds, 9% sum of 4 sites) and lowest for the measurement of weight (0.01 % 
digital scales, 0.05% beam balance scales). 
Arm Muscle Circumference 
Mid upper arm circumference and subtraction of TSF may be used to estimate arm muscle 
circumference (AMC), an indicator of muscle mass and hence protein malnutrition. AMC is 
an index of skeletal muscle mass, which accounts for approximately 30% of the LBM, a useful 
tool in assessing protein mass. Furthermore, an assessment of arm muscle area (AMA) may 
then be made from arm muscle circumference. 
Upper arm anthropometry assessments (AMC, AMA and TSP) make two main assumptions: 
1) the upper arm is cylindrical, which ignores the contribution made by the humerus and 2) the 
symmetrical distribution of fat around the arm is a constant fraction of bone to muscle area 
(Heymsfield et ai, 1982). Appropriate bedside tools may be used to identify under-nutrition. 
Guidelines suggested by Bistrian (1980) may be adopted to define Protein-Calorie 
Malnutrition, that is upper arm anthropometry < 5th percentile of reference data or less than 
80% of mean standard reference value. Age and sex specific reference values exist for AMC 
and AMA data (Burr and Philips, 1983). 
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Hand Grip Dynanometry 
Chronic under-nutrition associated with end-stage malignancy contributes to muscle fatigue 
and weakness. Skeletal muscle function, assessed by grip strength has been shown to be a 
useful indicator of muscle function and hence malnutrition (Kildjian et al, 1980; Webb et ai, 
1989). In a study by Phillips (1986) a low grip strength identified a population nutritionally 'at 
risk', correlating under-nutrition with muscle weakness. Kalfarentoz et al (1989) described 
hand grip dynanometry as a useful and inexpensive test which when compared against a 
subjective prognostic nutritional index, hence reflected reduced muscle strength in 
undernourished patients with gastro-intestinal cancer. Webb and colleagues (1989) have 
devised age and sex specific reference data for hand grip dynanometry. 
Bioelectrical Impedance Analysis 
Bioelectrical impedance analysis (BIA) measures the passage of a small alternating electric 
current (800J,1A) through extra-cellular water, measuring body resistance and impedance. Fat 
tissue is anhydrous and therefore all body water and fluids are bound in the fat free mass. Intra 
and extra cellular fluids behave as electrical conductors and cell membranes act as imperfect 
reactive elements (Foster and Lukaski, 1996). Body fluids and electrolytes are responsible for 
electrical conductance and cell membranes are involved in capacitance. A hydration fraction is 
used to calculate lean body mass and fat mass calculated by the difference from body weight. 
Population specific equations may be used to determine body composition (Roubenhoff, 
1991). 
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There is limited published data on the use of BIA measurement in the management of patients 
with advanced cancer, including those with pronounced cachexia symptoms (Fredix, 1989). 
Gray (1988) found that BIA accurately reflected changes in total body water during normal 
starvation. In a recent study by Simons and colleagues (1995), 41 patients with advanced 
cancer, mainly primary lung diagnosis, underwent nutritional assessment including fat mass 
estimation by BIA and total body water determination by deuterium dilution. BIA was shown 
to have a predictive role in the assessment of nutritional status when compared to the reference 
method, deuterium dilution technique. 
Jacobs (1996) highlights a major problem in the assessment of changes in lean tissue or the 
distribution of body water in severely ill patients. There is no accurate way to separate these 
changes from those solely due to alterations in hydration state. The inability of BIA to detect 
changes in body composition due to altered hydration states and to accurately assess the 
distribution of water between intracellular and extra-cellular compartment, limits its clinical 
use in starvation (Birmingham et ai, 1996). In many patients with cancer, oedema is a 
significant confounding variable resulting from the malignancy, hypoalbuminaemia, and even 
lymphoedema (Kushner, 1992). Any changes in fluid retention may lead to inaccurate body 
composition determination, as the arm and leg contribute to approximately 90% of total 
impedance and therefore reflect whole body changes (Deurenberg et ai, 1989). However, BIA 
is a viable technique for comparing group means in a population survey (Coward et ai, 1988). 
In addition to anthropometry, BIA has an important role when more invasive methods are not 
practical (Guo et ai, 1996). 
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In addition to anthropometry, BIA has an important role when more invasive methods are not 
practical (Guo et at, 1996). 
1.5.4 Biochemical indices of nutritional status 
Nutritional status may also be assessed using the measurement of hepatic protein synthesis but 
only if there is no ongoing inflammatory response. Albumin, a plasma protein with a half life 
of approximately 12 days is often inappropriately used as a nutritional indicator. Low albumin 
concentrations often noted in advanced cancer patients may not accurately reflect protein 
status but may be an index of 'illness'. This may be due to the expansion of the body cell 
mass and the subsequent dilution effect of serum albumin. 
It is perhaps more appropriate to consider albumin in conjunction with an acute phase protein 
such as C-Reactive Protein (CRP). Elevated serum CRP (>lOmg/L) coupled with low serum 
albumin «30gIL) reflects the 'illness' of the patient rather than the nutritional state, whereas 
normal CRP coupled with low serum albumin is reflective of protein depletion. 
1.5.5. Assessment of dietary intake 
Another component of nutritional assessment is the determination of dietary intake. The 
measurement of the habitual intake of food is said to be one of the most difficult tasks to be 
undertaken in nutrition research (Acheson et af 1980). Problems include both the 
determination of dietary intake and the conversion of this information to nutrient value. 
There are two main techniques to estimate dietary intake: 1) recall of food consumed and 2) 
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measurement or recording of food eaten. Both methods are discussed in this section with 
reference to their practical use and validity within palliative care. 
The 24-hour recall method is a simple and straightforward method relying on patient's ability 
to recall the exact intake in the previous 24 hours. However, a single day may not be 
representative of dietary intake due to daily variations. This is particularly evident with 
patients suffering from advanced cancer whose daily intake is influenced by a myriad of 
symptoms associated with a changeable disease process. The seven day recall method, 
providing a more, representative estimate of dietary intake, may be an inaccurate method due 
to the reliance of memory over a 7 day period (Block and Hartman, 1989). 
The recording of intake by weighing, measuring or estimating portion sizes may provide a 
reasonably accurate measurement of dietary intake. Bingham (1991) found a significant 
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difference between the measurement of the food intake by estimating the weight of food 
portions and measuring the portion sizes. Patients frequently under- or over- report creating a 
biased result. In the clinical setting, these errors were overcome by weighing food items. To 
estimate food intake, this time-consuming method involves weighing food presented to the 
patient and thereafter weighing any uneaten food. Intake may then be converted into actual 
nutrient intake by the use of a dietary analysis package or dietary analysis food tables 
(McCance and Widdowson, 1992). Measurement by the investigator removes the emphasis on 
the quantity of food eaten by the patient and may also reduce any patient anxiety that would 
influence consumption. These are indeed important considerations in patients with advanced 
cancer when there is a requirement for sensitive and unobtrusive techniques. 
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The weighing technique has previously been adopted by researchers to assess the dietary 
intake of patients with advanced cancer and appears to be the most non-invasive and 
appropriate means of assessing intake. Walsh and colleagues (1983) used a partially 
individualised weighed technique. For five consecutive days, food offered to patients in the 
hospice setting was weighed when served. Individual plate wastage was subtracted from this 
original plate weight to give an estimated individual intake. However, foods provided by 
visitors were not included in the assessment of daily dietary intake. 
Bingham and colleagues (1994) assessed the accuracy of seven methods of dietary assessment, 
namely, a simple 24 hour recall, a structured 24 hour recall method using photographs of 
portion sizes, two food frequency questionnaires, a seven day estimated record, a structured 
food frequency record and a structured food frequency record containing photographs of 
portion sizes. Dietary intake, measured by a four day diary method, was correlated with 
weighed records (Bingham, 1991). 
Codi and colleagues (1992) devised a simple and easily acceptable tool used by patients to 
quantify daily calorie intake as compared to normal intake. Six key words were used to refer 
to different levels of food intake on a category scale. The patient assessed their dietary intake 
as one of these five categories: 'no intake', 'very little intake', 'normal', 'a lot' and 
'maximum' intake. 'Normal' referred to the same amount usually eaten before illness, 
whereas 'a lot' referred to intake superior to the norm. Developed from a scale used by 
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patients to assess their pain intensity, this scale could be further adapted to assess the intensity 
of other nutritional related symptoms such as appetite, dry mouth and even taste perception. 
1.5.6 QOL and nutritional status in advanced cancer 
Despite the well-documented need to measure QOL in pa11iati~~ care, it is a parameter that is 
indeed difficult to define and measure. An assessment instrument must take into account 
aspects of life and lifestyle that are important to individuals and measure the gap between 
experiences and expectations. Many assessment tools take into consideration key domains of 
QOL namely, physical symptoms, psychological distress, cognitive function, body image and 
sexual function (Cella, 1994). 
QOL assessment tools need to be short so as not to burden the patient who may tire easily and 
also to maintain compliance. It has been recommended by Finlay and Dunlop (1994) that 
questionnaires should take no longer than 15 minutes to complete. Most authors now accept 
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that the best source of information should be directly from the patient in order to eliminate 
observer bias. There is a very real danger that others may impose their own perception of 
anxieties into their assessment of the patient. In addition, it is important that the procedure for 
conducting research that it does not impinge on the patients QOL. There is a need to conduct 
the questionnaire sensitively within a supportive environment (Finlay and Dunlop, 1994). 
An assessment of QOL may encompass the impact of symptoms such as alteration in taste 
perception and weight loss. In palliative care, there appears to be no reference tool for 
measuring QOL. Reliability (the ability to measure accurately and consistently what it is 
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meant to measure) and validity (the extent to which a tool measures what it purports to 
measure) are important considerations when choosing an assessment tool. More importantly, 
an assessment tool needs to examine questions relevant to the purpose of the test to provide a 
comprehensive coverage of the important constructs of interest that have been made. Several 
widely used tools in the clinical setting will be discussed with reference to their suitability for 
this particular study. 
Global assessment of QOL 
Firstly, a global measurement such as "How do you rate your feeling of well-being to-day?" 
may be recorded on a visual analogue scale. However, this rating does not give any indication 
about the relative contributions of the components ofQOL. General measures ofQOL may not 
be specific enough to capture small but significant changes in health status or levels of disease 
severity. This approach is more popular as it is multifactorial, individual, and dynamic. 
Donnelly and Walsh (1996) suggest that objectives of assessment of cancer patients may differ 
as the disease progresses, rendering it difficult to combine all domains into one QOL 
instrument. 
The recently developed SEIQoL (Schedule for the evaluation of individual QOL) is an 
example of a global assessment of QOL (O'Boyle and Waldron, 1997). It measures three 
areas of QOL: 1) areas of importance highlighted by the patient, 2) how they currently regard 
their QOL in each of these areas and 3) what the relative importance of each of these areas for 
overall QOL. The clearest advantage of such a tool is that it incorporates the unique 
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perspective of the individual patients, therefore, focusing on issues that are pertinent to the 
patients own QOL. 
Multi-dimensional assessment of QOL 
Multidimensional assessment tools have been widely used within oncology (Spitzer et ai, 
1981). This index measures five areas, including physical activity, aspects of daily living, 
perception of own health, support from family and friends and outlook on life. A main 
advantage is the simplicity of the tool, which is quick to complete, and has been designed to 
be used by physicians to assess patients QOL. However, poor agreement between the patient 
and physician assessments have been reported using this tool (Slevin et ai, 1988), highlighting 
the increasing importance of patient rather than doctor ratings. Maguire and Selby (1989) 
report that concentrating on five aspects of life reflects an over-reliance on the correlation 
between the different items that are components of each item. However, the Sptizer QOL tool 
has not been widely used in patients with advanced cancer. 
The Rotterdam Symptom checklist, measuring the impact that treatment for cancer has on 
psychosocial functioning (Dettaes et ai, 1988) is derived from items contained in several 
existing questionnaires. It contains 38 items each on a 4 point scale and asks respondents how 
much they have experienced particular symptoms over the last week. Although this 
questionnaire is lengthy to use, it has shown to have high reliability and validity against 
independent interviews. 
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Visual analogue scales 
Visual analogue scales (VAS) have widely been used to rate subjective feelings and are useful 
when repeated tests are required. However, idiosyncratic interpretations of end phrases may 
reduce the clinical significance of individual scores (Maguire and Selby, 1989). Padilla and 
colleagues (1983) developed a tool to assess QOL in patients with cancer. This consists of a 
14 item set of linear visual analogue scales, which specifically examine the patient's general 
physical condition, normal activities and personal attitudes regarding their QOL. The tool 
distinguished differences in QOL between healthy volunteers and patient with cancer that 
included those who were undergoing radiotherapy. Other linear analogue scales have been 
designed by Priestman and Baum (1976) and are increasingly b~ing applied to palliative care. 
PsychosocialAleasures 
The Hospital Anxiety and Depression Scale (HAD Scale, Zigmund and Snaith, 1983) is a 
validated tool consisting of 14 items which rate individual responses on a 4 point scale. Of 
these 14 items, 7 are concerned with anxiety and 7 with depression. It is designed to be 
completed by patients is quick to use and has proved useful as a screening instrument in the 
clinical setting (Girling et ai, 1994). More recently, Hammerlid and colleagues (1997) found 
that, in a longitudinal study of patients with head and neck cancer receiving active treatment, 
the use of the HAD scale was sensitive to changes in symptoms during the study year. In this 
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study, symptoms such as swallowing problems, dry mouth and taste changes that increased 
over the treatment period, were associated with increasing psychological distress. 
A literature search of assessment tools used in this area has failed to reveal a wholly 
satisfactory tool for the purposes of this current study. The main limitations are the length of 
completion and the amount of irrelevant data that would be unnecessarily collected. For this 
current study, a tool needed to be adapted to suit the aim; of the research, that is,' the 
assessment of QOL in relation to the impact of taste changes. Therefore, the main objectives 
of the tool adapted from the HAD scale was that it would reflect issues that were clinically 
relevant, satisfy research issues, and was practical to implement to provide a standardised 
assessment. 
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1.6. Altered taste perception associated with advanced cancer 
1.6.1 Altered taste perception and QOL 
Gustatory and olfactory perceptions play important roles in the determination of food selection 
and dietary intake and subsequent enjoyment of food (Drewnowski, 1997). The presence of 
taste aberrations in cancer cachexia has been cited as a factor contributing to cancer anorexia 
(DeWys 1978, Grosvenor et ai, 1989; Duffy and Ferris, 1989). There is little information 
regarding the impact of changes in taste perception on dietary habits and nutritional status 
despite the indications that it may affect food intake and may have a significant effect on a 
" 
patient's already poor nutritional status. An alteration in this function may disproportionately 
affect QOL and the ability to cope with changes in taste perception may therefore contribute to 
psychological and social well-being. 
Harrison and colleagues (1997) examined the impact of radiotherapy and associated symptoms 
such as altered taste perception, swallowing difficulties and pain on the QOL of 36 patients 
with cancer of the tongue. Using functional and performance scales, QOL was altered by the 
impact of treatment or symptoms highlighted. Although the prevalence of oral problems may 
be greater in patients with cancer of the tongue who had received radiotherapy, the importance 
of taste changes in QOL is indicated. 
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1.6.2 Taste perception in patients with advanced cancer 
One of the first nutritional studies in the hospice setting used a structured questionnaire to 
assess the prevalence of subjective changes in weight, appetite, taste perception and food 
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preference (Walsh et aI, 1982). Four fifths of patients (20 out of 25 patients) experienced 
weight loss, 17 reported anorexia and an alteration in taste perception was prevalent in 
approximately half of the patients (n=13). Of these 13 patients, five reported a general loss of 
taste, and the others more specific changes in taste acuity such as increased ability to perceive 
bitter and sweet tastes. As a consequence of taste alterations, seven patients were found to 
have an aversion to sweet foods and six had an aversion to meat and similar products. 
Changes in taste acuity were not related to any gastrointestinal symptoms, the length of illness 
or survival. In a recent review of oral problems Krishnasamy (1995) reported that in almost 
200 cancer patients receiving palliative care, 77% were experiencing xerostomia, 37% taste 
alterations and 33% were experiencing other problems such ~s swallowing difficulties and 
soreness of the mouth. The prevalence of such symptoms is similar to findings of Aldred and 
colleagues (1991) who, from subjective information, found that, 26% of a heterogeneous 
hospice patient group (n 20) reported taste disturbances. Poor dental health and oral 
Candidiasis were noted as factors that may exacerbate poor taste perception by creating a 
physical barrier to taste bud stimulation. 
Taste changes occurring in patients with cancer may result from both the disease process and 
therapeutic regimens (Mossman and Henkin, 1978; Holmes, 1993). With respect to treatment 
side-effects, changes in taste sensitivity may be attributable to cell death and to the damage to 
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microvilli of taste cells (Conger, 1973). Chemotherapy regimens act by utilising chemicals 
that interfere with mitotic activity and therefore destroy proliferating cells such as those of the 
taste buds. This was further highlighted by Beidler and Smith (1991) who demonstrated that 
the mitotic inhibitor vinblastin sulphate reduced dietary intake in an animal study. Holes 
(1993) found that in 72 patients undergoing cancer chemotherapy, 82% attributed the 
avoidance of one or more foods such as coffee, tea, citrus fruit, chocolate and red meat to taste 
aberrations. In this study, no relationship existed between food avoidance and primary tumour 
types. Cruikshank and colleagues (1989) noted that, in a group of head and neck cancer 
patients receiving radiotherapy, (n=74), 80% reported oral problems that included a dry mouth 
and altered taste perception which was associated with weight loss in this group of patients. 
Over twenty years ago, the prevalence and magnitude of taste aberrations in cancer patients 
was first investigated. DeWys (1974) found that half of a group of 50 heterogeneous patients, 
reported a reduction in the pleasurable aspect of taste. The presence of other cancer-related 
symptoms such as weight loss, early satiety and the feeling of fullness were recorded by a 
semi-structured interview and were positively correlated with.alterations in taste perception. 
In addition, the extent of disease was classified and patients with farther advanced disease 
more frequently reported taste alterations. Taste changes were reflected in food items that 
patients had consequently avoided which included meat products (32% patients). Taste 
perceptions for the four primary tastes (sweet, sour, salt and bitter) were objectively measured 
using the forced-choice technique described by Henkin and colleagues (1963) and compared 
with taste thresholds of 17 healthy controls. Most strikingly in the tumour group, a 
heightened bitter taste and a reduction in sweet taste were noted. Thirteen patients subjectively 
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reported a loss of taste in addition to a meat aversion. 
The dietary intake of 40 patients was assessed using five-day food diaries from which energy 
intake was estimated and noted as significantly lower in patients with heightened bitter taste 
perception. Weight loss was also associated with an altered taste acuity where despite normal 
intakes, it was found that 16 out of 17 patients with a reduced ability to perceive sweet taste 
had experienced significant weight loss (at least 2.3 kg loss in two months). Twelve patients 
with no recent weight loss had normal taste thresholds. The authors postulated that a lower 
bitter threshold was perhaps due to amino acids eliciting a bitter taste and therefore altering the 
plasma levels of sub-threshold stimulus and lowering threshold for bitter taste which was then 
translated into a dislike for a number of food items. No further investigation of the causes of 
altered thresholds were made. Kare and colleagues (1969) described this subjective response 
as a blunting of physiological reflexes. DeWys (1974) highlighted clinical implications based 
on these results, namely, that patients may benefit from the addition of sugar to food and that 
alternatives may be provided for meat products. 
Ovesen and colleagues (1991) found that weight loss per se in cancer patients was associated 
with altered taste perception. In this study the forced choice technique (Henkin et aI, 1963) 
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was used to assess the thresholds for four primary tastes of 27 patients diagnosed with small 
cell lung cancer and 24 controls. Results revealed no differences in taste profiles between 
groups, however, within the cancer group, weight losing patients had significantly lower bitter 
thresholds when compared to weight stable cancer patients (p<O.05). Those who responded to 
therapy appeared to have normal threshold profiles. 
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Research in an elderly cancer group needs to consider changes~ttributed to the ageing process 
(Weiffenbach et aI, 1986). Almost two decades ago, Hill and Almli (1980) described 
developmental alterations in the chorda tympani nerve responses to sweet perception. Chorda 
tympani nerve responses to glucose and fructose increased significantly with advancing age. 
Murphy (1993) noted that in the elderly, a decline in taste perception thresholds had the 
potential to interfere with food selection and subsequent dietary intake. Most studies indicate 
that the elderly have reduced taste sensitivity and may also recognise and identify common 
odours less well (Cain and Stevens, 1989). Several decades ago, Kalmus and Trotter (1962) in 
a longitudinal study, found that in a period of 10 to 15 years after initial testing, taste 
sensitivity had deteriorated each year. Duffy and colleagues in 1995, examined the taste 
perception and dietary intake of 120 elderly women. In this group of patients who were 
nutritionally at risk, a lower olfactory perception was associated with reduced preference for 
the sour and bitter taste of food items and an increased intake of sugars. Interestingly, elderly 
women who were experiencing an alteration in taste perception also experienced less interest 
in social aspects of food intake. 
Gee and colleagues (1988) evaluated the taste thresholds of 30 elderly and 30 young subjects 
using graded concentrations of standards. Vitamin intake was assessed over a 4 day period 
using a combination of dietary recall and food records. A positive association between the risk 
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of low vitamin A intake and diminution of taste function was found in both age groups. In the 
elderly, a significant positive correlation between the risk of vitamin A deficiency and sour 
(p<O.05) and salt (p<O.05) was noted. However, in this study, no assessment of plasma 
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vitamin A was made and the accuracy of a 4 day recall method to assess vitamin status has 
previously been questioned (Bingham, 1991). It has been suggested that vitamin A plays an 
important role in taste integrity, as it is required for the synthesis of non-specific 
mucopolysaccharides in the epithelial cells of taste buds, an accumulation of which may 
impair the access of taste molecules to taste bud receptors ;(Bernard and Halpern, 1968). 
Imamine and colleagues (1990) have reported interesting results associated with a reduction in 
the transport protein for vitamin A (retinol-binding protein), and a reduction in taste 
perception. 
There appears to be some debate as regards to the exact magnitude of taste aberration 
occurring in the elderly. This debate may be due to the difference in measurement techniques, 
definition of normal threshold levels, or the heterogeneity of the group (medical and 
nutritional status). Schiffman (1997) published a literature review of chemosensory alterations 
in the elderly highlighting a reduction of taste function. Age-related changes were associated 
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with a reduction in turnover of taste buds, a poor nutritional status or certain medications 
which may reduce mitosis of epithelium cells, thereby altering normal taste bud physiology. 
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1.6.3 Assessment of gustatory perception 
The main aim of techniques used to assess taste thresholds is to assess detectable differences 
of the amount or quality of sensory properties within a particular group. A detection threshold 
is the minimum value of a sensory stimulus needed to give rise to a taste sensation. A 
recognition threshold is the minimum value of a sensory stimulus permitting the identification 
of the sensation (Schiffman et aI, 1994). 
In 1963, Henkin and colleagues first described the forced choice technique for sensory 
perception assessment which has subsequently been widely adopted by researchers (William 
and Cohen, 1978; DeWys and Walters, 1975; Conger, 1973; Hall et aI, 1980). The forced 
choice technique uses exponentially increasing concentrations of the tastes namely, sodium 
chloride for salt, sucrose for sweet, citric acid for sour and quinine chloride for bitter. For 
each taste, one drop of solution and two drops of placebo (distilled water) were randomly 
placed on the tongue. DeWys and Walters (1975) used a three-stimulus, forced choice 
technique to measure the detection and recognition threshold for the taste qualities of salt, 
sweet, sour and bitter. However, this method and involves sampling of a large number of 
solutions, unsuitable for patients with advanced cancer. 
Based on the tool by Henkin, the international standard of sensory appraisal (ISO 1991) 
describes a set of objective tests for familiarising assessors with sensory analysis. This method 
minimises any extraneous factors such as colour, temperature and odour that may disguise or 
equate to a taste perception. However, thresholds vary inversely with the size of the area 
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stimulated, smaller areas producing higher thresholds than larger areas (McBurney, 1969). 
This is important in patients with a dry mouth, were methods that employ a drop technique 
may underestimate the taste perceived. One main advantage of the International standard of 
sensory appraisal is the short range of concentration of stimuli used. Previous work by the 
current research team (Maybank et a11994, unpublished data) indicates that in the elderly, a 
reduced range of concentrations may be used for the detection and recognition thresholds 
measurements. 
Within a defined range of solutions, Miller and Bartoshuk (1991) highlight criterion bias in 
which one subject may decide that a taste is very easily noticed while another might decide 
that a taste was present only when they were very certain. This may be dealt with by 
providing the subject with water between solution to allow comparison of solution with water 
and therefore, ensures that the measurement is conducted from a zero baseline. In addition, 
McBurney and Pfaffman (1963) suggest that there may be sufficient sodium chloride in saliva 
to influence thresholds for NaCl. This error may be reduced by ensuring adequate rinsing of 
the mouth before tasting any solution. 
Another technique is the up-down procedure that can be used with a variety of responses from 
the subject. This is a test described by Bartoshuk (1978) in which subjective responses 
determine the concentrations used in the assessment. If the subject indicates the presence of a 
stimulus, then the concentration of the stimulus is decreased in the next sample likewise, if the 
subject fails to indicate a stimulus, then the concentration is subsequently increased, 
generating a series of 'runs' of the subject's perception of the stimulus. 
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The use of aqueous solutions bear little resemblance to the sensory perception of food in 
which many compounds of tastes are present. Trant and colleagues (1982) suggested that it 
may be tenuous to extrapolate from simple aqueous medium to complex food items. In the 
study by Trant and colleagues, supra-threshold concentrations of 4 taste substances dissolved 
in appropriate beverages, namely, sodium chloride in tomato juice, citric acid in lemonade, 
sucrose in cherry drink and urea in tonic were measured. The main advantage of this 
technique is that it provides a framework upon which to base hedonic judgements. Ames and 
colleagues (1993), measured salt and sweet taste intensity in both aqueous solution and in 
simple foods. Six concentrations of each taste were prepared and, in addition, strained peas 
with six different concentrations of sodium chloride and apple sauce with sucrose were used. 
Taste supra-threshold intensity and pleasantness of the samples were assessed using linear 
scaling. A positive correlation was shown between the aqueous samples and food items. 
More recently, tests have been devised incorporating real foods. Researchers in the 
Netherlands have studied changes in taste perception in elderly patients using a taste 
perception/preference test (de Jong et aI, 1996). Four food items were used with two 
concentrations of each added tastes namely, potato salad (salt taste), natural yoghurt (sour 
taste), fruit yoghurt (sweet taste) and fruit juice (bitter taste). 
" 
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1.6.4. Physiology of chemosensory perception 
Taste, in addition to texture and temperature senses, combine with odours to produce a 
perception of flavour. Other sensory mechanisms which include taste, smell, texture, viscosity 
and temperature of food playa role in the regulation of gastri~ secretion and gastrointestinal 
,.' 
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mechanisms. In turn, alimentary signals play an important role in peripheral mechanisms of 
hunger, thirst and may also influence central neural mechanisms regulating food intake 
(Bartoshuk, 1978). Taste sensation is the experience of quality of the four primary tastes, 
namely, sweet, sour, salt and bitter. Additional descriptions have been used for example, 
umami, astringent (correlating with bitter), acrid, putrid, sapid or aromatic. 
A mouth contains approximately 10,000 taste buds (Stubbs, 1989) which have a life span of 
approximately ten days (Beidler and Smith, 1991). Taste buds are ovoid structures located on 
structures of the oral cavity such as the tongue, soft palate, larynx, epiglottis, uvula and upper 
one third of the oesophagus. Taste buds are contained in small specialised structures called 
papillae (Schiffman and Gatlin, 1993) which are innervated by the chorda tympani and 
glossopharyngeal nerves (Mistretta, 1991). At the base of the taste bud afferent taste nerve 
axons invade the bud, where chemical synapses occur between serotonergic basal cells and 
taste receptor cells. 
Cells of taste buds transform energy into neural information about the stimulus and 
concentration. Gustatory sensations originate in the interaction between a stimulus molecule 
and a putative receptor located in a taste pore at the tip of a taste bud. Hydrophilic tastes 
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(weak acids, sour), salts (salt and bitter), amino acids (sweet, bitter), proteins (sweet and bitter) 
are dissolved during mastication and reach microvillar processes of taste receptor cells by 
passing through saliva and the mucus layer covering the taste pore (Kinnamon and Getchell, 
1991). 
Taste stimulation consists of an interaction between stimulus molecules and receptor 
molecules producing action potentials in the nerves that supply the taste bud. After this 
reaction reaches an equilibrium, continued stimulation with the adapting solution will evoke 
no additional taste (Muller, 1991). If a flow of concentration series of a taste solution is 
extended across the tongue the taste is initially strong but begins to fade in seconds. Nerve 
fibres enter the base of taste buds and chemical synapses are formed with either the basal or 
nuclear region of taste cell (Kinnamon and Getchell, 1991). Messages are transmitted from 
taste buds to the cortex, however, some information reaches the hypothalamus, involved in 
feeding behaviour. The diameter of taste pores can vary because of a variety of physiological 
mechanisms. 
Beyond the innervation of the taste cells, taste transduction describes the mechanism by which 
the specific type of stimulus energy is transformed into an electrical response within a 
I·
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specialised sensory cell. Numerous transduction pathways postulated are based on 
experimental evidence derived from electrophysical, pharmacological, biochemical and 
molecular biological studies. Transduction provides receptor cells with a means of coupling 
chemical stimulation to neurotransmitter release at afferent synapses. Each taste possesses its 
own transduction mechanism, initiated when sapid chemicals interact with sites on the apical 
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membrane of taste receptor cells. The membrane of the taste cell is negatively charged on the 
:. 
inside with respect to the outside. A taste substance causes partial loss of this negative 
potential resulting in depolarisation. This leads to changes in'the physical characteristics of 
the membrane such as increased membrane permeability and an influx of sodium ions. This 
receptor potential generates impulses in taste fibres perhaps by secreting a chemical 
transmitter that stimulates nerve endings. 
Olfaction plays an important part in the perception of the overall sensory quallity of food items 
(Wysocki and Pelchat, 1993). Nerve cells, located in the superior part of the nostril are 
important in stimulating the olfactory system. Axons extend through a small bone called the 
cribiform plate to the olfactory bulb from which neurons project to the limbic area of the brain. 
Olfactory receptor cells are bipolar nerve cells with cilia projecting into the mucus that coats 
the inner surface of the nasal cavity. The cilia react with odours in the air and stimulate the 
olfactory cells. Odour molecules bind to the protein receptors in membranes and increase the 
permeability of the receptor cells, creating a receptor potential. As a result, receptor potentials 
depolarise cells and initiate nerve impulses. 
Olfactory cells are renewed approximately every 30 days that, like gustatory receptors, renders 
them vulnerable to nutritional deficiencies (Schiffman, 1994). Both gustatory and olfactory 
perceptions play important roles in flavour and satiety. This ~as demonstrated by Rolls and 
",' 
Rolls in 1996 in which satiety was influenced by both chemosenses. In this set of 
experiments, satiety was influenced when food was chewed and smelled before swallowing 
and highlights the sensory specific neural controls on food intake. 
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1.6.5. Impact of treatment on taste perception 
A loss of taste sensitivity results from not only anatomical ch~ges that occur during normal 
ageing but also from certain diseases, pharmacological, surgical (Henkin, 1970) and radiation 
interventions. Altered taste perception has been associated with weight loss in patients with 
Autoimmune Deficiency Syndrome (Graham, 1995). In a study of 750 patients who were 
experiencing some form of altered taste perception, Deems and colleagues (1991) found that a 
blunting of taste perception in most cases reflected olfactory loss. This chemosensory 
dysfunction occurred in patients with a range of diagnosis including upper respiratory tract 
infection and head trauma. 
Anecdotally, patients often associate altered taste perception with pharmacological 
'\ 
interventions. Tamoxifen, an anti oestrogen drug, used as adjunct treatment in breast cancer 
has been subjectively associated with dampening of chemosensory perception (McDaniel et ai, 
1995). However, Schiffman and Gatlin (1993) highlight that it is difficult to speculate on the 
mechanisms by which drugs alter chemosensory functions due to combined effects of 
pharmacological regimens. Ackerman and Kasbekar (1997) reviewed literature in the past two 
decades concerning drugs associated with any magnitude of alterations in taste perception. 
These studies included a wide range of patients namely, the elderly, chronically ill, patients 
with thermal injury and those with reduced appetite. Mechanisms identified as involved with 
sensory disturbances include damage of nerves, altered influx of calcium and other ions, 
chelation or depletion of tissue-bound zinc, disturbed second messenger synthesis and altered 
~: 
prostaglandin synthesis. The latter mechanism may also be implicated in patients with 
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advanced cancer who, as a result of disease mediated cytokine synthesis, may have altered 
prostagalndin synthesis. 
An aqueous environment containing saliva is an important factor in taste perception (Spielman 
1990). The main constituents of saliva are water, electrolytes, proteins and mucus required to 
protect mucus membrane, lubricate food and hence facilitate eating. Cations in saliva such as 
Na+ and Ca 2+ ensure adequate charge carriers to produce depolarising taste receptor 
potentials during taste stimulation. In addition, salivary proteins function as carrier molecules 
for lipophilic tastants. Although saliva itself is tasteless, salivary ions can influence taste 
thresholds such as, bicarbonate ions that influence salivary pH and the detection of sour 
modalities. Taste stimuli are known to influence saliva composition and flow. Most tastants 
enhance flow in a concentration-dependent manner and also alter the ion concentration. Sour 
stimuli, via sympathetic pathways, enhance saliva flow and the concentration of calcium ions 
in the saliva. Salivary glands are also susceptible to damage by radiation to the head and neck 
regions (Beidler and Smith, 1991). Rhodus and Brown (1990) suggests that one in five elderly 
:·;t" " 
patients, xerostomia was associated with a reduction in taste perception. Sodium (Na+) is 
reported to influence the taste threshold of Sodium chloride (NaCl). Lower thresholds of 
sodium have been noted in experiments after rinsing the mouth (Kinnamon and Getchell, 
1991). 
Galili and colleagues (1978) studied short-term alterations in salivary secretion with 
pharmacological agents and subsequent food preference behaviour. This animal study 
demonstrated that a reduction in saliva flow resulted in changes indicative of a change in taste 
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perception. On the contrary, Christensen et al (1984) found that reduced saliva flow caused no 
major changes in taste thresholds except for minimal changes related to sour taste modality. 
This later study does not support previous results, perhaps due to the different methods used to 
alter saliva flow. More recently, Fox (1987) noted large discrepancies between the subjective 
feeling of a dry mouth and objective changes in salivary gland dysfunction. In addition, 
Weiffenbach and colleagues (1986) found that objective and subjective measures of taste 
perception were unaffected by saliva function. In relation to the effects of radiotherapy, 
.~ 
Congor (1973) suggests that chemosensory changes are a side effect resulting from either the 
direct effect of radiation on salivary glands reducing saliva flow or due to the direct effect on 
nerve and taste cells which are also affected by radiotherapy. A more recent study by 
Backstrom and colleagues (1995) found that in 35 patients who received radiation to the head 
and neck regions symptoms, a dry mouth was frequently reported and associated with a poor 
dietary intake. Within the hospice setting, there is evidence to suggest that these taste changes 
occur in patients not receiving any such treatment. 
1.6.6 Nutritional status and taste perception 
.. " 
A number of studies have implicated undernutrition as a causative factor in producing 
alterations in taste perception. This is not surprising as a high turnover rate of cells may be 
influenced by nutrient supply. This was demonstrated by Ohara and colleagues (1994) where 
a impaired taste perception was evident during protein malnutrition in rats. The authors 
related zinc depletion to changes in the length of papillae surrounding the taste buds. Zinc is 
required for the synthesis and activity of salivary protein gustin that plays a role at taste bud 
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receptor level (Henkin, 1994). Heyneman (1996) demonstrated that zinc supplementation in 
" 
daily doses of 25-100mg was an efficacious treatment for taste'dysfunction secondary to zinc 
depletion. However, the authors highlight that there was not sufficient evidence to suggest 
treatment in patients with altered taste perception that do not exhibit low serum zinc 
concentrations. In disease where the inflammatory response is triggered, redistribution of zinc 
and possibly albumin will occur and this low zinc in plasma may be reflecting disease and not 
nutritional status. Low nutrient intake or altered protein metabolism mediated by 
pathophysiological levels of cytokines may reduce the synthesis of both of these transport 
protein (Chevalier, 1995) and the consequent reduction in these essential micronutrients at 
cellular level may cause taste abnormality. 
Bernard and Halpern (1968) identified a role of vitamin A in taste transduction mechanisms. 
In animals who were vitamin A deficient, the nerve activity evoked by tastes applied to the 
tongue was reduced by 50%. This suggested that vitamin A plays a role in 
mucopolysaccharide synthesis at taste reception level. Vitamin A plays an important role in 
the integrity, growth and differentiation of epithelial tissue found in taste buds (Gershoff, 
1981). In a study by Biesalski and colleagues (1985), guinea pigs supplemented with vitamin 
A free diet over 90 days, showed morphological changes in the mucous membrane of cells. In 
vitamin A deficiency, papillae in which taste buds are embedded were altered, shortened and 
showed squamous cells covering the epithelium. Taste buds were hindered by a dense layer of 
" 
squamous cell resulting in a loss of sensitivity during deficiency. Interactions exist between 
many vitamins and minerals. Smith and colleagues (1973) demonstrated the requirement for 
zinc in maintaining the normal concentration of vitamin A in plasma. In this clinical study, 
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three groups were either fed a diet deficient in vitamin A and zinc, a diet supplemented with 
vitamin A and deficient in zinc or a diet supplemented with vitamin A and zinc. For the group 
supplemented with vitamin A only, liver levels of vitamin A were the highest but serum levels 
were half of the group supplemented with vitamin A and zinc. 
',' 
Despite the number of studies conducted examining the relationship between nutritional status 
and taste perception, there appear to be no consistent results. This may indeed be due to the 
variation in the characteristics of patients between groups, the heterogeneous nature of the 
groups, the presence of metastatic disease, the selection of appropriate control groups and the 
measurement of taste perception. It is tenuous to extrapolate results from simple aqueous 
medium to complex food media. Kamath and Booth (1983) suggested that thresholds cannot 
be used to assess the relative sensory intensity as food contains tastes in concentrations higher 
than those of threshold values. Therefore in an attempt to examine the true clinical picture, 
researchers have begun to explore the selection of foods which result from complicated 
recognition by senses of smell and taste. Neilsen and colleague's in 1980 noted that in a large 
group of cancer patients (n 133), reported alteration in taste perception was associated with the 
incidence of other nutritional-related symptoms. Almost all patients with reported altered taste 
perception (80%) and 49% of other group also experienced early satiety. In addition, 70% 
patients with altered taste perception and only 37% patients with no alterations in taste 
experienced anorexia. 
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Other nutrition-related symptoms have been associated with altered gustatory perception. 
Brush and Halpern (1970) hypothesised that gastric distension may modify the gustatory 
perception. Gastric distension affects the efferent activity in the chorda tympani and 
glossopharyngeal nerves that mediate taste responses via central connection of gastric vagal 
fibers. 
1.6.7 Mediators of the malignant disease process and altered taste perception 
Nutritional deficiencies and side-effects of treatment may not fully explain alterations in taste 
perception. The lack of any single nutrient consistently correlating with taste perception 
indicates that causes of altered taste perception are multifactorial. Many studies have reported 
changes in one or two taste modalities solely and not a uniform change as would be expected 
in sensory damage to taste cells. One of the main unanswered questions relates to the 
mechanisms whereby one taste modality is altered. 
Recently, animal studies have yielded interesting results in this area. Smith and colleagues 
(1994) examined the preferences of tumour bearing and non-tumour bearing rats for 5 
chemical tastes. Over 300 rats were provided with a 2- bottle test from which a liquid was 
selected (taste solution or water) from day 3 after implantation of tumour until death. Both 
groups equally avoided quinine hydrochloride and hydrochloric acid solution, indicating that 
the tumour growth produced no disruption in taste perception. However, a difference was 
observed in the preference for sucrose solution. The tumour bearing rats maintained a high 
preference for sucrose and saccharin until approximately 20 days, which then decreased with 
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advancing tumour growth. A reduction in calorie intake preceded the changes in sucrose and 
saccharin preference by several days. Altered preference for sweet but not salt taste suggests 
food related taste cues may be more susceptible to the development of taste aversions during 
tumour growth. This study demonstrated that experimental tumours may induce a decline in 
food intake, resulting from a change in taste perception. 
Other work suggests that a peripheral site may also be involved and that sensory nerves may 
be mediators of reduced dietary intake associated with cachexia. Exton and colleagues 
(1995a) demonstrated that taste aversions are a manifestation of the inflammatory response. 
Bernstein (1994) showed that TNFa alone may be responsibl~ for the induction of anorexia 
and learned food aversions. Work by Goehler and colleagues (1995) investigated the direct 
effects that cytokines such as IL-l/3 and TNFa exert on the brain. Their work demonstrated 
that in animal studies, subdiaphragmatic vagal transection attenuates conditioned taste 
aversions induced by IL-l/3 and TNFa and also blocked both ILI/3 and TNFa induced pain 
and fever. This suggests that cytokines modulate neural activity via the activation of vagal 
afferents. This work supports the theory that cytokines may play an important role in the 
avoidance of novel tastes with which they have been paired (conditioned taste aversions). 
Cytokines appear to alter central nervous system function either by direct cytokine entry into 
the brain via active transport processes at circumventricular qrgans at which the blood-brain 
barrier is weak, or by indirect influences via the induction of central signals subsequent to 
binding to cerebral vascular endothelia (Moltz 1993), or by peripheral action through 
activation of afferent nerve activity. Indeed, peripheral processes exclusive of central 
processes influence taste receptor function. Similarly, other workers have shown that in 
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disease, endotoxins, mainly lipopolysaccharide, are responsible for many symptoms such as 
fever and inflammation (Bret-Dibat et af, 1995; Sehic and Blatteis, 1996). In addition, 
-, 
endotoxins stimulate macrophages to release both eicosanoids and cytokines that may cross 
the blood brain barrier and subsequently activate neural processes (Watkins et ai, 1995). In an 
animal model, chorda tympani (CT) section in conjunction with activation of the inflammatory 
response by lipopolysaccharide did not cause any diminished response to sodium taste 
perception which is the normal response to this CT section (Phillips and Hill, 1996). This 
suggests that the immune system ameliorates the effects of combined chorda tympani section 
and dietary sodium restriction. Immune modulation of taste afferent nerves has not been 
assessed in animals without CT section. 
Taste information is conveyed from the taste receptors to the brain stem via afferent pathways 
(Hermann et af 1983). Cytokines may be responsible for the activation of afferent neural 
pathways, altering afferent information and hence enhancing perception of peripheral 
sensation. The altering of pathways has been implicated in pregnancy induced sickness 
(Brewin, 1980). Andrews and Whitehead (1990) suggested that hormones may sensitise the 
area postrema that receives inputs from visceral afferents and subsequently stimulates emetic 
pathways. Likewise, abnormal neural activity was associated with altered taste perception in a 
case reported by Miller and Bartoshuk (1991). Following removal of the right chorda tympani 
nerve, salty taste was heightened, despite no stimulation of the taste buds. This afferent nerve 
was stimulated without the activation of sensory receptors or normal transduction 
mechanisms. 
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From the literature, several aspects of flavour perception in cancer patients have not been fully 
explored. A limited number of studies in the palliative care setting have investigated the 
prevalence and magnitude of altered taste perception. However, little is known of the impact 
of altered taste perception on dietary intake, food choice, nutritional status and QOL in 
palliative care. The exact mechanism by which gustatory and olfactory changes occur remains 
" 
elusive. This data would prove pivotal in the appropriate nutritional management of 
chemosensory abberations , an integral component of palliative care. 
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1.7. Study Hypotheses 
This study concentrates on patients with advanced cancer, examining gustatory and olfactory 
perception. The impact of gustatory perception on quality of life, nutritional status and 
dietary intake is explored. In addition, the relationship between blood cytokine concentrations 
and gustatory perception are investigated with the following null hypotheses. 
Null Hypothesis (1): There is no difference in the gustatory thresholds of the 4 primary taste 
(sweet, sour, salt and bitter) between patients with advanced cancer and 
age matched controls. 
Null Hypothesis (2): There is no difference between the olfactory perception of patients with 
advanced cancer and age matched controls. 
Null Hypothesis (3): There is no relationship between gustatory perception and quality of life 
in patients with advanced cancer. 
Null Hypothesis (4): There is no relationship between gustatory perception and nutritional 
status in patients with advanced cancer. 
Null Hypothesis (5): There is no relationship between gustatory perception and dietary intake 
in patients with advanced cancer. 
Null Hypothesis (6): There is no relationship between gustatory perception and blood 
cytokine concentration and gustatory perception. 
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2. 1 Subjects 
Patients with a histologically proven diagnosis of cancer admitted to st. Colwnba's Hospice, 
Edinburgh were assessed for inclusion to the study. Prior to recruitment, infonnation sessions 
were held within the Hospice to increase awareness of the study as prospective research had 
not previously been conducted in this environment. Staff were provided with infonnation 
regarding the study objectives, recruitment criteria and the use of assessment tools within a 
tenninally ill group of patients. 
Control subjects of similar age were recruited from a geriatric assessment unit at St. John's 
Hospital, Livingston, W. Lothian. For the purposes of distinguishing the two sample groups 
in the subsequent chapters, they will be referred to as cancer patients and control subjects. 
2.1.1 Inclusion criteria 
The inclusion criteria for cancer patients and control subjects were as follows: 
i. Age ~ 18 years. 
ii. Willingness to participate as indicated by signed infonned consent (Appendix 4). This was 
obtained from patients and subjects prior to conducting any study related procedure. 
iii. Patients scoring at least 8 out of lOon the abbreviated mental test were included in the 
study (Jitpunkel et aI, 1991; Appendix 5). 
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In addition, for cancer patients: 
i. A clinical diagnosis of cancer. 
2.1.2 Exclusion criteria 
The exclusion criteria for cancer patients were as follows: 
i. Patients currently or six weeks after receiving chemotherapy, radiotherapy or drug 
treatment for oral Candidiasis were excluded from the study as these treatments are known 
to have a significant effect on taste perception (Mossmand and Henkin, 1978). 
ii. Patients in severe distress or deemed unsuitable for inclusion by medical staff due to either 
an increase in symptom severity or shortened time to death. 
For the control subjects: 
1. Patients with a CRP concentration> 1 Omg/l were excluded. 
The first line of selection was whether all of the inclusion criteria and none of the exclusion 
criteria were met. The selection process subsequently incorporated the opinions of medical 
and nursing staff regarding patient suitability. 
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2.2 Ethical considerations 
Ethical approval was granted by the Medical and Oncology sub-committee of Lothian Health 
Board (Appendix 1). All data processed were identified by patient number, thereby ensuring 
that the patient's identity remained unknown. 
Communicating in a sensitive manner on an on-going basis ensured that the patient's decision 
regarding their participation was respected. Following identification of suitable patients, 
contact was made by a member of the nursing staff who informed the patient of the study and 
enquired if they were interested in participating in the study. Prior to consenting, information 
regarding study procedures was provided by the researcher (Appendix 3). Patients were free 
to withdraw from the study at any time, hence acknowledging their autonomy. 
Research in the palliative care setting has been aptly described as a 'minefield' with regard to 
ethical issues (Brewin, 1986; DeReave, 1994). During the study design, inherent limitations of 
assessment tools within this study population were acknowledged. The philosophy of hospice 
care in maximising QOL was paramount when choosing methodologies. The length of time 
required to complete an assessment, the ease and comfort in doing so were considered key 
issues in selecting appropriate methodology. Methods that are inconvenient, uncomfortable, 
unsuitable for bedridden subjects, time consuming or requiring large amounts of equipment 
are unsuitable for patients with advanced cancer. 
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2.3. Nutritional assessment 
2.3.1 Weight 
For research purposes, patients were weighed in light indoor clothes using portable scales 
(Wylex scale, accuracy to 0.2 kg) and informed of their weight on request. 
Control subjects were weighed in light indoor clothing on admission and thereafter at weekly 
intervals (Wylex scale, accuracy to 0.1 kg). Body weight was compared with age and sex 
specific 'ideal' weight tables (Lehmann et aI, 1991). Changes in weight reported by patients 
and controls were noted as an indicator of recent changes in body composition. 
2.3.2. Body mass indices 
Reference values for both demiquet (males) and mind ex (females) were used as indices to 
compare weight with height. (Lehmann et aI, 1991). 
For Females: (Mind ex) = k2 
(demispan)ml 
For Males: (Demiquet) = k2 
(demispan) m 
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Demispan was used in the calculation to derive demiquet (males) and mindex (females). For 
the measurement of demispan, a measuring tape anchored between the middle and ring fingers 
was extended along the outstretched arm to the sternal notch. The arm was horizontally 
abducted in neutral flexion, the wrist in neutral rotation. The metal tape was fitted at the zero 
point with a button connected with shirring elastic, which anchored it between the fingers. 
Measurements were made to the nearest 10mm. Regression equations produced by Bassey 
(1986) for estimating height from demispan, for both males and females were used. Height 
was calculated to the nearest O.Olm 
Females: Height (cm) = 1.45 x demispan (cm)) + 60.1 
Males: Height (cm) = (1.40 x demispan (cm» + 57.8 (Bassey,1986) 
2.3.3 Triceps skinfold thickness 
A measurement was made of TSF with the subjects arm relaxed at the side. The elbow was 
flexed at 90 degrees with the palm facing superior. The tape was positioned perpendicular to 
the long axis of the upper arm and the maximum circumference was recorded on the non-
dominant arm (Shimokata et ai, 1989). TSF was measured on the posterior aspect of the arm, 
over the triceps muscle at a point midway between the lateral projection of the acronium 
process of the scapula and the inferior margin of the olecranon process of the ulna. Skinfolds 
were picked up with the thumb and index fmger along the axis of the upper arm and 
measurements taken using calipers (Holtain Ltd., Pembroke~hire, UK). With the calipers 
exerting a constant pressure at varying openings of the jaws, the width of opening was read off 
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on a scale incorporated in the apparatus. The mean value recorded from three measurements 
was compared with age and sex reference data (Burr and Philips, 1983). 
2.3.4. Arm muscle circumference 
:', 
From the measurement of TSF, a record was made of the arm circumference (MUAC) taken at 
the midpoint between the lateral projection of the acronium process of the scapula and the 
inferior margin of the olecranon process of the ulna. AMC (mm) was calculated using the 
following formula derived from Gurney and Jeliffe (1973): 
AMC (mm) = MUAC - [1t x TSF(cm)] 
1t = 3.14 
The measurements were compared with age and sex specific r~ference data (Burr and Philips, 
1983). 
2.3.5. Arm muscle area 
Arm Muscle Area (mm2) was derived from AMC using the following formula derived from 
Gurney and Jeliffe (1973): 
AMA (mm2) = [AMC(mm»)2 
41t 
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The results expressed as cm2, were compared with age and sex specific reference data (Burr 
and Philips, 1983). 
2.3.6 Hand grip dynamometry 
Hand grip strength was measured by a single spring hand held dynanometer using the non-
" 
dominant hand. Patients were asked to press the dynanometer in one hand and readings were 
taken when the maximal grip strength was reached. In the dynanometer, movement of the free 
end of a coiled tube moves in response to an applied force which is transmitted through a lever 
system to a lightweight pointer on a kilogram scale (Klidjian et a/1980). Three readings were 
taken (a three minute rest period between readings) and the highest value recorded. Results 
were compared with reference standards derived from the assessment of 184 mobile 
independently living elderly subjects (65-90years) in England (Pearson et aI, 1985). The 
presence of any physical disability of the hand such as rheumatoid arthritis was noted, as these 
conditions may affect the interpretation of results. 
2.3.7 Bioelectrical impedance analysis (BIA) 
BIA involves the passage of a small alternating electric current (50kHz) through the body 
between the wrist and the unilateral ankle. The corresponding voltage was measured by an 
analyser (RJL Systems, Detroit, USA) to assess the impedance (ratio of voltage to current). A 
four electrode technique was used with one pair of electrodes for passing current into the body 
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and another pair serving as the resulting voltage drop (Foster and Lukaski, 1996). Assuming a 
constant hydration of lean tissue, resistance and reactance of the current is used to determine 
total body water using the equation from which lean body mass was derived (Fearon et ai, 
1994). Subsequently, by subtraction from calculated lean body mass, fat mass was estimated 
as follows: 
FFM (kg) = (0.671 x 104 x H2/R) + 3.1S + 3.9 
Where H = Height (m), R = Resistance n, S = Gender Female (0) Male (1) 
(r = 0.94, SEE = 3.1 kg) 
2.4 Clinical assessment 
For all subjects, the following relevant medical history, obtained from medical notes, was 
documented prior to nutritional and chemosensory assessment: 
i. Diagnosis. For cancer patient this included tumour type, previous aggressive 
treatment, time since diagnosis, presence and site of any metastatic disease, 
ii. Drug regimens (medication prescribed regularly and as required) 
111. Other relevant metabolic pathologies such as diabetes mellitus. 
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2.5 International standard for sensory appraisal of gustatory perception 
Principle a/technique 
The principle of the International Standard for Sensory Appraisal lies in the presentation of 
aqueous solutions corresponding to certain taste qualities, at a given concentration and in a 
known order. All substances are water-soluble in order to impart specific taste (Birch and 
Westwell 1994). This tool assesses taste acuity by measuring detection and recognition 
thresholds and assesses taste sensitivity by measuring intensity scaling of more concentrated 
tastant (Drewnowski, 1997). 
Method 0/ determining taste thresholds 
The procedure for determining taste thresholds used an ascending series in which the subject 
was presented with increasing stimulus concentrations until the subject reported that it was 
detected and subsequently recognized. Before beginning the assessment, subjects rinsed their 
mouth with water at room temperature. A 20ml sample at the lowest concentration of the first 
taste solution was presented to the subject, who was instructed to rinse the fluid around the 
entire oral cavity. Solutions of increasing concentrations were presented in turn. The subject 
then assessed whether the sample tasted differently from water. If so, the subject was asked to 
describe the taste (recognition). A wide variety of terms were acceptable to describe the tastes 
for example, acid, sharp, tart, citrus and vinegar were all considered acceptable for the sour 
taste of citric acid. 
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Tasteless, still and odourless water was used to cleanse the palate and to prepare dilutions. 
Stock Solutions were prepared using the listed solutions (table 2.1) derived from food-grade 
reference substances. Test solutions were prepared from the fresh stock solution on the day of 
testing according to the concentrations given below: 
Caffeine (Bitter Stimulant) Concentrations: O.015mM, O.03mM, O.06mM, 
O.l2mM, O.24mM, 0.48mM 
Sodium Chloride (Salt stimulant) Concentrations: l.5mM, 3mM, 6mM, 12.5mM, 
25mM,50mM 
Citric Acid (Sour Stimulant) 
Sucrose (Sweet Stimulant) 
Concentrations: O.075mM, O.15mM, O.3mM, 
O.6mM, 1.2mM, 2.4mM 
Concentrations:l.5mM, 3mM, 6mM, 12mM, 
24mM, 48mM 
" 
To avoid distraction, the assessments were conducted in a private room or quiet area of the 
ward. Between each taste sample, subjects were presented with water to cleanse the palate. In 
order to avoid sensory fatigue, 3-5 minutes were allowed between each stimulus tested. 
Assessments were performed on two occasions to prevent fatigue but within 24 hours, 
following the same time interval after mealtimes. In addition, patients were asked whether 
they had noticed any changes in their taste perception. 
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Table 2.1 Specification of taste stock solution 
Taste Reference food grade substance Concentration gil 
Bitter Crystallized caffeine (monohydrate) 0.54 
M =212.12 
Salt Anhydrous Sodium Chloride 4.00 
M= 58.46 
Sweet Sucrose 24.00 
M= 342.3 
Sour Crystallized citric acid (monohydrate) 1.20 
M=210.14 
M=Molarity 
75 
2.5.1 Modification of assessment tool for use in elderly advanced cancer patients 
The length of time to complete assessments is an important consideration when selecting 
methodology for use in patients with advanced cancer. The international assessment of 
sensory appraisal involves assessment of 24 solutions. In order to prevent tiredness, increase 
compliance and accuracy a shorter modified version of the test is more appropriate in this 
patient population. 
Subjects 
The international standard of sensory appraisal was performed on a group of elderly patients 
attending a Geriatric assessment unit, St.John's Hospital, W.Lothian (n=18, 8M:lOF, mean 
age = 72± 4.5 years). 
Method 
The test was performed on 2 occasions, assessing the gustatory threshold profiles of 2 tastants 
at each occasion. On each occasion, the test was performed in a quiet part of the ward in order 
to minimize any distractions. Detection and recognition thresholds of the 4 primary tastes, 
namely, sweet, sour, salt and bitter were assessed. 
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Results 
Figure 2.1-2.4 show the taste profiles for the 4 tastants at 6 different concentrations. For each 
tastant the lowest concentrations were neither detected or recognition by patients. Therefore in 
order to shorten the test, the following 4 higher concentrations may be used: 
Threshold Score 
1--------------2 -------------- 3 -------------- 4 
Bitter 0.6mM O.l2mM 0.24mM 0.47 mM 
(Caffeine) 
Sweet 6mM 12mM 24mM 48mM 
(Sucrose) 
Sour 0.3mM 0.6mM 1.2mM 2.4mM 
(Citric acid) 
Salt 6mM 12.5 mM 25mM 50mM 
(Sodium Chloride) 
Increased Concentration of Taste --------------------------------> 
Decreased Sensitivity of Taste -----------------------------------> 
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2.5.2 Comparison of threshold ranges for an elderly and a young group 
In the literature, there is considerable evidence to suggest that the elderly have higher 
gustatory thresholds than younger counterparts. A described in section 2.1, patients attending 
a geriatric assessment unit were recruited to act as a control group. Comparing the gustatory 
thresholds of an elderly group and a younger adult group assessed the appropriateness of using 
an elderly control group in this current study. 
Subjects 
Eighteen patients were recruited from the Geriatric assessment unit, Stjohn's hospital, 
W.Lothian (8M:I0F, mean age 72 ± 4.5 years). Fifteen adults were recruited from Queen 
Margaret University College, Edinburgh (5M:16F, mean age 29 ±..3.6 years). None of the 
elderly group were acutely ill and none of the adult group were, ~mokers. 
Methods 
The International standard of sensory appraisal was used to determine the detection and 
recognition thresholds of both groups. Within the geriatric assessment unit, the test was 
performed in a quiet part of the ward to avoid any distractions and performed at the same time 
of the day. For the adult group, the test was performed in a sensory appraisal laboratory, 
likewise, to minimize any distractions that would interfere with the subject's gustatory 
perception. Gustatory thresholds (sweet, sour, salt and bitter) were analysed using the Mann-
Whitney test to compare data of the 2 independent groups. 
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Results 
Figures 2.5-2.8 show the thresholds ranges of both the elderly and adult groups. For the 
detection of all 4 tastants, the elderly group exhibited higher thresholds as compared to the 
younger adults (p<O.05). In addition, the elderly exhibited higher recognition thresholds for 
sour and bitter tastants (p<O.05). These results indicate that the elderly experienced a blunting 
of their taste perceptions as compared to the younger counterparts. 
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2.5.3 Intra-subject repeatability for each tastant. 
As highlighted in chapter 1.6.3, the international standard of sensory appraisal used to 
determine taste profiles is potentially susceptible to intra subject error. It is therefore 
necessary to perform pilot study to determine the reliability of the subjects perception of 
gustatory perception. 
Subjects 
Ten subjects were recruited from Queen Margaret University College, Edinburgh (5M:5F, 
mean age 27 ± 2.5 years). 
Methods 
The International standard of sensory appraisal was performed on 2 separate occasions at the 
same time of the day with a 7-day period. The gustatory test was performed under standard 
conditions, in a sensory appraisal laboratory. Repeated thresholds were analysed using 
spearmans correlation coefficient. 
Results 
The sensory rating for both the detection and recognition profiles are shown in figure 2.9-2.12. 
For the detection and recognition of all 4 tastants, no significant differences were noted 
between the 2 repeated samples. The results indicate that there was no significant difference 
between the repeated assessments. 
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2.6 Assessment of olfactory perception 
A simple and non-invasive qualitative assessment using common everyday odours to assess 
olfactory acuity and recognition was used (Schiffman, 1994). Patients and controls were 
screened using the abbreviated mental test (Jitpunkel, et ai, 1991) which allowed for the 
inaccuracy of recognising an odour due to memory loss. 
A small sample of each odour was placed in individually labelled bottles. Subjects were 
presented with each odour bottle and instructed to identify each odour with one minute 
intervals between assessing the contents of each bottle. The following odours were assessed in 
the same order for each patient: Citrus, Garlic, Ammonia, Menthol, Iso-amy Acetate (pear 
drops), Benzaldehyde (Almonds), Vanilla, Acetic Acid (Vinegar), Gennolene, Eugenol 
(Cloves). For each odour detected and identified, a score of 1 was given. Alternative 
responses were acknowledged as correct for odours, for example, the smell of lemons were 
noted as a correct response for citrus odour. 
:,' 
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2.7 Dietary intake assessment 
2.7.1 Subjective assessment of symptoms influencing dietary intake 
, I 
An assessment of commonly occurring oral and gastrointestinal symptoms was made based on 
a subjective global assessment (SGA) tool. This was previously designed for use in patients 
with cancer to assess the impact of nutritional support on nutritional status and QOL (Ottery, 
1995; Appendix 7). In addition, a record of any pharmacological intervention was made. 
2.7.2 Objective assessment of dietary intake 
Within the hospice, patients were provided meals from a bulk system of food provision in 
which the type and quantity of food was chosen at each meal time. Within the geriatric 
assessment unit, although the meals were provided by a pre-plated system, the control subjects 
had a choice of food items and portion sizes. The three day weighed intake technique was 
used for the estimation of food consumed. This involved weighing food presented to the 
patient and thereafter weighing any food uneaten. Food items provided by visitors were also 
included in this assessment. Nutrient intake of the quantity of food consumed was then 
estimated using a dietary analysis package (Compeat, Nutrition Systems, London). 
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Dietary intakes were compared with Dietary Reference Values (Department of Health, 1991): 
Energy (Daily Reference Value): 
Male 65-74years=10MJ, >75years=9MJ 
Female 65-74years =8MJ, >75years =7MJ) 
Protein (Reference Nutrient Intake) 
Male 65-74years =60g, >74years =54g 
Female 65-74years =60g, >75years =69g. 
Estimated energy requirements were calculated from the estimating Basal metabolic rate 
(BMR) using the Schofield equation (Schofield, 1985) and applying an appropriate physical 
activity factor (PAL, Department of Health, 1991): Estimated energy requirements = BMR x 
PAL PAL (x1.3) was selected for patient and controls with a sedentary lifestyle. 
Schofield equation for calculating BMR: 
30-60 years BMR (men) = (0.048 x W) - (0.011 x H) + 3.670 (sem = 0.7) 
BMR (women) = (0.034 x W) + (0.006 x H) + 3.530 (sem=0.466) 
Over 60 years BMR (men) = (0.038 x W) + (4.068 x H) - 3.491 (sem=0.66) 
BMR (female) = (0.033 x W) + (1.917 x H) + 0.074 (sem=0.43) 
W = Actual of usual weight (kg) 
H = Height (cm) 
A = Age (years) 
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2.7.3 Assessment of food selection 
The reporting of any changes in food selection associated with altered taste perception was 
recorded. Patients were asked specifically if they experienced any changes in their taste 
perception (Appendix 7). Alterations in food selection associated with altered taste perception 
were assessed by means of the two open-ended questions: 
Have you noticed any changes in the taste of food or drink? 
Have you noticed any changes in the smell of food or drink? 
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YES/NO 
YES/NO 
2.8 QOL assessment 
Within this current study, an interview style questionnaire was based on validated questions 
from the Hospital Anxiety and Depression Scale (HAD scale; Zigmund and Snaith, 1983). The 
tool was extensively reviewed by senior medical and nursing staff before implementation on 
the ward. In addition, it was piloted on three patients attending the Day hospice to firstly, 
assess the length of completion and secondly, assess the ease of answering the questions. 
Feedback was received at all stages of the study design period and used to modify the tool 
(Appendix 6). 
Reflection during research for people who are facing emotional pain in terminal stage of their 
illness may be a distressing experience (de Raeve, 1994). Within the context of this research, 
an interview was used to provide a structured assessment within a supportive environment as 
to not distract from the QOL of the patient or interviewer. The interview was performed by 
two observers, a nurse lecturer in palliative care with experience working with terminally ill 
patients and the researcher. Responses from subjects were allocated to one of five categories. 
The first set of questions was posed to subjects reporting altered taste perception and all 
patients responded to the second section of question. The assessment of the impact of altered 
taste perception on quality of life was not performed on the control group. The tool outlined 
above was modified from the HAD for use in patients with advanced cancer and not a healthy 
elderly group. Although there is a lack of information regarding comparison between both 
groups, it was beyond the scope of this study to validate the use of the tool in both groups to 
provide meaningful data for comparison. 
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2.9 Biochemical analysis 
2.9.1 Cytokines 
Principle of assay 
Plasma cytokine concentration were measured by the ELISA (enzyme linked immunoassay) 
method. This assay employs the quantitative sandwich enzyme immunoassay technique were 
a monoclonal antibody specific for a cytokine has been pre-coated onto a microtiter. 
Blood sampling 
EDTA- anti-coagulated blood was obtained from patients. Plasma was obtained by 
centrifugation at 3000 rpm for 10 minutes. After collection, samples were stored at -20°C 
until batch analysis could be performed in order to reduce inteI.lSsay error. ,Serum analysis of 
TNFa, ILI/3 and IL6 were performed with commercial ELISA kits (R&D Systems Europe, 
Oxfordshire, UK). 
Immunoassay procedure 
The following components were brought to room temperature and prepared: wash buffer, 
substrate solution and cytokine standard. All samples and standards were assayed in duplicate 
using the following technique: 
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1. 50JlI assay diluent was added to each well. 
2. 200JlI standard or sample was added t~ each well and incubated for 2 hours at room 
temperature. Any cytokine present in the sample was bound by the immobilized antibody. 
5. Wells were aspirated and washed 3 times plate. 
6. 200JlI conjugate (enzyme-linked antibody specific for cytokine) was added to each well and 
incubated for 2 hours at room temperature. 
7. Wells were aspirated and washed 3 times. 
8. 200JlI substrate solution was added to each well and incubated for 20 minutes at room 
temperature. The colour developed in proportion to the amount of cytokine bound in the 
initial stage 
9. 50JlI stop solution was added to each well to stop the colour development. 
10. Intensity of cytokine bound was measured by optical density of each well was determined 
within 30 minutes using a mirotiter plate reader set to 450nm wavelength correction. 
Construction of standard curve 
The average reading was made from duplicate readings, from which, the average zero standard 
of optical density was subtracted. Optical density for the standards and the concentration of 
the standards were used to produce a standard curve. The concentration of cytokines in each 
sample was determined from the standard curve. 
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2.9.2 Serum albumin 
Bloods samples taken through routine blood letting were spun and processed. Serum albumin 
was measured using an automated bromocresol green dye binding technique. This was 
performed at accredited laboratories at the Western General Hospital, Edinburgh and St. 
John's Hospital, Livingston, Lothian. 
2.9.3 Serum CRP 
CRP was used to assess the presence and the magnitude of an on-going acute phase response. 
A CRP measurement of> 10mg/l was taken as an indication of a positive acute phase response 
(Thompson et aI, 1992). A competitive binding immunoassay method was used to analyse 
CRP in serum. This method allowed a tracer labeled antigen and the antigen in the sample 
under investigation to compete for binding sites on the antibody molecules. When competitive 
binding occurs, the more tracer-antigen complex that binds to the antibody molecule, the less 
tracer-antigen complex that remains in solution. If a sample contains a high concentration of 
the antigen, after the competitive binding reaction reaches a steady state, there is a low 
concentration of bound tracer in the reaction mixture and polarization is" low. The precise 
relationship between polarization and concentration of the unlabelled protein in the sample is 
established by measuring the polarization values calibrated with known concentration of the 
protein. Using the polarization values generated for each sample in the assay, the 
concentration of protein in known samples were calibrated using the stored calibration curve. 
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The assays were performed at St. John's Hospital, Livingston, Lothian and Western General 
Hospital, Edinburgh. 
2.10 Data evaluation and statistical considerations 
Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS, 
version 6.6). To assess the prevalence and magnitude of altered taste perception in patients 
with advanced cancer, the variables of subjective taste and smell perception were assessed 
using descriptive and qualitative analysis. The objective measures of chemosensory function 
(thresholds ranges 1-4) in the unpaired cancer and control groups were analyzed using Mann-
Whitney test. Subjective reporting of changes in taste perception between the cancer and 
control groups was compared using Chi-squared analysis. 
Comparison of taste perception, nutritional status and dietary intake between the cancer and 
control groups was determined using a student t-test. QOL and food selection data were 
analyzed using Chi-squared analysis. In addition, the relationships between mediators of the 
disease process, CRP and taste perception were established using t-test and correlation 
coefficient analysis. 
Extreme data points were determined by plotting box plots (SP~S, version 6.6). Outliers were 
identified as values more than 1.5 box-lengths from 25th and 75th percentiles. 
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3.1 Introduction 
Null Hypothesis (1): There is no difference in the gustatory thresholds of the 4 primary 
tastes (sweet, sour, salt and bitter) between patients with advanced cancer and age 
matched controls. 
Null Hypothesis (2): There is no difference between the olfactory perception of patients 
with advanced cancer and age matched controls. 
The following chapter explores both the gustatory and olfactory profiles of patients with 
advanced cancer (n=56) compared to age matched controls (n=42). Both subjective and 
objective measurements of gustatory and olfactory perceptions are made. 
The international standard of sensory appraisal (ISO 1991) was used to determine the 
detection and recognition thresholds of four primary tastes (sweet, sour, salt and bitter). A 
common food odours test was used to provide an indication of the olfactory perception. 
Open-ended questions were asked to capture information about the cancer patients (n=50) 
and control subjects (n=42) perception of their gustatory and olfactory chemosenses. 
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3.2 Results 
3.2.1 Demographic Data 
Patients with advanced cancer 
Patients with advanced cancer admitted to St.Colwnba's Hospice for palliative care were 
assessed for inclusion to the study. Written informed consent was obtained from 56 
patients who fulfilled all of the inclusion criteria. Reasons for admission to the hospice 
ward included symptom control (n=38; 68%), respite care (n=9; 16%) and continuing care 
(n=9; 16%). 
Histologically proven primary twnour diagnosis and presence of any metastatic disease in 
patients are shown in figure 3.1. Mean age of these patients was 72.4 ± 9.7 sem years 
(range 50-91 years). Fifteen male (27%) and 41 females (73%) were recruited, the former 
predominantly presented with large bowel (colon and rectwn' n=5) and prostate (n=3) 
carcinoma. Whereas, for females, the main primary twnour diagnosis was breast (n=12), 
large bowel (colon and rectum, n=10) and ovarian carcinoma (n=6) (Table 3.1). 
o!; 
Control Group 
A comparable control group, comprising 46 patients admitted to a Geriatric Assessment 
Unit were recruited (20 Male, 26 Female). A reduction in mobility was the main reason for 
admission to the Geriatric Assessment Unit (Table 3.2). The mean age of the patients was 
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77.9 ± 6.3sem years (range 66-91 years). This hospitalised control group had no indication 
of an on-going inflammatory response as confirmed by measurement of serum CRP (mean 
CRP 5.2 ± O.5sem mg!l; range <1.5-9.0mgll). Of these patients, seven were admitted to the ,.i 
, , 
Geriatric Assessment Unit for the management of a urinary tract infection. However, they 
exhibited no elevation in CRP, which was performed within the assessment period and 
were therefore included in the analysis. Apart from the 46 patients, an additional two 
control subjects were excluded as an elevated serum CRP was noted. 
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Table 3.1 Classification of cancer diagnosis of male and female cancer patients 
Male Patients (n=IS) 
Primary 
Tumour 
Prostate 
Rectum 
Colon 
Lung 
Bile Duct 
Pancreas 
AML 
Stomach 
Ceacum 
Unknown 
n 
3 
3 
2 
1 
1 
1 
1 
1 
1 
1 
% male 
sample 
20 
20 
13 
7 
7 
7 
7 
7 
7 
7 
Female Patients (n=41) 
Primary 
Tumour 
Breast 
Colon 
Ovary 
Rectum 
Lung 
Pancreas 
Kidney 
Stomach 
Oesophagus 
Liver 
Unknown 
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n 
12 
7 
6 
3 
3 
3 
2 
1 
1 
2 
1 
% female 
sample 
29 
17 
15 
7 
7 
7 
5 
2 
2 
5 
2 
.t; 
I 
I 
Ii I 
I. 
Table 3.2 Reasons for admission to the Geriatric Assessment Unit (Controls) 
Reason for Admission n % Controls (n 46) 
Reduced Mobility (rehabilitation) 27 59 
Urinary Tract Infection 7 15 
Leg Pain 5 11 
Osteoarthritis Assessment 4 9 
Other 3 2 
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3.2.2 Taste perception profiles 
From the standard dilution taste test (International standard for sensory appraisal, 
ISOI991), detection and recognition profiles for the primary tastes (sweet, sour, salt and 
bitter) were derived. The concentration at which each primary taste was detected and 
recognised was quantified on a scale rating 1 to 4, where 1 indicated the lowest 
concentration of taste likewise, threshold number 4 represented the strongest concentration. 
The number of patients not detecting or recognising the tastant at thresholds 1-4 was also 
noted. Mann-Whitney non-parametric test was used to analyse the difference in taste 
thresholds between the cancer and control groups. 
For both cancer patients and control subjects, the recognition and detection profiles for 
each primary taste are shown in figures 3.2 to 3.5. Significant differences were noted 
between both groups with respect to the recognition and detection thresholds of bitter taste 
modality (Figure 3.2). Cancer patients had a lower threshold for bitter detection (p<O.005) 
and recognition (p<O.05) when compared to the control subjects (Figure 3.2). Thirty five 
per cent (n=16) of control subjects did not detect, and 74% (n=32) did not recognise the 
bitter taste (Chi-squared = 10.45, p<0.05). In contrast, when compared to controls, a 
greater number of cancer patients detected and recognised bitter at the lowest concentration 
whereas only 18% cancer patients (n=10) did not recognise bitter and 9% (n=5) did not 
detect the bitter taste. 
'J 
In this study, the majority of control subjects detected and recognised salt either at the 
highest concentrations or not at any level (Figure 3.3). The salt recognition profiles for 
108 
cancer patients reflected a similar threshold pattern. This suggests no difference in the 
ability of cancer patients and control subjects to recognise salt taste. However, the 
detection of salt was remarkably higher in the cancer group when compared to controls 
(p<O.05, Figure 3.3). 
Concerning sour taste modality, the group of cancer patients eXhibited a significantly lower 
threshold for sour detection (p<O.05) when compared to the control subjects. There were 
no differences between the groups in the recognition of sour taste (Figure 3.4). 
For the detection of sweet perception, no significant differences were noted between the 
detection and recognition thresholds of the cancer and control groups (Figure 3.5). 
Based on the above information, the null hypothesis (1) is rejected and the following 
hypotheses are accepted: 
, 
" 
Patients with advanced cancer exhibit significantly lower gustatory detection thresholds 
for bitter, salt and sour tastes compared to age-matched control subjects. 
Patients with advanced cancer exhibit significantly lower gustatory recognition thresholds 
for bitter taste compared to age-matched control subjects. 
3.2.3 Olfactory perception 
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In this study the relationship between the chemosenses, gustation and olfaction was 
assessed. To assess olfactory perception, patients were asked to identify samples of 10 
common odours from which scores were attributed to the number of odours correctly 
identified. For example, a score of 5 out of 10 indicated that 5 out of 10 samples were 
correctly identified. 
The number of odours identified by cancer patients were significantly higher than that of 
control patients (p<0.05). Median number of odours identified by cancer patients was 5 
(Inter-quartile range 1.8) and for controls was 2 (Inter-quartile range 1.6, p<O.OO 1). The 
majority of control patients (90%) identified between 1 and 4 odours whereas 95% of 
" . .'" 
cancer patients identified between 3 and 8 samples (Figure 3.6). 
Based on these results, the null hypothesis (2) is rejected and the following hypothesis is 
accepted: 
Patient with advanced cancer exhibit significantly lower olfactory thresholds compared to 
age-matched control subjects. 
3.2.4 Reporting of olfactory and gustatory changes 
The subjective reporting of any altered gustatory and olfactory perception were recorded 
using 2 open ended questions (see appendix 6). This data was used to compare the impact 
of altered gustatory perception on outcome measures such as QOL assessment, dietary 
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intake and food selection. In addition, sUbjective changes were compared with objective 
gustatory and olfactory assessments. 
None of the control subjects reported any recent or previous alteration in gustatory 
perception. Neither a loss of taste or specific taste changes were noted within the control 
group. In addition, current or recent changes in olfactory perception were not evident in 
any of the control subjects. 
Almost three quarters of patients with cancer (n 41; 73%) reported experiencing altered 
taste perception during the course of their malignant disease (Table 3.5). Of these cancer 
patients, 68% (28 out of 41) associated changes in taste perception with a loss of olfactory 
perception. The cancer patients also noted enhanced changes in taste perception. Ten 
patients (18%) reported an increase in bitter taste of food and 6 patients reported enhanced 
sweet perception (Chi-squared = 4.92, p<O.05). 
Fourteen patients (34%) first noticed gustatory changes at diagnosis. However, for 
additional 14 patients (34%), the onset of taste aberrations was more recently noticed, 
within a few weeks prior to questioning. Approximately half of all of the cancer patients 
had received previous chemotherapy or radiotherapy as part of treatment, but not less than 
3 months before inclusion in the study. However, only 5 patients (18%) associated the 
onset of taste changes with any previous periods of radiotherapy or chemotherapy. 
For patients reporting noticeable taste changes, approximately half (53%) reported 
experiencing a continuous change in taste perception. In addition, 14% described changes 
111 
in taste perception as at times less noticeable and 14% as at times improving. The 
prevalence of taste aberrations was examined when patients were stratified by primary 
tumour diagnosis. Table 3.6 highlights the reporting of taste changes in patients with a 
variety of tumour diagnoses. The majority of patients within each tumour sub-group 
reported altered taste perception. Within this heterogeneous group, 60% (n= 18) patients 
with metastatic disease reported changes in taste perception. 
The association between objectively measured changes using the dilution test and reported 
taste thresholds of cancer patients was determined. Associations between the subjective 
and objective assessments of taste perception were noted with respect to bitter and sweet 
tastes. All subjects who reported a noticeable increase in bitter taste perception (n=10) 
detected bitter at levels 1-4, of whom 8 recognised the taste of bitter. Likewise, 80% of 
patients who reported an increase in sweet perception (4 out of 6), whereas only 20% of 
subjects who did not report this phenomenon, recognised sweet at the lowest 2 
concentrations (Chi-squared = 4.95, p<O.05). 
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Table 3.3 Description of changes in taste perception by patients with cancer 
Description of gustatory changes Cancer patients 
n % 
Loss of taste 19 34 
(blunting of sensitivity) 
Enhanced bitter perception 10 18 
Enhanced sweet perception 6 11 
Enhanced salt perception 3 5 
Unspecified taste aberration 3 5 
No change in taste perception 15 27 
Table 3.4 Prevalence of altered taste perception stratified by primary tumour 
Primary Tumour Patients who reported an alteration in taste 
Location perception n=41 
n % patient reporting % tumour 
changes group 
Bowel 10 24 67 
Breast 9 22 75 
Ovary 5 12 83 
Prostate 2 5 67 
Lung 2 5 50 
Kidney 1 3 50 
Unknown 2 5 100 
Other 10 24 83 
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3.2.5 Drug regimens of patients with advanced cancer 
A total of 63 different types of medications were prescribed for patients with advanced 
cancer. To facilitate interpretation, these generic drugs highlighted in table 3.7, have been 
grouped by indication. Of these patients, ten had received more than one type of analgesic 
during participation in the study. 
Medications were examined in relation to both subjective reporting of taste changes and 
the objective determination of taste profiles. Following chi-squared analysis, medication 
regimens indicate no differences in the number of drugs taken by patients stratified by 
subjective taste perception (Figure 3.7 and Table 3.8). Similar patterns of prescribed 
medications may be seen with all sets of patients. In addition, medication regimens 
amongst those patients who detected and recognised bitter and sweet tastes were also 
examined (table 3.9). No differences between groups were reflected in the taste profiles. 
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Table 3.5 Medication prescribed for patients with advanced cancer 
Indication n % total group (n=56) 
Analgesic 52 93 
Anti-emetic 16 29 
Laxative 29 52 
Anti-diarrhoeal 3 5 
Steroids 16 29 
Diuretic 9 16 
Sedative 32 57 
Table 3.6 Medication stratified by reporting of taste changes 
Indication Taste changes No taste changes 
reported n=41 reported n=15 
n(%) n(%) 
Analgesic 41 (100) 13 (80) 
Anti-emetic 8 (20) 7 (47) 
Sedative 38 (93) 12 (73) 
Laxative 20 (49) 8 (60) 
Anti-diarrhoea 2 (5) 1 (7) 
Steroids 10 (24) 6 (40) 
Diuretic 5 (12) 2 (27) 
.; ~; 
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Table 3.9 Medication stratified by bitter taste perception 
Bitter detected Bitter not detected at any 
(thresholds 1-4) n=51 level n=5 
n % n % 
Analgesic 31 92 4 75 
Nausea 11 32 2 40 
Laxative 20 59 2 40 
Anti diarrhoea 3 9 0 0 
Steroids 9 26 2 40 
Diuretic 5 15 0 0 
Sedative 27 79 4 88 
= 
Bitter recognised n=46 Bitter not recognised at any 
= 
(threshold 1-4) level n=10 
n % n % 
= Analgesic 19 95 10 100 
Nausea 7 35 4 36 
Laxative 8 40 6 55 
Anti diarrhoea 3 15 0 0 
Steroids 3 15 9 50 
Diuretic 4 20 1 10 
Sedative 15 75 4 41 
-
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3.3 Discussion 
3.3.1 Recruitment 
Patients with advanced cancer 
Within this cohort, 56 patients successfully completed the study assessments and an 
additional 18 patients, who did not complete all of the assessments, withdrew due to a 
deteriorating medical condition. Although, the majority of patients were recruited 
following adequate symptom control, this drop-out rate of 24% highlights that recruitment 
and retention of patients receiving palliative care in this study was difficult mainly due to 
changing medical condition. In an attempt to maximise recruitment, clinical research of 
this nature involved time in screening patients, a procedure which involved attending the 
medical and nursing ward rounds and increasing awareness of all staff of the study 
inclusion criteria through regular training sessions. Study progress and results were 
disseminated at meetings with medical and nursing staff. 
It was acknowledged that rigorous exclusion criteria might impinge on the number of 
subjects recruited and possibly introduce selection bias that may limit the interpretation of 
the results. No specific cancer types were excluded from the study. 
A variety of primary tumour diagnoses were noted within this group of elderly cancer 
patients. The tumour type in this heterogeneous group reflects the main classification of 
primary diagnosis observed in the UK epidemiological picture (WHO Classification, 
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1983). The main tumour diagnosis for males was lung cancer and for women breast cancer. 
In an advanced stage of their illness, the majority of subjects (67%) had metastatic disease 
but the time available did not allow for a greater number of patients recruited to this study 
to examine taste profiles in relation to specific tumour type. Despite the heterogeneous 
nature of these patients, this study has focused on patients with an advanced stage of 
disease receiving palliative care who have not received any recent radiotherapy or 
chemotherapy. This is the first study of its kind and the following results uniquely 
contribute to the knowledge and understanding of taste perception not attributable to 
aggressive treatment regimens in patients with advanced cancer. 
Control Patients 
The predominance of females recruited in the majority of studies of elderly populations 
was reflected in this current study within both the control subjects (57% female) and cancer 
patients (73% female) (Schiffman, 1994). 
The sample of elderly subjects recruited from the Geriatric Assessment Unit were 
appropriately matched controls for several reasons. Firstly, this group were of similar age 
as that of the cancer patients and none had evidence of neoplastic disease or an ongoing 
inflammatory response. None of the patients were acutely ill as confirmed by serum C-RP 
levels. In addition, patients were assessed prior to discharge. Secondly, with regard to 
taste perception, the pilot study demonstrated higher thresholds for all four tastes in the 
control elderly group when compared to a younger group of subjects. In this study, a 
blunting of taste perception noted in the control subjects supports the recent work of 
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Schiffman (1997) who demonstrated a deteriorating taste sensitivity with age. This is 
important in controlling for the effects of age on normal taste bud physiology in the cancer 
group whose mean age was similar to that of the controls subjects (Weiffenbach et aI, 
1986; Hill and Almi, 1980). In addition, the analysis of the taste profiles of the controls 
and younger counterparts suggests that the chosen gustatory assessment tool had the ability 
to detect expected differences in taste profiles. This is important data as it validates the use 
of 4 rather than 6 concentrations in the adapted sensory appraisal test. 
3.3.2 Prevalence of altered taste perception in patients with advanced cancer 
Establishing the taste profiles of control subjects was fundamental to the study in order to 
subsequently compare with profiles of the cancer patients. Although not significantly 
different, taste profiles indicate that the control subjects exhibited a blunting of taste 
',' 
perception as compared to their younger counterparts and hence demonstrate changes in 
taste perception attributed to the ageing process. In this study, more than half of patients 
with advanced cancer reported an alteration in their taste perception during the course of 
their illness. For the majority of these patients, gustatory changes were reported as a 
blunting of taste perception coincident with ageing. It may also be characteristic of 
nutritional deficiency associated with advanced cancer which will be discussed in chapter 
6. Although, no specific taste changes were noted in control subjects, Duffy and 
colleagues (1995) noted a lower sensitivity for bitter and sour taste in a healthy elderly 
population. However, specific changes in taste perception were also observed in the cancer 
group. More than one third of patients reported an increase in bitter taste perception and 
others reported a heightened sensitivity to salt and sweet tastes. For some patients, an 
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increased sensitivity to bitter accompanied a general blunting of taste. In contrast, none of 
the control patients reported any changes in gustatory and olfactory perception. This study 
uniquely highlights specific and predominant changes in taste perception not attributed to 
cancer treatments such as radiotherapy and chemotherapy. Moreover, patients did not 
associate the onset of gustatory and olfactory changes with any previous treatment. This 
.( 
suggests that chemosensory changes are not evident as a side effect of treatment but may 
be attributed to the malignant disease process. 
Apart from the malignant state in the cancer patients, there may be other differences from 
the control group that would attribute to differences noted with gustatory and olfactory 
perceptions. Other known conditions include chronic liver disease (Madden et aI, 1997) 
and nutritional deficiencies (Schiffman, 1991). None of the control patients had evidence 
of liver disease. Although antropometric and assessments of dietary intake revealed no 
overt nutritional deficiencies within the control group, no biochemical assessment was 
performed to detect any sub-clinical under-nutrition. In " addition, obesity has been 
!, 
associated with heightened hedonic responses to fat containing stimuli (Drewnowski et aI, 
1985). However, no evidence of obesity was evident within either group. 
Only 3 out of 35 patients questioned were unable to precisely attribute the change in taste 
perception to one of the 4 pnmary tastes (sweet, sour, salt or bitter). These patients 
associated their alteration in taste perception with a particular food item for example, an 
increase in sweet perception was described 'as though an extra spoonful of sugar has been 
added'. Responses were often very descriptive where a blunting of taste perception was 
described as 'food just tastes like cotton wool'. Previously, Mott and Leopold (1991) 
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reported that as many as 13 out of 50 patients could not accurately classify taste 
disturbances. Food items are a composite of taste and smell and it may therefore be 
difficult to distinguish between specific tastes. 
The prevalence of altered taste perception in this present study was higher than that 
previously reported by DeWys and colleagues (1974) who observed this symptom in more 
than half of a group of 50 heterogeneous cancer patients. Likewise, approximately half of 
\ 
patients in a hospice setting studied by Walsh and colleague~ in 1982 were experiencing 
gustatory changes. However, the heterogeneous group of patients with advanced cancer 
studied by Walsh included patients who had received recent radiotherapy or chemotherapy 
which is known to cause a blunting of taste sensation (Conger 1973, Beidler and Smith 
1991, McDaniel et aI, 1995). It is interesting that in the current study, which included 
patients who had not received any recent treatment, that the prevalence of altered taste 
perception is greater than that noted by Walsh and colleagues. It must be recognised that, 
methodological differences may play a part in the non-homogeneity of findings in the 
determination of taste profiles. One such difference lies in the various sensory appraisal 
techniques used such as the 'forced choice' technique (Henkin, 1963) and the 'up-down' 
technique (Bartoshuk, 1978). Many studies in cancer patients have included patients who 
have received medication that may influence taste perception such as Nystatin for 
treatment of oral thrush. This methodological difference may also in part explain 
differences in taste perception studies with certain disease states including cancer studies. 
This is particularly relevant to cancer patients who have received active chemotherapeutic 
agents or radiotherapy treatment, which may directly alter taste bud physiology. 
Medication regimens and altered taste perception 
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Previous studies have reported that specific medications such as Nystatin for oral thrush 
may affect taste perception. To examine the causes of alteration in taste perception noted 
in this study, the pharmaceutical regimen of all recruited cancer patients were documented. 
None of the patients were receiving any medications that are known to influence taste 
perception. Although, in many cases, patients were prescribed a number of medications for 
symptom control, there appeared to be no pattern in either the number or type of 
medications. 
With particular reference to bitter perception, there was no difference in the type of 
medication for patients with heightened sensitivity as compared to the remaining patients. 
The effects on taste perception of the duration or cumulative dosage or medication that 
patients were receiving remains an area of interest for future studies. 
3.3.3 Taste perception profiles 
When comparing the objectively measured taste thresholds for the four primary tastes, 
significant differences were highlighted between taste thresholds of the cancer patients and 
control subjects. Each of the four taste qualities of sweet, soUr, salt and bitter will now be 
discussed. In addition, patterns of taste aberrations in relation to olfactory perception and 
reported taste perception are highlighted. 
Salt perception 
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For the detection of salt, patients with advanced cancer demonstrated heightened salt 
detection when compared to the control subjects. In other words, salt was detected 
significantly earlier in the cancer group compared to the controls. Carson and Gormican 
(1977) have previously reported significantly higher thresholds for salt taste in a group of 
patients with breast and colon cancer. However, the majority of studies in this area have 
not demonstrated an alteration in this taste modality in cancer patients. In this current 
study, it is difficult to explain the reasons for heightened salt detection coupled with a 
suppressed salt recognition in cancer patients. It may be suggested that differences in salt 
detection reflect difficulties in recognising salt perception whereas the detection of a taste 
requires no decoding of stimulant. However, when extrapolating these results into the 
selection of food items, detection thresholds may be important in determining food 
selection although there is little evidence for thresholds alone to be related to food 
·1 . 
selection. Alternatively, an elevated salt threshold has been associated with an increased 
concentration of sodium ions in saliva prpduction (McBurney and Pfaffman, 1963). The 
chemical nature of salt perception involves translocation of salt taste into the receptor cell 
through passive movement of sodium ions through the apical channels innervated by the 
chorda tympani (Spector and Grill, 1992). In this current study, assessment of saliva was 
considered invasive in terminally ill patients. Anecdotally, a dry mouth indicative of 
reduced saliva production, was not associated with an alteration in taste perception by any 
cancer patients. 
Sweet Perception 
Differences in the detection of sweet taste between the cancer patients and control subjects 
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were noted. Within both groups, more than half of individuals did not recognise sweet 
perception at any level. Likewise, few individuals detected sweet taste. This highlights 
either a blunting of sweet perception in both cancer patients and control subjects or 
suggests that the test stimuli were too weak. Although not reflected in objectively 
measured profiles, an increase in sweet perception was reported by 17% of cancer patients 
compared to none of the control group. The reasons for this inconsistency are unclear but 
may be due to differential signalling mechanisms related to sweet perception. 
Bitter Taste Perception 
The most notable comparison between cancer patients and controls was in the detection 
and recognition of bitter taste. Patients with advanced cancer exhibited significantly lower 
thresholds for bitter taste compared to controls. This finding has not previously been 
reported in patients with advanced cancer receiving only pal~~ative care. Previous research 
has found an increase in threshold for bitter and sour in cancer patients receiving treatment 
(Carson and Gormican, 1977). Within other homogeneous tumour types which have 
included patients receiving treatment, elevated bitter taste sensitivity has been noted 
(DeWys and Walters, 1975; Williams and Cohen, 1978; Settle et aI, 1979; Hall et aI, 
1980). In these studies, the effects of treatment regimens shadow the impact of the disease 
process on taste perception. 
When taste perception profiles of the cancer group were stratified by tumour histology, 
patients with breast and bowel cancers had a greater sensitivity for bitter taste perception. 
I ~. 
This may have merely reflected the number of patients re~~ited in each of these two 
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tumour types. However, part of this explanation may lie in the fact that 50% of breast 
cancer and 88% of colon cancer patients had lost weight and 82% exhibited metastatic 
disease. This is indeed important considering that weight loss has previously been 
associated with higher taste thresholds (Ovesen et ai, 1991). However, the group studied 
by Ovesen was limited to that of small cell lung cancer who were receiving treatment. 
These results suggest that metabolic effects of these 'solid' tumours influence bitter taste 
more readily than other primary tastes. In this current study;:~pproximately three quarters 
of patients had known metastatic disease. Of these, 60%. of subjects with metastatic 
disease reported experiencing altered taste perception. 
Settle and colleagues (1979) observed a significantly higher recognition thresholds for all 
tastes in subjects with metastatic disease compared to healthy controls. This suggests that 
taste aberrations are influences by tumour site. Different sited tumours are associated with 
specific metabolic effects. For example pancreatic tumours are associated with rapid 
weight loss and breast cancer with minimal amounts of weight loss. This may in some 
way explain the differences but metabolic effects will be discussed more thoroughly ,in 
chapter 7. It may be argued that difference in methodologies adopted and patient 
populations may explain these inconsistencies. 
Mechanisms of bitter taste appear to be the most complex in terms of transduction 
mechanisms. Alterations at the transduction level may explain why heightened bitter taste 
profiles were only evident in these patients with advanced cancer. The mechanisms of 
which may be related to metabolic effects of the tumour or the host response to the tumour. 
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Sour Perception 
Sour detection thresholds of cancer patients were significantly lower than that of the 
control subjects. This suggests that the cancer group had the ability to detect sour at a 
lower concentration. No differences were noted in the sour recognition profiles of these 
two groups. Shifts in sour perception may be associated with heightened bitter taste 
perception due to difficulties in distinguishing between these two modalities. At a cellular 
level, both sour and bitter taste perceptions are mediated by K+ channels, which regulate 
the depolarisation of the taste cell and the subsequent activation of neurotransmitter 
release. Based on this information, a change in sour and bitter taste as demonstrated in this 
current study, may simultaneously occur as part of the taste perception neural processes. 
It is important to review the results with caution. Within both groups, there is potential for 
cognitive bias, that is, subjects report what they believe or want to be correct (Mela and 
Rogers, 1998). This may be particularly so with cancer patients who may assign a higher 
threshold to a stimulus that they like but is associated with previous treatment. 
3.3.4 Olfactory perception 
.~ . 
When considering changes in gustatory perception, the association with olfactory 
perception must be addressed as both chemosenses are important determinants of food 
selection and hence dietary intake in healthy adults (Bernstein, 1994). It is important to 
note that the patients and controls were screened using the abbreviated mental test to 
include patient with an adequate memory. This reduced the error in identifying odours due 
to memory loss. 
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In this study, comparisons were made between the objective markers of gustatory and 
olfactory chemoreception. Results reveal that the control subjects identified fewer odours 
when compared to the cancer patients indicating a general heightened olfactory perception 
in advanced cancer, which suggests a close interplay between gustatory and olfactory 
chemosenses as there are in healthy people. Further investigation revealed that patients 
with heightened bitter taste perception also exhibited heightened smell perception. This 
suggests that the mechanism of altered gustatory perception occur at the same time as 
olfactory perception. As with gustation, no control subjects experienced changes in self-
reported olfactory perception. The association between gustatory and olfactory 
chemosenses in advanced cancer has not previously been reported and together may be 
. :1'
important in the development of food aversions and altered satiety mechanisms, a 
knowledge of which is crucial in the appropriate management of nutritional support in this 
population. Attempts to minimise the impact of odours in food preparation methods might 
improve the impact of sensory influences on food selection and dietary intake. This factor 
may be important in product development of nutritional supplements for example 
strawberry odour may not smell as fresh strawberries to patients. 
3.3.5 Subjective taste reporting 
;":. 
The relationship between the subjective reporting of taste changes and the objectively 
measured taste profiles are important for two main reasons. Firstly, if the objective 
research tool is used as the basis of intervention, it must mirror what the individual reports. 
When considering management of this symptom, the objectively measured profiles will 
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prove important in determining the efficacy of any subsequent nutritional intervention. 
Secondly, subjective reporting reflected in objective assessment indicates that the objective 
tool accurately assesses taste perception. 
For bitter taste, results indicate that all patients who reported heightened sensitivity to 
bitter taste, recognised bitter at the lowest concentrations. These results provide further 
justification for using the chosen objective tool. DeWys and colleagues (1974) previously 
reported a correlation between subjective and objective taste perception in cancer patients. 
However, in other clinical states for example, liver cirrhosis, no correlation was noted 
between subjective and objective assessments of taste perception (Madden et aI, 1997). 
In this study, the technique for measuring taste perception was similar to that used in this 
current study. For example, responses of bitter detection were divided into either 'yes' 
indicating that bitter was objectively detected or 'no' indicating that bitter was not detected 
at any level assessed. A similar scoring strategy was adopted in this current study to reveal 
an association between the subjective reporting of taste changes and the detection and 
recognition of bitter taste. All ten patients who reported an increase in bitter taste 
perception, detected bitter and 8 recognised the taste of bitter using the objective 
assessment technique. 
It is foreseeable that in certain cases there may be no correlation between objective and 
subjective taste perceptions. The reasons for this may be twofold; firstly, as highlighted by 
~ . 
Kamath and Booth in 1983, the perception of aqueous solutions may not be accurately 
translated into the perception of food items in which compounds of several tastes are 
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present. Also subjective taste reporting involves not only concentration effects but also 
tactile senses. Secondly, the emphasis that patients with advanced cancer place on 
nutritional symptoms and the experience of altered taste perception may be overshadowed 
by more predominant symptoms such as pain and fatigue. In contrast, the awareness of 
symptoms associated with the disease process may heighten patients' awareness of any 
changes in taste aberrations. .:; 
For each primary taste, detection and recognition thresholds were noted at different 
concentrations. The physiological principles underlying detection and recognition 
perceptions differ and this in part may explain differences in the concentrations at which 
tastes are detected and recognised. Shepherd (1991) describes the first operation in sensory 
transduction (encoding of a stimulus into an electrical response) as detection of sensitivity 
of a taste, followed by recognition of a stimulus. This may in part explain the intra-subject 
differences in the detection and recognition of a stimulus. Neuronal processing of 
recognition may be different to those of transduction and therefore affected differently in 
disease states. 
From results obtained and comparison with published data, the use of four compared to the 
standard six solutions was appropriate for both the control and cancer group of patients. 
For all four tastes, a number of cancer patients detected the taste within the range of 
concentrations. The use of four solutions however does reflect the difference in thresholds 
between the two groups and avoids the use of a lengthy assessment tool. However, for 
patients who detected tastes at the lowest concentration, the precise detection threshold 
needs to be further explored using a wider range of solutions of weaker concentrations. In 
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addition, a subjective element is present in the interpretation of taste perception by the 
patient was acknowledged. In this current study, solution concentrations and techniques of 
assessment such as the time of day that the test was performed and the assessment 
environment were standardised. 
3.3.6 Summary 
The most notable pattern emerging in this study of patients with advanced cancer is that of 
a heightened bitter taste perception. The possible causes of the altered bitter taste 
perception are further examined in chapter 7. These results have previously been 
demonstrated in cancer patients but not in a group of patients with terminal advanced 
cancer receiving palliative care only. This study suggests that these patients demonstrate 
different patterns of taste perception compared to patients receiving active treatment or 
medication that may influence taste perception. In addition, the patients with advanced 
cancer demonstrated heightened olfactory perception as compared to age matched controls. 
These results are important in terms of the impact on the management of symptoms 
associated with malignancy, of which symptom control is fundamental to the maintenance 
of QOL of patients. 
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4.1 Introduction 
Null Hypothesis (3) There is no relationship between gustatory perception and quality of 
life in patients with advanced cancer. 
Fifty patients with advanced cancer completed the semi-structured interview based on the 
HAD scale (Appendix 6). This examined firstly, the impact of altered taste perception on 
QOL and secondly an assessment of some general aspects of QOL (Table 4.1 and 4.2). 
The assessment of QOL, a subjective outcome measure, is considered in relation to the 
subjective reporting of changes in taste perception. This assessment contextualised the 
impact of taste aberrations on QOL, in terms of the enjoyment of food and changes in food 
selection. Examples of responses given by patients to each question are reported in this 
chapter to illustrate any impact that altered taste perception may have on QOL. 
4.2 Results 
4.2.1 Have the taste changes affected your eating habits? 
Almost half of the patients reporting taste changes (n= 16, 46%), attributed a reduction in 
dietary intake to a change in taste perception. Only one patient reported that their dietary 
intake increased due to altered taste perception. In addition, 40% patients (n=14) 
consequently reported a change in food selection resulting from altered taste perception. 
Changes in food selection are further explored in chapter 6. This data suggests that for 
some patients, altered taste perception had an impact on not only the amount of food 
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consumed but also the type of food selected. 
"I eat diffirent ready-made meals now because all food taste the same" 
(70 year Female, Colonic cancer with liver metastases) 
"I love baton buns with strawberry jam but it tastes like cotton wool" 
(75 year Male, Gastric cancer) 
"I do eat different foods now. I often want something tasty but I have an extra problem 
that at home I do not feel well enough to cook" 
(75 year Female, Ovarian cancer) 
4.2.2 Do you sometimes feel hungry but the taste puts you off! 
The question 'Do you sometimes feel hungry but the taste puts you off?' explored the 
impact of altered taste perception on appetite.; Of the group of cancer patients, 14% 
experienced early satiety (n=8). However, of the remainder, despite either occasional or 
frequent feelings of hunger, 40% (n=19) reported that an altered taste of food reduced their 
appetite. Although not statistically significant, for patients who did not experience early 
satiety, altered taste perception had a negative impact on their appetite. 
"Ifrequently feel hungry at night butfood often does not taste right" 
(54 year Female, Breast cancer) 
4.2.3 Have the taste changes affected your general enjoyment of life? 
Of the 35 patients reporting taste changes, almost three quarters reported that the presence 
of altered taste perception affected their general enjoyment of life. This was described as a 
significant negative effect by 20% patients and as quite a lot by 24% patients. Although 
not statistically significant, for additional 24% patients, altered taste was noted as having 
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little effect on appetite. 
"As a diabetic, diet has always affected my lifestyle and now my taste changes have an 
effict on my life " 
(65 year Female, Breast cancer) 
For other respondents, taste changes did not impinge on their QOL and were regarded as 
one of several symptoms associated with their illness: 
"Taste changes have little effect of my life as it is just a minor part of what has been 
happening in relation to my disease" 
(89 year Female, Breast cancer) 
"Taste changes do not have any effect on my enjoyment of life ... ... that would put too 
much emphasis on the role that food plays in life" 
(62 year Male, Prostate cancer) 
4.2.4 Have the taste changes affected those close to you? 
In relation to other aspects of everyday life, either family or friends noticed the presence of 
taste changes. Almost one third of patients (31 %) described altered taste perception as a 
major worry for their carers. In addition, 17% reported that friends and/or family 
occasionally noticed this symptom. This question was not applicable for 17% patients who 
lived alone. More than three quarters patients reported that this concern was associated 
with a concern for weight loss and anorexia. The following responses by patients reflect 
some concerns of carers: 
"My husband tries to please me by buying meringues but /just don't eat them" 
(65 year Female, Breast cancer) 
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"Yes, it is a major worry for my family and when my family see me eating it is a victory" 
(74 year, Female, Lung cancer) 
"Taste changes are not noticed by my family, as I do the cooking for my wife as she is ill 
too" 
(63 year, Male, Kidney cancer) 
4.2.5 Do you ever feel too tired to eat? 
This question was used to explore the impact of fatigue on the dietary intake in the group 
of cancer patients. Responses for both groups, that is, those who experienced taste changes 
and those who did not experience any changes. Tiredness was widely reported as a 
symptom that affected appetite (n=27). Although, not significant, tiredness was noted as 
more prevalent among patients with taste changes (n=19, 49%) compared to those patients 
who did not report any changes (32%). 
4.2.6 Has your illness affected the interest you take in your appearance? 
This question addressed the impact of weight loss and associated altered body image. 
Approximately, one third of all subjects (n=18) associated a lack of interest in their 
appearance with their illness. Of these patients, approximately 50% (n=8) also reported an 
altered taste perception. This data suggests that a reduction in appetite and dietary intake 
contributing to weight loss may have a negative effect on QOL. 
"I rarely take an interest. When you are in pain you can't be bothered" 
(74 year Female, Pancreatic cancer) 
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"No, I take the same interest in my appearance but I am concerned a great deal about my 
loss of weight" 
(78 year, Female, Ovarian cancer) 
4.2.7 How often do you socialise with your friends and family? 
The majority of patients (70%) enjoyed sociable activities. Chi-squared analysis revealed 
no association between the presence of taste changes and socialising. The majority of 
patients either experiencing taste changes (67%) or not (80%) enjoyed socialising with 
family and friends. 
4.2.8 Do you enjoy watching the television, listening to the radio or reading a 
newspaper? 
With regard to these pastimes, almost half of all patients frequently enjoyed watching 
television, listening to the radio or reading a newspaper. For patients who were 
experiencing taste changes, one third (30%) reported that a lack of concentration reduced 
their participation in any of these activities, whereas this only applied to 6% who did not 
notice any altered taste perception (Chi-squared = 7.99, p<O.Ol). 
"Some days I enjoy watching television, but I often find it difficult to concentrate on 
television" 
(67 year, Female, Ovarian cancer) 
4.2.9 Do you have a hobby? Do you still enjoy it? 
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Approximately half of all patients felt unable to maintain any previous hobbies due to a 
lack of energy. This applied to both patients with or without any disturbances of taste 
perception. 
4.2.10 Do you ever feel tense and nervous? 
More than half of patients with taste changes reported that they felt tense and nervous 
either quite often or most of the time. This compares to one third (35%) patients who did 
not experience any taste changes (Chi-squared = 22.5, p<O.OOl). 
"I'm always highly strung but this has settled now while being in this hospice" 
(89 year female, rectal cancer) 
"Very rarely, only when my son questions why I don't eat well" 
(76 year female, rectal cancer) 
"I get tense quite often and worry about my condition" 
(63 year male, kidney cancer) 
"Get tense quite often, I admit that I've always been a bit of a worrier, mainly about 
money and bills" 
(75 year, female, ovarian cancer) 
4.2.11 Summary 
It would appear that there are differences in the quality of life parameters between the 
patients with advanced cancer and control subjects. Therefore the null hypothesis (3) is 
rejected and the following hypothesis is accepted: 
142 
There is a significant relationship between gustatory perception and certain parameters of 
quality of life in patients with advanced cancer. 
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Table 4.1 Impact of altered taste perception on QOL 
Have the taste changes affected your eating habits? NS 
Response Eat more Eat less Eat different Eat at different No 
Category food food foods times Change 
n 1 16 14 2 2 
% 3 46 40 6 5 
Do you sometimes feel hungry but the taste puts you off? NS 
Response All of the Frequently Occasionally No Never feel 
Category time hungry 
n 2 7 7 14 5 
% 6 20 20 40 14 
Have the taste changes affected your general enjoyment of life? NS 
Response Had a Quite a lot A little No Improved 
Category significant change 
negative effect 
n 7 8 8 10 0 
% 20 26 26 28 0 
Have the taste changes affected those close to you? NS 
Response Yes it has Yes it has Occasionally it No No close 
Category become a caused has been noticed relationship 
major worry friction s 
n 11 2 6 10 6 
% 31 6 17 29 17 
NS = Not Significant 
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Table 4.2 Patient responses stratified by altered taste perception 
Do you ever feel too tired to eat? 
NS 
Response All of the Often Occasionally Never Less tired 
Category time than before 
% taste changes 5 20 24 51 
n=35 
% no taste changes 13 7 24 56 
n=15 
Has your illness affected the interest you take in your appearance? 
NS 
Response Yes, I Yes, I No, should 
Category don't want rarely try harder 
to see take an 
myself interest 
% taste changes 6 34 6 
n=35 
% no taste changes 7 33 0 
n=15 
How often do you socialise with family and friends? 
NS 
Response Frequently Rarely, Iamnot 
Category lam a very 
not up sociable 
to it person 
% taste changes 80 17 3 
n=35 
% no taste changes 67 27 6 
n=15 
No,just 
the same 
46 
60 
I have lost 
interest in 
being 
sociable 
0 
0 
Do you enjoy watching television, or reading a newspaper? 
Chi-squared = 7.99, p<O.OOI 
0 
0 
Take 
more 
care than 
before 
8 
0 
Never, 
sadly I 
find it too 
exhausting 
0 
0 
Response Frequently 
Category 
Some days I 
do and some 
days I don't 
Rarely, I 
cannot 
Rarely, I 
never did 
No 
% taste changes 
n=35 
% no taste changes 
n=15 
43 
47 
17 
41 
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concentrate 
30 3 7 
6 6 o 
Do you have a hobby, do you still enjoy it? 
Chi-sguared = 15.4, E<0.01 
Response Yes, no Some Rarely, I NO,I No 
Category change days I do cannot have no hobby 
concentrate energy 
% taste changes 20 34 0 23 23 
n=35 
% no taste changes 39 6 9 6 40 
n=15 
Do you ever feel tense and nervous? 
Chi-sguared = 22.5, E<0.001 
Response Most of Quite Only when I Very Never 
Category the time often go to the rarely 
Doctor 
% taste changes 20 34 0 23 23 
n=35 
% no taste changes 29 6 6 6 53 
n=15 
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4.3 Discussion 
4.3.1 Taste changes and QOL 
'. 
Results highlighted in this section identify aberrations of taste perception as a symptom 
that may impinge on QOL. This information has not previously been reported in patients 
receiving no active treatment and is pivotal in the management of symptoms associated 
with malignant disease in order to maximise patients' QOL. 
The subjective information regarding aspects of QOL illustrated that for many patients 
altered taste perception was felt to have impinged on QOL. For some patients, irrespective 
of the magnitude of taste changes, this symptom was associated with appetite loss and 
changes in food selection which are key components ofQOL. 
A variety of responses to the question 'Have your taste changes affected your general 
enjoyment of life' were received. The majority of patients reported that diet played an 
important part in their life. This concern was extended into their period of illness when 
changes in taste perception and appetite were prevalent. In contrast, for the remaining 
patients, taste changes were not a priority whereas other predominant symptoms such as 
pain and nausea had a greater impact on QOL. These symptoms may also indirectly affect 
nutrient intake, nutritional status and subsequent QOL. The impact of altered taste 
perception was further explored in relation to specific daily activities. Although the 
majority of patients frequently enjoyed socialising, they reported that this symptom 
impinged on many social aspects of their life. In particular, patients reported a negative 
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impact on the enjoyment of food and the inability to participate in the social aspect of 
eating. 
Altered taste perception may not directly influence QOL but indirectly as a consequence of 
contributing to other symptoms such as weight loss and fatigue. Weight loss is considered 
as a major factor influencing QOL in cancer patients receiving chemotherapy (Cohen and 
Mount, 1985). In this current study, weight loss and altered body image was associated 
with a lack of interest in appearance. It may not be totally surprising considering that body 
image was of prime concern for many patients as almost 75% of patients reported to have 
recently lost a considerable amount of weight. Time was allowed during the structured 
interview to discuss how this component affected patients' QOL. This was necessary to 
allow additional time to explore areas of concern that had arisen during questioning. The 
information in this current study suggests that altered taste perception may contribute to a 
negative effect on body image by reducing appetite that may contribute to weight loss. 
In this study, almost half of the subjects (49%) experiencing taste changes reported that, 
fatigue affected their dietary intake. These data are explored further in chapter 6. 
Likewise, from this subjective information, tiredness and the lack of concentration 
appeared to interfere with the amount of time spent socialising and the interest in hobbies 
such as watching television or reading newspapers. This information also highlights the 
multifactorial nature of QOL. 
The final question ' do you ever feel tense and nervous?' allowed a more precise 
exploration of aspects of everyday life perhaps not previously captured by the other 
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questions that contributed to a period of tension. The cause of the feeling of 'tension' was 
gauged as an important indicator of QOL, allowing subjects to incorporate individual 
distinct values into the assessment process. Several issues, not included in the physical 
domain, such as social support, anxiety and depression were reported to have increasing 
importance since diagnosis. These issues are often the focus of QOL techniques. 
4.3.2 QOL assessment tool 
Where treatment is palliative, the contribution that is made' by perceived gustatory and 
olfactory aberrations may have a great significance in terms of QOL and have a significant 
detrimental effect not only on the patient but also on the carer. 
The interview style questionnaire was a non-invasive technique and easy to perform. This 
style of assessing QOL fulfilled one of the main aims of conducting research within 
patients with terminal disease that is, not impinging on the QOL of patients whilst 
assessing this variable (Maguire and Selby, 1989). The length of time taken to complete 
each question varied as it allowed the subjects to explore areas of concern with the two 
observers present. Although the questionnaire was based on validated questions from the 
,'. 
HAD scale, numerical scoring was not validated within this population. Assumptions 
cannot be made as to the numerical weighting of quotations as individual question 
responses may have a different impact on QOL. In the present study, emphasis was 
focused on the physical domain, which addressed the impact of taste changes in relation to 
other physical symptoms such as tiredness, appetite, hobbies, and an interest in physical 
appearance. An inclusion of questions covering other domains of QOL for example work 
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practices would result in a lengthy measurement in this setting. The focus of the impact of 
altered taste perception would be lost amongst the numerous questions. 
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5.1 Introduction 
Null Hypothesis (4): There is no relationship between gustatory perception and 
nutritional status in patients with advanced cancer. 
This chapter provides up to date information on the nutritional status of 2 groups of elderly 
patients, one with advanced cancer receiving palliative care and a non-acutely ill group. 
Secondly, the relationship between nutritional status and gustatory perception is also 
examined. Body composition was determined using upper arm anthropometry, BIA and 
hand grip dynanometry in both the cancer and control groups. 
5.2 Results 
5.2.1 Comparison of nutritional status of cancer patients and control subjects 
Upper arm anthropometric measurements of TSF, AMC and handgrip dynanometry were 
determined in both control subjects and cancer patients (Table 5.1 and Table 5.2). Body 
;, 
weight, when expressed as a percentage of mean reference data, was significantly lower in 
cancer patients (n=38) when compared to controls (n=36, p<0.05). Mean weight of 
controls was 60.8 ± 2.4sem kg representing 95 ± 3.51sem percentage of mean reference 
data (Lehmann et aI, 1991). Control subjects did not report any significant amounts of 
weight loss (>10% usual weight in 3 months; table 5.1). All control ~ubjects were above 
50% of reference data for weight and handgrip (Lehmann et aI, 1991; Burr and Phillips, 
1993). Mean TSF represented 126% reference data. Indicators of muscle mass (AMC and 
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AMA), and also hand-grip dynanometry, indicative of muscle function, were significantly 
lower in cancer patients when compared with control subjects (p<O.OI, p<O.05, p<O.05 
respectively). 
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Table 5.1 Comparison of weight status of cancer patients and control subjects 
Cancer Patients Control Patients p value 
n mean ±sem n mean ±sem 
Weight (kg) 38 57.5 2.2 36 60.8 2.4 NS 
Weight * 38 85.7 3.0 36 95.0 3.5 <0.05 
Female weight (kg) 29 87.9 3.7 22 97.2 4.2 NS 
Mindex 29 77.9 6.1 22 81.9 3.8 NS 
Male weight (kg) 9 78.6 1.1 14 91.5 2.4 NS 
Demiquet 9 75.1 1.0 14 77.5 8.7 NS 
* Expressed as percentage mean reference data (Lehmann et at 1991, Burr and Phillips, 
1993) 
NS = Not Significant 
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Table 5.2 Comparison of anthropometric data of cancer patients and control 
subjects 
Cancer Patients Control Patients p value 
n mean ±sem n mean ±sem 
TSF (nun) 44 12.1 1.0 40 14.1 1.1 <0.05 
TSF Female (nun) 31 12.9 0.9 24 15.2 1.5 <0.05 
TSF Male (mm) 13 10.2 1.3 16 12.5 0.7 NS 
TSF '" 44 87.1 8.6 40 126.7 8.6 <0.05 
AMC(cm) 44 20.1 0.8 40 23.2 0.7 <0.05 
AMC Female (cm) 31 22.2 0.6 24 25.3 0.8 <0.05 
AMC Male (cm) 13 15.1 1.1 16 37.8 0.5 <0.05 
AMC'" 44 93.0 4.9 40 106.8 5.3 NS 
AMA(cm2) 44 352.4 24.9 40 440.7 27.6 <0.05 
AMA Female (cm2) 31 381.1 23.6 24 481.9 26.3 <0.05 
AMA Male (cm2) 13 181.0 26.7 16 491.6 27.9 <0.05 
AMA'" 44 93.8 6.6 40 131.6 7.8 <0.05 
Hand grip (kg) 44 14.4 1.4 38 21.3 2.2 <0.05 
Hand grip Female (kg) 31 17.6 1.2 22 19.6 2.4 <0.05 
Hand grip Male (kg) 13 8.6 1.5 16 23.6 1.8 <0.05 
Hand grip '" 44 14.4 1.4 38 21.3 2.2 <0.05 
* Expressed as percentage mean reference data (Lehmann et at 1991, Burr and Phillips, 
1993) 
NS = Not Significant 
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Bioelectrical Impedance Analysis 
BIA was performed in 38 cancer patients and 36 control subjects to further explore the 
nutritional status of both groups (Table 5.3). Significant peripheral oedema (n=5) and the 
inability to assess weight due to reduced mobility (n=18) excluded the remaining cancer 
patients from this nutritional assessment. Eight control subjects admitted for reduced 
mobility, were also excluded from this assessment. 
Analysis of BIA parameters for both cancer and control groups are shown in table 5.3. 
When expressed in relation to body weight, no differences were noted between the two 
groups. Mean FM was significantly lower in patients with cancer as compared to controls 
(20.0 ± 1.7sem kg vs. 23.2 ± 2.5sem kg; p<0.05). No significant differences in both TBW 
and BCM were noted between both cancer patients and control subjects. 
BlA and Anthropometric Parameters 
I : ~ 
The relationship between BIA and anthropometry within the group of advanced cancer 
patients was examined. TSF was positively correlated with measurements ofFM derived 
from BIA (r=0.67, p<0.05, Figure 5.1). 
. , 
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Table 5.3 Comparison of BIA parameters of cancer patients and control subjects 
BIA Parameters Cancer patients Control Subjects p 
n=38 n=36 value 
mean ±sem range mean ±sem range 
Fat Mass(kg) 20.0 1.7 3.4-35.6 23.2 2.5 5.5-38.3 ns 
Fat Mass * 34.8 1.5 7.2-38.7 38.2 4.8 14.0-41.2 <0.05 
Lean Body Mass (kg) 37.5 1.4 28.3-67.6 37.6 3.2 30.5-62.3 ns 
, 
, . 
Lean Body Mass * 65.2 1.3 62.6-93.2 61.8 ' 1.8 58.8-86.0 ns 
Total Body Water (1) 30.3 1.1 20.7-49.3 33.5 1.3 19.6-45.5 ns 
Total Body Water * 53.6 1.8 45.7-68.9 55.0 1.2 21.0-52.0 ns 
Body Cell Mass (kg) 17.9 0.9 3.6-27.5 19.7 1.3 6.5-49.4 ns 
Body Cell Mass * 30.5 1.2 11.5-39.5 32.6 3.1 14.9-57.5 ns 
* Expressed as a percentage of body weight 
NS = Not Significant 
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Hand Grip Dynanometry 
Patients with cancer had a significantly lower mean muscle function as assessed by hand 
grip dynanometry (14.4 ± 1.4sem kg) when compared to control subjects (21.3 ± 2.2sem 
kg; p<0.05; Table 5.2). Positive correlation between muscle mass and function was 
observed between hand grip dynanometry and AMC (r=0.46, p<0.05; Figure 5.2) and hand 
grip dynanometry and weight (r=0.61, p<O.OOI; Figure 5.3). 
Weight history of patients with advanced cancer 
Weight was measured in 38 out of 56 cancer patients (73%). It was not practical to assess 
the weight of the remaining 18 patients with advanced cancer due to reduced mobility. 
Almost three quarters cancer patients (n=27) reported some degree of weight loss within 
the previous three months. Overall, the mean weight loss expressed as a percentage of 
usual body weight was 3.1 ± 1.0 sem % (range 0 - 23%) where eight patients lost more 
than 10% usual weight within the previous three months (mean loss 16.1 ± 1.7sem kg, 
range 11 - 23%). No significant difference in weight was noted between the male and 
females of both the cancer and control groups. 
Weight loss was reported in the majority of patients with primary colonic carcinoma (8 out 
of9 patients) and rectal carcinoma (5 out of 6 patients). Approximately, 50% (n=6) breast 
cancer patients had lost weight (mean loss 5.2 ± O.5sem % weight within the previous three 
months). Measurements of weight and upper arm anthropometry in weight stable (n=11) 
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and weight losing cancer patients (n=27) are compared in table 5.4. In addition, weight 
losing cancer patients had significantly lower AMC and derived AMA measurements. 
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Table 5.4 Anthropometric parameters of weight losing and weight stable 
patients with cancer 
Anthropometric Mean±.sem p 
Parameter 
value 
Weight Losing cancer Weight Stable cancer 
patients(n=27) patients (n=l1) 
Weight (kg) 56.5 ± 2.4 60.4 ± 5.6 NS 
Weight * 85.7 ± 3.5 85.6 ± 6.7 NS 
AMA(cm2) 326.6±25.9 480.4 ± 181.6 <0.05 
AMC(cm) 19.3 ± 1.1 23.5 ± 1.5 <0.05 
TSF(mm) 11.4 ± 6.1 13.9 ± 2.1 NS 
NS = Not significant 
.,. Expressed as a % mean reference data (Lehmann et al 1991; Burr and Philips, 
1993) 
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5.2.2 Altered Taste Perception and its Relationship with Nutritional Status 
The nutritional status of patients was stratified according to whether patients experienced 
, 
altered taste perception. No differences in upper ann anthropometric parameters (TSF, 
AMC, and AMA) were noted between subjects stratified by taste changes (Table 5.5). 
Likewise, there were no significant differences in BIA parameters between these two 
groups (Table 5.6). 
The weight history of cancer patients was explored in relation to the taste profiles. No 
associations between weight and any of the taste modalities (sweet, sour, salt and bitter) 
were noted. Patients reporting weight loss (n=28) exhibited a heightened ability to detect 
bitter taste compared to weight stable counterparts (n=10) and also compared to the control 
:. 
subjects (p<0.05; Mann-Whitney test, Figure 5.4). In addition, subjects who reported 
weight loss exhibited heightened bitter recognition thresholds compared to controls. This 
data suggests that cancer patients who presented with weight loss had an enhanced ability 
to detect bitter perception. 
Based on this information, the null hypothesis (4) is rejected and the following hypothesis 
is accepted: 
Patients reporting weight loss exhibited a heightened ability to detect bitter taste compared 
\ 
to weight stable counterparts and also compared to the control subjects. 
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Table 5.5 Comparison of anthropometric parameters in cancer patients stratified 
by subjective reporting of taste changes 
Subjective Reporting of taste changes 
Reported taste changes No taste changes reported 
" 
n mean ±sem n mean ±sem 
Weight (kg) 27 59.4 3.2 11 53.9 2.4 
n=38 
%IBW* 27 86.3 4.9 11 84.6 3.4 
TSF (mm) 30 12.2 1.1 14 10.6 1.6 
n=44 
TSF* 30 83.9 10.0 14 81.6 13.0 
AMA(cm2) 30 372.8 33.6 14 219.4 31.9 
n=44 
AMA* 30 93.7 9.0 14 87.4 9.0 
Hand grip (kg) 30 16.1 2.1 14 16.9 2.1 
n=44 
AMC(cm) 30 20.8 1.0 14 18.6 1.6 
n=44 
AMC* 30 99.8 4.6 14 79.5 10.2 
* Expressed as a % reference data (Lehmann et ai, 1991; Burr and Phillips, 1993) 
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Table 5.6 Comparison of BIA parameters in patients stratified by subjective 
taste changes 
Subjective Reporting of taste changes n=38 
Patients reporting taste Patient not reporting 
changes n=27 taste changes n=11 
mean ±sem mean ±sem 
Fat Mass (kg) 19.3 18 21.7 1.6 
Fat Mass ... 21.6 2.0 40.2 2.3 
Lean Body Mass (kg) 43.7 2.1 36.3 2.1 
Lean Body Mass ... 61.3 1.7 74.7 21 
Body Cell Mass (kg) 17.5 1.3 18.6 1. 
Body Cell Mass ... 28.9 1.7 33.3 1.1 
Total Body Water (1) 28.4 1.6 33.3 1.6 
Total Body Water ... 50.5 2.7 56.4 1.7 
* Expressed as a percentage of body weight 
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5.3 Discussion 
Examination of the nutritional status of patients with advanced cancer was made and 
compared with age matched controls. The group of elderly subjects were appropriate 
controls as none had evidence of metabolically active disease. In addition, no subjects 
reported any recent weight loss with mean anthropometric parameters above 50% of 
reference data. 
5.3.1 Nutritional status of patients with advanced cancer 
Body weight was lower in the cancer patients when compared to the controls and was 
significantly different when expressed as a percentage of reference data. The differences in 
i 
weight status between cancer and control groups may be attributable to gender differences. 
However, weight expressed as mindex (Female) and demiquet (Male) body mass indices, 
revealed no differences between both groups. 
The mean weight of the cancer group may not be representative of all of the group studied 
with advanced cancer as not all patients were weighed due to reduced mobility. Since the 
weight status between cancer and control groups was not significantly different this may 
suggest that in the presence of cancer, there is an expansion of the extracellular water 
which would result in an increase in weight. This is not supported by the body 
\ 
composition results that, using BIA, demonstrated no significantly differences in the TBW 
component of the cancer patients as compared to the control subjects. Looking more 
closely at weight loss in the cancer group studied, BIA revealed a reduction in both FM 
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and LBM that highlights the components of weight loss and the value of assessing 
nutritional status using several assessment tools. Although there are limitations in the use 
of BIA as highlighted in chapter 1, these results support the anthropometric results and 
highlights a depletion of lean and fat mass in cancer patients compared to control subjects. 
Catalona and colleagues (1993), found that despite no sign!ficant changes in LBM:FM 
,,' 
ratio, alterations in TBW occurred in cancer patients. Considering the evidence to suggest 
an expansion of extracellular water, the use of isotopes such as 77 Br (bromine) to determine 
BCM and 3H20 (tritium) for TBW would further explore the nutritional status of cancer 
patients. However, the use of isotope research to assess nutritional status may not be 
appropriate for use in the palliative care setting. 
When evaluating nutritional status, it is important to consider weight in relation to the 
amount of recent weight loss rather than reference values of weight which, based on 
healthy adults, may have limited value in this area of research. Recent weight loss is 
indicative of changes in the clinical and nutritional status of these patients and adds a more 
dynamic perspective as comparisons are made from individual patients baseline. However, 
the accurate determination of weight change due to the course of the illness was limited as 
no records of weight were kept and therefore in this study, weight loss was assessed from 
the patients recalled pre-illness weight. It is acknowledged that there may be errors in 
establishing a precise degree of weight loss due to reduced memory function. 
Almost three quarters of patients with advanced cancer reported significant weight loss that 
included 8 patients who lost more than 10% body weight in the previous 3 months (mean 
loss 16.1 ±1.7sem %). This is certainly an amount that may have a negative impact on 
'I 
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prognosis. A similar degree of weight loss has previously been reported by Falconer and 
colleagues (1995) who noted that in 21 patients with pancreatic cancer, weight loss was 18 
± 2sem % mean weight (59.3 ± 2.8sem kg) as compared to 16 healthy controls who were 
weight stable (mean weight 72.4 ± 3.6sem kg). 
The location of the tumour has also previously been associated with the degree of weight 
loss. However, in this study, weight loss was evident in patients with a variety of primary 
diagnosis categories including breast, lung, stomach, large~'bowel, ovary and pancreas. 
Approximately half of patients with breast cancer, one of the predominant tumours studied, 
experienced a substantial degree of weight loss in three months prior to assessment. 
Previously, studies in cancer patients have not demonstrated weight loss amongst subjects 
with this tumour type (Knapp et ai, 1991). This may reflect the effects of symptoms 
associated with advanced stage of disease that impinge on the dietary intake and alterations 
in metabolism. In this present study the weight loss may merely reflect the advanced stage 
of disease progression in patients with terminal malignancy. Recently, Wigmore and 
colleagues (1997) noted weight loss (10-20% pre-illness weight) in a group of patients with 
advanced unresectable pancreatic cancer. This greater degree of weight loss may be 
affected by pancreatic involvement that would further exacerbate weight loss experienced 
by patients. 
Weight loss demonstrated in this study was reflected by lower indices of upper arm 
anthropometry and hand grip dynanometry when compared to controls. Within the cancer 
group, muscle mass as indicated by AMC and AMA were significantly lower in patients 
who had lost weight compared to those who were weight stable. In addition, 
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anthropometric data indicated that self-reported weight loss was reflective of a lower lean 
body mass indicated by both arm muscle circumference and arm muscle area. 
Moreover muscle function as demonstrated by hand grip dynanometry was lower in cancer 
patients compared to control subjects. These results indicated a loss of muscle mass and 
associated muscle function in patients studied. These results are in contrast to a study of 
cancer patients by Watson and Salmon (1980) which indicated a relative sparing of lean 
tissue in weight loss of cancer patients reflecting a state similar to simple starvation. 
Although it is unclear as to the extent of the disease in that study, body fat mass which was 
assessed by skinfold thickness and isotope tracer technique ~as almost entirely depleted. 
Likewise, Deurenberg and colleagues (1989) indicated that a similar degree of weight loss 
(lOkg), was reflective of 70-80% loss of fat mass. 
The majority of studies in cancer patients have excluded those with advanced stage of 
disease and hence these results contribute significantly to the understanding of the 
nutritional status of cancer patients experiencing weight loss in the latter stage of the 
disease. Considering the present results, a loss of muscle mass denotes a catabolic state. 
Further investigation of the mediators of weight loss in cancer namely pro-inflammatory 
cytokines and the associated inflammatory response is fully discussed in chapter 7 . 
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5.3.2 Gustatory perception and nutritional status 
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Following determination of the nutritional status of patients with advanced cancer, the 
taste perception profiles of these patients were examined to investigate any relationship 
with nutritional status. 
Within the cancer group, no differences were noted in the nutritional status of patients 
stratified by subjective taste reporting. In a study by Walsh and colleagues in 1982, weight 
loss was not associated with alteration in taste perception. It is perhaps not possible to 
distinguish the exact impact of altered taste perception on the nutritional status as other 
symptoms characteristic of advanced cancer such as pain and nausea may have a 
confounding impact on an already poor nutritional status. However, it is acknowledged 
that any measurable impact of altered taste perception on food preference and dietary 
intake will have an impact on the nutritional status of patients.' 
,I 
Bitter taste perception and weight status 
Conversely, the impact of nutritional status and in particular any change in nutritional 
status associated with a dynamic disease state on taste perception was also considered. 
Considering the high prevalence of weight loss in almost three quarters of the cancer 
patients, this parameter was examined in relation to taste perception. Interesting results are 
reported in relation to weight losing patients and bitter taste perception. Cancer patients 
who reported a significant degree of weight loss (> 10% pre-illness weight) exhibited an 
increased ability to both detect and recognise bitter taste compared to control subjects. 
This observation has not previously been reported in a heterogeneous group of cancer 
patients receiving only palliative care and suggests that subjects with cancer who presented 
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with weight loss have a greater aberrant response to bitter taste. No differences were noted 
with respect to the other three primary tastes, salt, sour and sweet. This observation is in 
line with findings by Ovesen and colleagues in 1991 who noted that patients with 
significant weight loss had lower bitter thresholds when compared to weight stable cancer 
patients. These observations were made in patients with small cell lung cancer where 44% 
subjects exhibited a significant amount of weight loss (median weight loss 5kg). It is 
important to note the difference between both studies namely, the heterogeneous nature 
and advanced stage of disease in this current study. 
Weight loss may be indicative of the metabolic response occurring in patients with 
advanced cancer and associated inflammatory response (Bernstein, 1994). Therefore, the 
results of this current study suggest that weight loss is associated with a heightened bitter 
taste perception. The mediators of the inflammatory response which cause weight loss 
may be associated with altered taste perception and will be further explored in chapter 7. 
Alternatively, these results may indicate that weight loss and an associated breakdown of 
LBM, which provides substrates for gluconeogenesis, may influence taste perception. 
These may alter circulating amino acid profiles to such extent that they influence 
hypothalamic feeding centres. An imbalance at this level may influence central taste 
perception. 
5.3.3 Assessment of nutritional status of advanced cancer patients 
It is perhaps appropriate to discuss the use of the tools chosen to measure nutritional status 
in this current study. Methods used to determine nutritional status in this study have 
previously been applied in the investigation of body composition of patients with advanced 
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cancer (Wigmore et ai, 1996). A few points may be made with regard to the use of the 
chosen tool from observation in this current study. 
BIA proved to be a useful non-invasive bedside tool in this subject setting as it was quick 
to perform. Although results mirrored anthropometric analysis, the accuracy of BIA in 
determining body composition is limited in patients where there are changes in fluid 
compartments that may provide erroneous results and create a bias in the estimation of 
total body water. Although in this current study, five patients were excluded due to 
significant peripheral oedema, the degree of changes in fluid balance in the remaining 
subjects were not accurately known. 
Within the cancer group, TSF was the only non-invasive procedure performed in the 
presence of oedema as other sites such as the sub-scapular and iliac crest are less accessible 
and more prone to oedema and wo~ld therefore influence results. In addition, 
incorporation of measurements at other sites increasing the length of assessment would 
perhaps reduce recruitment or lead to incomplete data collection for patients. Despite 
errors in the measurement of fat mass by TSF, the assessment was standardised in order to 
reduce the inter-subject errors. 
Likewise, hand grip dynanometry appeared to be a useful bedside tool in assessing muscle 
function. In patients with advanced cancer, weakness, asthenia and fatigue are common 
symptoms and therefore the hand grip dynanometer has an important place in assessing the 
functional status of these patients. This may also be useful in the assessment of QOL, of 
which functional status is an integral component. 
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Chapter 6 examines the association between the second component of nutritional 
assessment, namely, dietary intake and taste perception. 
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6.1 Introduction 
Null Hypothesis (5): There is no relationship between gustatory perception and dietary 
intake in patients with advanced cancer. 
This chapter provides detailed information regarding the energy and macro-nutrient intakes 
of a group of randomly selected patients with advanced cancer receiving palliative care 
(n=23). These are compared with a group of healthy elderly patients within a geriatric 
assessment unit (n=16). In addition, the relationship betw~en dietary intake and taste 
perception was also investigated. The amount of food consumed was determined using a 
three day weighed intake technique and then converted to macro-nutrient intake using 
Comp-eat dietary analysis package (Nutrition Systems, London). In addition, actual 
energy intakes were compared with estimated requirements. 
6.2 Results 
6.2.1 Dietary intake of cancer patients and control subjects 
Macro-nutrient intake of cancer patients compared to control subjects 
Differences in dietary intake were noted between the cancer and control groups. This was 
reflected in a significantly lower carbohydrate intake in cancer patients (90 ± 10sem g) 
compared to controls (176 ± 12sem g; p<O.05). Likewise, the mean intake of fat (41 ± 
10sem g; p<O.05) and protein (35 ± 8sem g; p<O.05) of the cancer patients were 
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significantly lower as compared to controls (60 ± 5sem g and 67 ± 5sem g respectively, 
p<0.05). However, when these differences were expressed as a percentage of total energy 
intake, cancer patients had a significantly lower percentage intake of carbohydrate and 
•. greater percentage of fat compared to control subjects (p<0.05). Protein intake, expressed 
as a percentage of energy intake, was lower in cancer patients compared to controls. 
Macro-nutrient intake was compared with Dietary Reference Values (DRV; Department of 
Health, 1991). Within the cancer group, 21 out of 25 subjects consumed less than 80% 
DRV for energy. In addition, 17 out of 25 patients did not meet the DRV for protein. All 
control subjects had a dietary intake greater than 70% reference data for energy (mean 
intake 75.2% EAR), fat (mean 79.1 % RNI) and protein intake (74.3% RNI). 
When assessed in relation to weight, mean energy intake was significantly lower in the 
cancer group (0.06 ±0.05sem MJ/kg body weight) as compared to the controls (0.10 ±O.O 1 
sem MJ/kg body weight). Within the cancer group, a correlation was noted between 
energy intake and weight status (p<0.05, Figure 6.1). 
Dietary intakes of cancer patients were stratified by primary tumour diagnosis. Energy 
intake as expressed in relation to body weight was significantly lower in patients with 
breast carcinoma (p<0.05) and large bowel carcinoma (colon and rectum, p<0.05) 
compared to control subjects. 
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Predicted dietary energy requirements 
Predicted energy requirements were estimated using Schofield equation (BMR). A 
physical activity value applied appropriate for both cancer and control groups, was applied 
to BMR (Table 6.2). A physical activity level of 1.3, approl?riate for sedentary adults was 
used in the calculation. For the cancer patients, 65% consumed less than the required 
energy intake compared to 78% of the control group. 
Dietary intake and fatigue associated with advanced cancer 
Dietary intake was assessed in relation to fatigue in patients with advanced cancer. Scores 
were derived from responses to the question 'Do you ever feel too tired to eat?'. Although 
not statistically significant, patients who reported some degree of fatigue had lower energy 
intakes (mean 3.3 ±O.4sem MJ/day) compared to those who did not report any fatigue 
/, 
(mean 4.0 +O.72sem MJ/day). Likewise, mean protein intake was lower in patients who 
reported tiredness (33.7 + 5.2sem glday) compared to patients who did not report this 
symptom (43.4 +4.5sem g/day) (Chi-squared=1O.02, p<0.05). This data suggests that 
increased tiredness may be associated with reduced dietary intake in this cohort. 
'.1 
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Figure 6.1 Correlation between energy intake and weight status in patients with advanced cancer 
Table 6.1 Dietary intake of cancer patients and control subjects 
'j' 
Dietary Intake Cancer Group Control Group pvalue 
n=23 n=16 
mean isem range mean isem range 
Energy MJ 3.5 0.3 1.0-6.7 6.1 0.4 2.6 - 8.9 p<0.005 
Carbohydrate 90 10 28-168 176 12 75-261 p<0.05 
% energy intake 40.9 1.0 24.5-50.9 43.9 0.1 38-51 p<0.05 
Fat 41 10 13-84 60 5 28-103 p<0.05 
% energy intake 43.7 1.1 36.2-57.7 38.3 1.4 24-48 p<0.05 
<, 
Protein 35 8 10-73 67 5 22-92 p<O.OOI 
% energy intake 16 3 12-21 18 1 13-26 NS 
NS = Not significant 
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Table 6.2 Actual and estimated energy intake stratified by sex 
Cancer patients Control patients p value 
(10 Male, 13 Female) (5 Male, 11 Female) 
Males mean ±sem range mean ±sem range 
Energy MJ 3.8 0.2 2.3-6.7 6.3 0.4 5.2-8.9 p<0.05 
Estimated 5.3 1.3 4.5-6.6 7.3 0.5 6.5-9.2 p<0.05 
energy intakes ... 
Females mean ±sem range mean ±sem range 
Energy MJ 3.3 0.3 1.0-5.9 6.0 0.3 2.6-7.9 p<O.OS 
Estimated 5.1 1.2 4.4-6.7 6.6 O.S 5.2-7.3 p<O.OS 
energy intakes ... 
... Estimated using Schofield equation (Schofield, 1985) x Physical activity level (1.3, 
Department of Health, 1991) ',' 
" 
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6.2.2 Impact of altered taste perception on food choice 
Three out of 35 patients who reported taste changes were not able to associate their taste 
aberration to any particular taste. Of the remainder, 19 patients described a general 
blunting of taste. Of 22 patients who reported specific alterations in taste perception, six 
described these changes as an increase in the sweet perception of certain food items and 
four patients reported avoiding sweet tasting foods. Ten patients reported an increased 
bitter taste perception of foods and subsequently avoided meat (n=4), chocolate (n=4) and 
tea (n=2) products. In addition, three patients who reported heightened salt perception 
associated this with a reduced consumption of certain salty food items. 
6.2.3 Dietary intake and taste perception 
The reporting of alterations in taste perception by patients was examined in relation to 
dietary intake of patients with advanced cancer. Patients who exhibited early bitter taste 
recognition had a significantly lower mean percentage energy contribution from protein in 
) .,' 
their diet (15% versus 18%, p<0.05; Table 6.3). This was also noted when patients were 
stratified by subjective changes in bitter taste perception (Table 6.4). Although not 
statistically significant, the mean energy intake for patients who reported changes in bitter 
taste perception was 3.2 ± 0.7sem MJ/day compared to 4.6 ± O.4sem MJ/day in patients 
who did not report these changes. Likewise, the mean macro-nutrient intake of protein, fat 
and carbohydrate were also lower in the group who reported an alteration in bitter taste 
perception as compared to the patients who did not report any taste changes. 
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Based on this information, the null hypothesis is rejected and the following hypothesis 
accepted: 
Advanced cancer patients exhibiting early bitter taste recognition thresholds have a 
significantly lower mean percentage energy contribution from protein in their diet. 
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Table 6.3 Bitter recognition thresholds and dietary intake of cancer patients 
Patient recognising bitter Patients not recognising bitter 
taste at threshold 1-4 n=10 taste at any level 0=25 
Nutrient Mean ±sem Mean ±sem 
Energy MJ 4 1 3 1 
Fat (g) 67 7 51 5 
% energy Fat 40 1 44 4 
Protein (g) 38 6 31 6 
% energy Protein ... 15 2 19 2 
Carbohydrate (g) 99 17 78 15 
% energy 42 2 40 . ~ 3 
Carbohydrate 
* p<0.05 between cancer patients and control subjects 
".1' 
182 
Table 6.4 Nutrient intake of cancer patients stratified by subjective bitter 
taste changes 
Bitter taste Bitter taste 
changes not reported n=25 changes reported n=10 
Mean ±sem Mean ±sem 
Energy 4.6 0.4 3.2 0.7 
Fat (g) 49 9 40 6 
% energy Fat 44 1 44 2 
. Protein (g) 43 7 30 4 
% energy Protein • 18 1 15 1 
Carbohydrate (g) 105 18 83 11 
% energy 39 1 40 2 
Carbohydrate 
* p<O.05 between cancer patients and control subjects ., 
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6.3 Discussion 
6.3.1 Comparison of dietary intake of callcer and control groups 
This study conducted in the hospice setting, is one of few studies that has assessed the 
dietary intake of a group of patients with tenninal disease using the weighed intake 
technique. This current study has assessed 1he impact of sy~ptoms such as altered taste 
perception on dietary intake, which allows more appropriate dietary management in 
patients with advanced cancer. Few studies have accurately documented the dietary intake 
of patients with advanced cancer. This is mainly due to the difficulties in using a non-
invasive technique to assess dietary intake and merely an acceptance of the fact that in 
tenninally ill patients, nutritional intervention is futile and therefore unnecessary to assess 
dietary intake. 
This current study assessed the impact of alterations in taste perception on the dietary 
intake and food selection of patients with advanced cancer. The dietary intake of the 
cancer patients was compared with that of the healthy control subjects, to subsequently 
examine the association between altered taste perception and dietary intake. The dietary 
intake of the group of cancer patients was considerably low with regard to macro-nutrients 
when compared to both the control group and the estimated energy requirements. 
Although, reference data was age and sex matched, it may be more appropriate to consider 
the dietary intake of the cancer patients in relation to reference data based on an 
institutionalised group. It is important to note that, differences exist in the provision of 
meals within both the hospital and hospice settings. In this present study, the control group 
184 
were provided meals from a pre-plated system whereas the hospice adopted a bulk system 
of food provision in which the type and quantity of food were chosen at each mealtime. 
However, this does not deter from drawing comparisons between the two groups as a 
choice of food items and portion sizes for each meal time was provided with each group, 
allowing individual selection of food items. The three day weighed intake technique has 
been shown to reflect macro-nutrient status accurately (Bingham, 1991). However, micro-
nutrient status was not assessed as this would have required a longer period of dietary 
recording. 
When cancer patients were stratified by tumour diagnosis, patients with breast and large 
bowel cancer demonstrated lower energy intakes as compared to controls. This correlated 
with the considerable degree of weight loss noted in more that half of breast cancer and 
almost all of patients with large bowel cancer. To a certain extent these results 
demonstrate the effects of reduced intake on weight loss highlighted in chapter 5, weight 
loss was evident in over half patients within this group of cancer patients. However, as 
previously mentioned, despite adequate energy intake for anabolism, cancer patients may 
often fail to gain weight. 
Weight status was positively correlated with energy intake which is a unique finding using 
an accurate method to estimate dietary intake. Likewise, Grosvenor and colleagues (1989) 
noted that dietary intake, as expressed in relation to pre-illness body weight, was 
significantly lower in patients who were weight losing as compared to their weight stable 
counterparts. Ames and colleagues (1992) using a one day recall combined with a three 
day food record intake method, observed lower dietary intakes in patients with cancer 
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compared to control subjects. Giacosa and colleagues (1996), measuring food intake over 
a period of three days noted a greater energy intake than that measured in this current 
study. In this investigation by Giacosa's team, it is unclear as to the extent of disease 
progression or the presence of symptoms that may impinge on dietary intake. In this 
current study, the lower dietary intakes are reflective of an advanced stage of disease and 
using the weighed intake method to determine dietary intake. 
There are many acknowledged limitations when making comparisons of dietary intake 
between studies due to the heterogeneous nature of subjects and the assessment tools used. 
Few studies have investigated the dietary intake of patients receiving palliative care, using 
a three day weighed intake method because it is time consuming and requires a degree of 
I' 
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expertise. The dietary intake of the group of cancer patients measured in this current study 
is more likely to be representative of weight losing cancer patients experiencing altered 
taste perception because of the more stringent methodological approach used. ,These 
cancer patients have lower energy intakes than the elderly counterparts and contributes to 
loss of body mass. 
Factors influencing the dietary intake of patients with advanced cancer 
Examination of the impact of altered taste perception on dietary intake, revealed that other 
symptoms of advanced disease that may contribute to a redu~ed dietary intake need to be 
considered. It may be equally difficult to isolate the effects of tiredness on the dietary 
intake of patients experiencing a variety of symptoms associated with the disease. 
However, in this current study, fatigue was associated with low dietary intakes in cancer 
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patients. A lower energy intake was noted in patients who reported frequent episodes of 
fatigue as compared to those who did not report any changes in fatigue. This suggests a 
negative effect of symptoms such as fatigue on the dietary intake of patients with advanced 
cancer and illustrates another barrier to the successful achievement of recommended 
dietary intakes. 
" 
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Other symptoms associated with advanced cancer may impinge on dietary intake. Feuz 
and Rapin (1994) highlighted that the dietary intake of patients increased following 
adequate pain control. However, patients recruited to this present study had good pain 
control at the time of assessment. Further studies are required to assess changes in intake 
over a longer period and to assess the impact of symptom control on dietary intake. In 
order to record dietary intake over the course of the illness, a visual analogue tool would 
provide a non-invasive type of assessment in this patient population to gauge intra-subject 
changes using baseline assessments. 
:, 
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6.3.2 Impact of altered taste perception on dietary intake, 
A main aim of this study was to examine the impact of altered taste perception on the 
dietary intake of patients with advanced cancer. Almost half of cancer patients attributed a 
reduction in food intake directly to changes in taste perception. This is very important 
considering that although dietary intake was objectively measured, there appeared to be no 
difference in the total macro-nutrient intake of patients experiencing or not experiencing 
taste changes. This may suggest that intake was reduced due to altered taste perception in 
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patients whose intake was not already compromised by the disease. However, this would 
be assessed by longitudinal measurement of macro-nutrient intake. 
Protein intake and taste perception 
An inverse relationship was noted between salt taste perception and protein intake where 
patients with high salt threshold that is, a low sensitivity to salt, had a lower intake of 
protein. It is not clear as to whether the low protein intake resulted in a reduced ability to 
perceive salt taste. In an animal study by Ohara (1994), suppressed salt perception was 
associated with a protein deficiency state perhaps indicating that changes in taste with 
respect to salt in a cancer population is not due to undernutrition per se. 
Moreover, in this current study a significant number of patients who reported an increase in 
the bitter taste of certain food items such as meat and coffee had a lower protein intake 
when compared to patients who did not report any changes in bitter perception. A possible 
explanation is that patients with alterations in bitter perception consequently avoided foods 
with bitter compounds that are generally high protein foods such as meat. DeWys and 
Walters (1975) suggested that the correlation between meat aversion and lowered bitter 
threshold may be due to the amino acid, polypeptide or purine content of meat, compounds 
which in the pure form, have a bitter taste and hence in patients with heightened bitter 
thresholds may elicit an enhanced bitter sensation. Another explanation, suggested by 
Strohl (1993), is that the tumour may release circulating amino acids that have a bitter taste 
which stimulate a bitter perception. Subsequently, negative signals that are transmitted 
from the oral cavity when other bitter foods are eaten, may inhibit the appetite centre. If 
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this were the case then patients able to detect bitter taste would be expected to have a lower 
intake. However, this is not the case as patients are merely more selective in their food 
choice that may not significantly change their total energy or macro-nutrient intake. This 
study highlights that the alterations in taste perception have an impact on food selection 
that would impact on subsequent dietary intake. 
6.3.3 Impact of taste changes on food selection 
In this current study, changes in food selection, perhaps related to altered taste perception, 
' .. 
were widely reported by patients with advanced cancer. A general loss of taste was 
associated with change in the intake of a variety of foods that subjects had enjoyed prior to 
the onset of any taste aberrations. Increased sensitivity for sweet perception was reflected 
in the avoidance of sweet foods. In contrast, one patient found sweet foods more appealing 
and pleasant due to reduced sweet sensitivity. This is an important consideration with 
regard to the role that the enjoyment of food contributes to QOL in terminally ill patients. 
It may be difficult to evaluate the impact of alteration in gustatory function on nutrient 
intake without knowing the extent to which taste changes influence food selection. Trant 
and colleagues (1982) suggested that it might be tenuous to extrapolate from simple 
aqueous medium to complex food media. The link between taste thresholds and food 
selection have previously been disputed by Kamath and Booth (1983) where the authours 
highlighted that food selection was not solely dependant on taste perception. Other factors 
such as texture and aversions to food associated with periods of treatment play an 
important role in food choice of patients with advanced cancer. However, these patients 
189 
were not receiving active treatment and the impact of treatment associated food aversions 
were not investigated further in this population. However, in subsequent stages of this 
study, objective measures of taste perception provide a basis to measure the impact of any 
intervention. 
Alterations in food selection may have a secondary impact on the quantity of food 
consumed but it is beyond the scope of this current study to investigate how specific food 
items that are avoided contributed to the overall energy and macro-nutrient intake. These 
results have highlighted the potential impact that taste perception has on the selection of 
food items and the subsequent enjoyment of food as reported by these patients. 
Bitter taste perception and food selection 
Focusing on bitter taste perception is important as patients who reported changes in taste 
perception had significantly heightened sensitivity to bitter. However, approximately two 
thirds of taste changes reported by patients were specific to bitter perception and foods 
subsequently avoided were associated with bitter tasting foods. Ten patients reported the 
avoidance of food items characterised by bitterness that included; meat, tea, coffee and 
chocolate. Moreover, as highlighted in chapter 3, patients with advanced cancer 
demonstrated significantly lower thresholds for bitter taste, denoting heightened bitter taste 
perception compared to controls. The results of this current study are similar to that first 
published over 25 years ago by DeWys (1974) who noted an avoidance of meat products in 
almost one third of a heterogeneous cancer group. Likewise, Walsh and colleagues (1982) 
using a structured questionnaire found that almost half of patients who reported altered 
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taste perception, also reported aversions to meat. Similar foods such as meat and coffee 
are common targets of learned aversions in cancer patients (DeWys, 1974). Many of these 
studies do not control for the impact of treatment on taste perception and hence food 
selection. This current study uniquely highlights the impact of altered bitter taste 
perception, not attributed to chemotherapy or radiotherapy, on the food selection of a group 
of advanced cancer patients. 
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7.1 Introduction 
Null Hypothesis (6): There is no relationship between gustatory perception and blood 
cytokine concentration and gustatory perception. 
This chapter provides information regarding the plasma cytokine levels and associated 
! . 
acute response in a group of 37 patients with advanced cancer. Within this group, the 
association between cytokine response and taste perception was investigated. Plasma 
cytokine levels (TNFa, IL-1P and IL-6) were measured by ELISA technique. Albumin 
was measured by an automated bromocresol green dye binding technique. In addition, 
serum CRP used to denote the presence of an acute phase response was measured by a 
competitive binding immunoasay. 
7.2 Results 
7.2.1 Biochemical Analysis 
SerumCRP 
Used in conjunction with serum albwnin concentration, serum CRP denoted the presence 
of an inflammatory response. The mean albumin concentration of patients with cancer was 
within a normal range (28.7 ± 1.3 sem gil). An inflammatory response was indicated by an 
elevated CRP (> 1 Omg/l) in patients with albumin concentration within the normal range 
(Table 7.1). Nine patients with advanced cancer exhibited such a response. CRP analysis 
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perfonned on control patients indicated that all patients had a CRP < 10mgll (mean CRP 
5.4 ± 1.2 sem). 
Plasma Cytokine concentration 
Cytokine analysis was performed on samples obtained from the patients with advanced 
cancer. Plasma TNFa concentrations ranged from levels that were not detectable in assay 
(n=6) to a level of 42.38pg/ml. Mean values and ranges for all cytokines (IL-lP, IL-6, 
TNFa) are noted in table 7.1. Correlation analysis indicated a positive correlation of CRP 
with the cytokines, TNFa (r=0.59, p<0.05; Figure 7.1) and IL-6 (r=0.69, p<0.05 Figure 
7.2). In addition, TNFa correlated with IL-6 (r=0.74, p<0.05; Figure 7.3). Patients with 
an inflammatory response (n=9, CRP>lOgll) exhibited higher 1NFa levels (mean 27.6 
pglml ± 4.62 sem pg/ml) as compared to patients not mounting this response (mean 
9.62pg/ml ±.. 2.55sem pg/ml; p<0.05). 
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Table 7.1 Biochemical analysis of samples obtained from cancer patients 
Biochemical parameters 
Serum Serum Plasma Plasma Plasma 
CRP Albumin IL-IP IL-6 TNFa 
n 37 37 37 37 37 
Method Immunoassay Bromocresol ELISA ELISA ELISA 
green dye 
binding 
Unit mg/l gil pg/ml pglml pglml 
Mean 7.42 28.7 3.22 30.65 15.38 
±sem 2.2 1.3 1.07 5.34 2.72 
Range <1.5 - 17.4 25.1 -33.4 0*-28.5 0.5-114.8 0*-42.38 
* Not detectable in assay technique 
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7.2.2 Cytokines and dietary intake 
No correlation between the concentrations of the cytoki~es TNFa. and IL-l(3 with 
macronutrient intake were noted. However, in 23 cancer patients, plasma IL-6 
concentration showed a positive correlation with dietary fat intake (r=0.61, p<0.05; Figure 
7.4) In contrast, a negative correlation with carbohydrate intake and IL-6 was noted (r=-
0.53, p<O.05; Figure 7.5), indicating that increasing concentrations of IL-6 were noted in 
patients with highest dietary fat intake. 
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7.2.3 Cytokines and taste perception 
Association of the biochemical parameters and the 4 primary taste profiles of patients with 
cancer were assessed to investigate the association between biochemical parameters and 
taste aberrations. No associations were noted between the cytokines, IL-I~, IL-6 and any 
of the thresholds of the 4 tastes. 
An association was noted between objectively measured bitter taste thresholds and 1NFa. 
plasma concentration. Within the cancer group, patients with lower bitter taste thresholds 
(bitter sensitivity increased) had significantly higher plasma levels of TNFa. as compared 
to those patients with lower bitter taste sensitivity. In this study a high detection threshold 
was designated when an individual threshold of 4 was reached or not detected whereas a 
low threshold was designated as taste threshold concentrations 1,2 and 3. 
More specifically, for bitter detection, patients with a high threshold, that is, a low 
sensitivity to bitter had a mean 1NFa. concentration of 2.58± 1.85 sem pg/ml which was 
significantly lower (p<0.05) than patients who had a heightened sensitivity to the detection 
of bitter taste (l8.74± 3.42sem pg/ml). Similar results were seen for the recognition of 
bitter taste where the mean TNFa. concentration for patients with a high sensitivity to bitter 
(19.10 ± 5.4sem pg/ml) was significantly greater (p<0.05) than compared to patients with a 
low sensitivity to bitter recognition (11.32 ±3.4lsem pg/ml). Although not significant, 
plasma levels of IL-! ~ were higher in patients with heightened bitter sensitivity (Figures 
7.6 and 7.7). 
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In addition, the relationship between serum CRP and objectively measured taste perception 
was investigated. With regard to bitter taste, patients with heightened bitter sensitivity 
(low thresholds), had significantly higher serum CRP concentration (12.9± 1.58sem mgll) 
.. 
compared to patients with lower bitter sensitivity thresholds (5.44 ± 1.54sem mg/l). No 
differences were noted between the recognition of bitter taste perception. Analysis of the 
other tastes, namely, sweet, sour and salt revealed no association with cytokines or with 
the associated inflammatory response denoted by an elevated serum CRP. 
Based on the above information, the null hypothesis IS rejected and the following 
hypothesis is accepted: 
There is a relationship between heightened bitter taste perception and elevated levels of 
:t 
plasma cytokine, TNF a and production of the associated acute phase protein, CRP. 
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Table 7.2 Bitter detection and recognition thresholds and plasma TNFa. level 
Plasma TNFa. pglml 
mean + sem range 
Bitter Detection High Threshold n-ll 2.58 ± 1.85 0*- 15.31 
p<0.05 Low Threshold n=24 18.74 ± 3.24 1.18- 42.38 
Bitter Recognition High Threshold n 13 11.32 ± 3.41 0*- 30.62 
P<0.05 Low Threshold n=22 19.10 ± 5.4 0*- 42.38 
* Plasma levels not detected 
Table 7.3 Bitter detection and recognition thresholds and serum CRP level 
Serum CRP mgll 
mean + sem range 
Bitter Detection High Threshold n-ll 12.92 ± 1.58 8.1-17.4 
P<0.05 Low Threshold n=24 5.44 ± 1.54 <1.5 - 12.2 
Bitter Recognition High Threshold n-13 9.91 ± 1.57 <1.5 - 17.4 
NS Low Threshold n=22 6.52 ± 1.53 <1.5 - 12.2 
NS = Not significant 
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7.3 Discussion 
7.3.1 Cytokine production and associated acute phase response 
Cytokine levels ranged from not detectable in plasma to above normal elevated levels in 
the assay. Interestingly albumin concentration of cancer patients were within normal levels 
for a healthy population. With respect to CRP, this study has shown that one quarter of 
advanced cancer patients (9 out of 37) exhibited an elevated CRP (>IOmg/l) in the 
presence of normal albumin levels which is indicative of an ongoing inflammatory 
response. In addition, TNFa was correlated with CRP and IL-6 concentration. Likewise, an 
inflammatory response correlated with IL-6 concentrations. However, no such association 
was noted between IL-l p and CRP concentrations. 
These results support the association between cytokines and the inflammatory response 
denoted by elevated CRP. McMillan and colleagues in 1995 also suggested that the acute 
phase response was the basis of specific host immune response induced by the presence of 
a tumour. It is important to note that McMillan and colleagues designated a CRP 
concentration of >5mg/l as a marker of an acute phase response whereas, in this current 
study, a concentration of >10mg/l was used. Therefore, in this current study, the 
classification adopted by McMillan, although not commonly ~sed, would have resulted in a 
greater number of patients classified as having an inflammatory response. Fearon and 
colleagues (1994) suggested that changes in hepatic protein synthesis (increase in acute 
phase protein production) might be mediated by 11-6. It is important to note that TNFa. is 
a known mediator of IL-6 and subsequent CRP production. 
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The detection of TNFa in plasma has been controversial (Balkwill et ai, 1987). In this 
current study, in order to minmise errors in ELISA technique, samples were analysed in 
one batch. Blood letting was performed under the same conditions at the same time of the 
day. Standardisation of this technique therefore allowed co~parisons to be made within 
this current group of cancer patients. 
7.3.2 Cytokines and dietary intake 
Within the cancer group, a correlation was noted between plasma IL-6 concentrations and 
that of dietary fat and carbohydrate intake. Patients with elevated IL-6 concentrations 
demonstrated significantly higher fat intakes and lower carbohydrate intakes as compared 
to patients with lower plasma IL-6 concentrations. Although a correlation was noted 
between TNFa and IL-6, no association was noted between TNFa and any dietary intake. 
If!: ' 
, 
It is tempting to speculate that increased IL-6 may be caused by higher dietary fat intakes. 
The host cytokine response exhibited in this study requires arachidonic acid derived from 
dietary sources (Calder, 1996). With lower fat intakes, the percentage of carbohydrate 
intake may predominate and may subsequently attenuate IL-6 production, an important 
mediator of the inflammatory response. This is of particular interest as these results 
suggesting that cytokine production may influence dietary intake. These results also ' 
highlight the role that cytokines may play in taste perception associated with advanced 
malignancy. 
206 
7.3.3 Bitter taste perception and cytokine production 
The association between cytokine production, the associated inflammatory response and 
taste perception profiles were investigated. Patients who demonstrated an elevated lNFa 
were found to have increased ability to detect and recognise bitter taste. A similar 
association was noted between bitter detection thresholds ~d CRP. This suggests that 
patients with increased sensitivity to bitter had elevated lNFalevels. This was particularly 
important as patients with heightened bitter sensitivity noted changes in this taste modality. 
No association between cytokines and any of the other tastes namely, sweet, sour and salt 
were noted. 
These findings have not previously been noted in cancer patients. It is of great importance 
in light of the heightened bitter taste noted in the cancer patients and the impact of this 
phenomenon on dietary intake, food preferences and QOL highlighted in previous 
chapters. 
",.J 
These results suggest that higher plasma concentrations oflNFa may be responsible for an 
alteration in bitter taste perception noted in these cancer patients. In addition, the 
inflammatory response associated with lNFa has been associated with bitter taste 
aberration. There is recent electrophysiological evidence to suggest that cytokines may 
influence changes in the neurological pathways that mediate taste information. 
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7.3.4 Cytokines and neural pathways 
It has previously been demonstrated that cytokines modulate neural activity via the 
activation of vagal afferents. Much of the recent published evidence examining the causes 
of altered taste perception suggests that afferent neural pathways are sensitised. These 
connections project taste information into the brain stem from the taste receptor cells 
(Hermann et aI, 1983). Niijima and Meguid (1995) demonstrated that cytokines might 
activate gastro-intestinal afferents, thereby enhancing neuronal sensation by increasing the 
level of activity in nerves relaying information from peripheral nerve to brain. 
, 
The results highlighted in this chapter support recent evidence of the association between 
cytokine production, inflammatory response and altered taste perception. This may explain 
the change in bitter perception that is modulated at cellular level (Kinnamon and Getchell, 
1991). In a similar manner to visceral sensation, taste impulses reach the brain stem via the 
chorda tympani and are interpreted in the brain. Electrophysiological evidence from 
recordings taken from the tympani follOwing lipolysaccharide (LPS) administration, 
suggest that products of immune cells modulate peripheral gustatory system (Phillips and 
Hill, 1996). Injection of LPS in animals mimics the profile of the inflammatory response 
in man. It can therefore, be speculated that at this level, the; observed alterations in bitter 
taste may occur. 
Taste responses are often observed when blood concentrations are low and therefore a 
neuronal route mediated by cytokines in local tissue may explain the mechanism of action. 
This was reported by Goehler and colleagues (1995) who demonstrated induced taste 
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aversions and anorexia were reversed following subdiaphragmatic vagotomy in animal 
studies. Increased production of IL-l p was associated with an increased activity of vagal 
afferents. This work contributed further to the knowledge that cytokines are key 
messengers in the immune to brain signalling. IL-l p centrally mediated response effects 
are blocked by peripherally administered IL-l p antagonists, suggesting that there is a 
critical involvement of peripheral IL-l receptors. In addition, centrally mediated illness 
responses are blocked by vagotomy, suggesting that IL-lj3 directly or indirectly activate 
vagal afferents. The basis for the intervention study reported in the following chapter is 
based on the theory that an attenuation of the inflammatory response may influence bitter 
taste sensitivity and have a positive effect ~n food selection. 
I' 
" 
209 
8.1 Introduction 
8.1.1 Intervention with omega 3 fatty acids 
This chapter evaluates the impact of intervention aimed at minimising altered taste 
perception. The rationale for the use of this intervention is based on results highlighted in 
the previous chapters. The association between cytokine production, associated 
inflammatory response and alterations in bitter taste perception have been highlighted in 
chapter 7. 
Recent studies have demonstrated the use of anti-inflammatories and immunosuppressive 
mediators in regulating cytokine production (Tilg et aI, 1997): The use of pharmacological 
intervention in studies in the palliative care setting is limited due to ethical considerations. 
More appropriate intervention is based on novel nutritional substrates intervention aimed at 
ameliorating the acute phase response that may also have a positive effects on other 
nutritional symptoms associated with taste perception such as weight loss (Wigmore et aI, 
1996). 
It is established that dietary omega 3 fatty acids may modify inflammation (Sanders 1993). 
The inhibition of pro-inflammatory cytokines by omega 3 fatty acids may be a 
consequence of the direct inhibiting activity of the eicosano,ids namely, prostaglandins of 
the 3 series. One of the main precursors of the eicosanoid 3 series is arachidonic acid. It is 
thought that omega 3 fatty acids reduce arachidonic metabolites potentially involved in 
inflammatory processes resulting in the production of less active 2 series prostaglandins. 
Alternatively, the omega 3 fatty acid, eicosapentanoic acid EPA, may replace the 
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membrane uptake of arachidonic acid, competing for incorporation into leucocyte cell 
membrane. 
Considering the results to date and that of the pharmacological effects of omega 3 fatty 
.. 
acids inhibiting cytokine production, the following intervention study was conducted. To 
. date, no such intervention has been conducted within the hospice setting with patients with 
advanced cancer. 
8.1.2 Aims of the study 
The aims of this study are: 
i. To down-regulate the cytokine production and the associated inflammatory 
response. 
ii. To evaluate the effect of omega 3 fatty acid intervention on taste perception in 
patients with advanced cancer. 
iii. To evaluate the implementation of intervention in patients with advanced cancer in 
the hospice setting, acceptable to both staff and patients. 
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8.2 Methods 
8.2.1 Sample group 
Patients with advanced cancer were recruited from St.Columba's Hospice, Edinburgh. 
Previous studies that have used omega 3 fatty acid intervention indicate that 20 patients 
would allow analysis to 5% statistical significance (Wigmore et aI, 1996). Based on 
recruitment response reported in chapter 3, it was estimated that approximately 30 patients 
recruited would obtain 20 subjects for analysis, allowing a drop-out rate of 33%. 
More clinically stable patients were recruited at the discretion of the medical and nursing 
staff. In an attempt to characterise effects of omega 3 fatty acid supplements, outcome 
measures were compared to baseline. To assess any differences accountable to the 
intervention used, an appropriate control group would receive an iso-energetic quantity of 
fatty acids (placebo) without disturbing the ratio of n-3 to n-6 fatty acids present in their 
baseline. However, in palliative care, a placebo controlled study was considered 
unethical. 
Inclusion Criteria . 
i. Patients admitted to St.Columba's Hospice, Edinburgh with a diagnosis of cancer. 
No specific cancer types were excluded from the study. 
ii. Day Hospice patients. Ethical approval was obtained to allow the recruitment of 
. , 
, 
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patients from the Day Hospice centre to enable the generation of a wider sample 
population. 
Exclusion criteria 
i. Patients currently or six weeks after receiving chemotherapy, radiotherapy or drug 
treatment for oral candidiasis were excluded from the study as these treatments are 
known to have a significant effect on taste perception. 
Patients were free to discontinue their participation in the study at any time. In addition, 
the development of any adverse side-effects of the intervention excluded subjects from 
continuing in the study. Any subject whose condition deteriorated significantly or 
developed additional uncontrolled symptoms were also excluded. Throughout the study, 
information regarding the reasons for discontinuation were noted. 
8.2.2 Ethical issues 
Ethical approval was granted from the Medical and Oncology Ethics committee, Lothian 
Health Board, for this intervention study (Appendix 1). In addition to procedures outlined 
in chapter 2, approval was granted to: 
i. Administer a specific dose of omega 3 fatty acid intervention to a group of patients 
with advanced cancer. 
ii. Obtain blood samples solely for the purposes of research to allow the 
213 
accurate timing of blood letting according to the schedule of assessments. 
iii. Include Day Hospice patients. Patients who attended the Day hospice on a regular 
basis were considered for inclusion to the study. 
Informed consent was obtained from all patients before conducting any study related 
procedure (Appendix 3 and 4). Patients were given adequate verbal and written 
information about the nature and purpose of the study and the opportunity to ask questions. 
After having received study information, patients were allowed at least a 24 hour period, 
before consenting to participate. As outlined in the consent forms, subjects could not 
expect to derive any benefit from the intervention. 
8.2.3 Intervention 
Intervention focused on the use of omega 3 fatty acids. A highly concentrated marine fish 
oil in tryglyceride form, Pikasol, (Lube pIc., Denmark) in the form of O.5g capsules were 
provided. In fulfilment of the Medicines Act 1968, approval to conduct this research 
(clinical trials exemption certificate) was sought from the licensing authority (Medicine 
Controls Agency, Department of Health; Appendix 2). 
Description of intervention product 
Name: Pikasol® 
Composition: 65% long Chain fatty Acids 
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Other ingredients: 
Dosage: 
Manufacturer: 
of which 33% eicosapentanoic acid, 27% docosahexaenoic acid 
Vitamin A «1 J.U.! g n-3) 
Vitamin D «11.U. / g n-3) 
Vitamin E (4.4 I.U.! g n-3) 
6g ! day for 4 weeks 
Lube AlS pic., Denmark 
Pikasol @ (Lube pIc.) fish oil supplements, have previously been used in a number of 
clinical trials (Christensen et aI, 1996; Olsen et aI, 1992). More recently, Pikasol® has 
been used in a multi-center trial in pregnant women with pre-eclampsia, pregnancy induced 
hypertension, previous intrauterine growth retardation and chronic hypertension (Salvig et 
ai, 1996). 
Dosage 
Supplementation of 6g fish oil per day is considered non-toxic and not associated with any 
side-effects (Olsen et ai, 1992; Salvig et aI, 1996). However, as in the ingestion of any 
kind of oil, loose stools may be a consequence of ingestion. The dose of pikasol was 
achieved using the incremental method, that is, the daily dose gradually increased over the 
first week to the recommended dose as follows. 
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Day No. Capsules Consumed EPA 
1 2 (lg fish oil) O.33g 
2 4 (2g fish oil) O.66g 
3 6 (3g fish oil) O.99g 
4 8 (4g fish oil) 1.32g 
5 10 (5g fish oil) 1.65g 
6 onwards 12 (6g fish oil) 1.98g 
8.2.4 Intervention study outcomes 
The following assessments were made at baseline and following 4 weeks of 
supplementation. In a longitudinal study, where the influence of a disease or nutritional 
intervention in malnourished patients may lead to subtle changes in composition, accurate 
and precise measurements are required. Chapters 1 and 2 provide a fuller account of the 
use of the following assessment tools used in patients with in advanced cancer. 
Taste Perception 
Detection and recognition thresholds for the taste qualities of salt, sweet, sour and bitter 
were objectively determined for each patient using the International Standard for Sensory 
Appraisal. The repeatability of the measures of taste perception assessment has previously 
been addressed in chapter 2. In addition, patients were asked about their perception of 
taste sensitivity and of any changes that they have noticed during their illness. 
I;" 
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Assessment of body composition 
Nutritional assessment was performed on all subjects using upper arm anthropometry 
(skinfold thickness, arm muscle circumference), weight and hand-grip dynanometry. 
These tools have previously been used in longitudinal studies (Wigmore et ai, 1997). 
Measurements at baseline and following intervention were taken by the same trained 
observer to reduce any errors (Walker and Kindlen, 1988). 
QOL assessment 
In this study, the efficacy of intervention was measured by its ability to modify the 
subjective parameter, namely, QOL. The influence of sensory aberrations on QOL was 
assessed during a semi-structured interview technique. The semi-structured interview, 
based on the HAD scale, has been shown to accurately identify changes in QOL over time 
(Zigmund and Snaith, 1983). 
I," 
Blood Parameters 
Analysis was performed on blood samples taken from recruited subjects at baseline and 
following intervention. Plasma levels of cytokines (TNF ex, IL 1 P and IL6), serum CRP and 
serum albumin were assessed as described in chapter 2. Plasma levels of 00-3 fatty acids 
were measured after total lipid extraction by capillary gas chromatography to assess the 
amount of fatty acid uptake (Wilson et ai, 1992). Plasma fatty acid composition has been 
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shown to be good indicator of the habitual intake of dietary fat (Folsom et ai, 1995). In 
this study by Folsom and colleagues, fat intake measured using a food frequency 
questionnaire correlated with plasma fatty acid composition. 
Medical status 
Assessment of symptoms, drug regimens and any subsequent changes were reviewed and 
recorded at baseline and thereafter at weekly intervals or when significant changes 
occurred, until the end of the intervention period. 
Dietary intake 
A subjective assessment of food intake was constructed, based on a tool used to quantify 
food intake in longitudinal studies (Corlio et aI, 1992). This tool was designed to measure 
individual changes in dietary intake from baseline perception. Based on a visual analogue 
scale, patients choose one of five key words to describe their food intake as compared to 
normal (very little, little, normal, nothing, a lot). 'Normal' indicates no change compared 
to what was consumed before illness. In comparison, 'a lot' describes food intake that is 
superior to what was consumed before illness. Similar structured visual analogue scales 
have been used by Willcox and colleagues (1984) to measure subjective responses related 
to appetite, nausea and mood in patients with advanced cancer. 
218 
8.2.5 Schedule of assessments 
Study parameters were measured at baseline and following the intervention period (4 
weeks), using the following schematic representation of study procedures: 
Weeks 
Baseline 1 2 
Intervention Period 
Figure 1 Time Scale 
3 4 
Repeat 
Assessment 
During the Study, the following measurements were taken as follows: 
Baseline Week End of 
intervention 
Week 0 1 2 3 4 
Informed x 
Consent 
Demography x 
Medication x x x x x 
Check 
Medical Status x x x x x 
Compliance x x x x 
Diary Check x x x x 
(Day Hospice) 
Taste perception x x 
Blood Samples x x 
QOL x x i 
Anthropometry x x 
Dietary Intake x x 
Intervention Xl. x x X x z. 
I. Commenced following baseline assessments 
2. Stopped prior to assessment performed following intervention period 
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8.2.6. Compliance 
Throughout the study, monitoring of patient progress and compliance was required. On the 
ward, compliance was maximised by aclministering supplements as part of daily drug 
rounds (Appendix 9). At maximum dosage, patients received 12 x O.5g capsules either as 
3 capsules q.d.s or 4 capsules t.i.d. Two patients requested their prescription at mealtimes. 
Patients recruited from the Day Hospice were given diaries that highlighted the incremental 
dosage during the first week (Appendix 10). Subjects used this diary to record the number 
of capsules consumed daily, reasons for not meeting the required dosage if applicable and 
any side-effects observed. The diary was checked by the researcher weekly and any issues 
regarding compliance and any side effects recorded and discussed with the patient. 
Fortnightly supplies of supplements were given to the Day Hospice patients. 
Compliance of in-patients was effectively monitored by medical and nursing staff. Day 
hospice staff played an additional role in checking compliance during weekly visits. In 
addition, compliance was checked by measuring the plasma uptake of n-3 fatty acids and 
hence the incorporation of n-3 fatty acids in plasma cell membrane (total lipid extraction 
by capillary gas chromatography, Wilson et ai, 1992). 
To summarise, throughout the intervention period the following were monitored: 
1. Consumption of capsules. 
2 Side effects of consumption of fish oil capsules. 
3. Acceptability of dosage of supplements to subjects. 
4. Bowel habits. 
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5. Any possible reasons for non-compliance 
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8.3 Results 
8.3.1 Demographic data 
Twenty two patients (12 Male, 10 Female) with advanced cancer were recruited to the 
intervention study, representing 12% of all in-patient admissions within the 7 month 
recruitment period. Mean age was 76.5 ± 8.2sem (range 57-89) years. Table 8.1 highlights 
the primary diagnosis of patients of which more than half (54%, n 12) had diagnosed 
metastatic disease. 
Of the 22 enrolled patients, just over one quarter (n 6; 4 Male, 2 Female) completed the 
Supplementation trial (Table 8.2). The mean age of this sub-set of patients was 72 ± 
4.3sem (range 58-84) years. Of the six patients who completed the intervention trial, two 
were recruited from the Day Hospice. The demographic characteristics and reasons for 
non-completion of the remaining 16 patients are highlighted in table 8.3 
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Table 8.1 Primary diagnosis of cancer patients enrolled to the intervention study 
Primary Diagnosis Number of Patients n 22 % 
Lung 4 18 
Prostate 4 18 
Colon 3 14 
Rectwn 2 9 
Ovary 1 4 
Unknown 3 14 
Other 5 23 
Table S.2 Demographic characteristics of patients who completed the 
intervention study 
Patient Age Sex Diagnosis Metastatic Length of Reasons For 
Disease admission Admission to 
(days) Hospice 
-01 78 M Stomach Bone Day Hospice N/A 
02 61 M prostate 123 Continuing Care 
03 67 M Liver Bone 92 Continuing Care 
04 78 F Mengioma Day Hospice N/A 
05 84 F Ovarian 56 Symptom Control 
06 58 M Lung 36 Continuing Care 
223 
Table 8.3 Reasons for withdrawal from the intervention study following baseline 
assessment 
Age Sex Primary Metastatic 
Disease Diagnosis 
Reason: Clinical condition deteriorated 
89 F Unknown Lung 
88 M Prostate 
76 M Prostate Liver 
66 M Prostate Bone 
82 M Colon Liver 
68 M Unknown 
65 F Unknown Liver 
57 M Colon Liver, Bladder 
80 F Bronchus 
Reason: Too many supplements to take 
79 M Rectum 
87 F Ovary 
78 M Myeloma 
77 F Bronchus 
Reason: Patient changed their mind 
89 F Rectum Liver 
Reason: Supplement Aggravated Colostomy 
76 F Colon Brain 
Reason: Cataract Operation 
87 M Bronchus Liver 
Reason For 
Admission 
Pain Control 
Continuing Care 
Day Hospice 
Pain Control 
Respite 
Respite 
Continuing Care 
Continuing Care 
Pain Control 
Symptom Control 
Symptom Control 
Day Hospice 
Day Hospice 
Symptom Control 
Day Hospice 
Respite 
Withdrawn after baseline assessments performed 
Length of Stay 
(days) 
29 l. 
22 I. 
N/A t. 
11 1. 
14 1. 
55 I. 
53. 
21 3. 
9 1. 
28 2. 
21 2• 
N/A 2. 
N/A 3. 
14 I. 
N/A 1. 
32 days i. 
2 Took supplements for 7 days before withdrawing from study 
3 Took supplements for 14 days before withdrawing from study 
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8.3.2 Gustatory and olfactory perception profiles 
Baseline profiles 
Baseline assessment of taste perception was performed on all subjects (n 22) and compared 
with profiles of the age matched control group reported in chapter 3. A significant 
difference was noted between the cancer and control groups for bitter taste detection 
(p<O.05; Figure 8.1). Patients with advanced cancer had a significantly lower threshold for 
bitter detection compared to control subjects, indicating an increased ability to detect bitter 
taste perception. No other differences in taste detection and recognition profiles for sweet, 
salt and sour were noted between the cancer and control groups. 
Profiles following intervention 
Of the patients who completed the intervention period, comparisons were made between 
baseline assessments and post-supplementation taste profiles (Table 8.4). No pattern of 
changes of taste profiles were noted following supplementation. 
Likewise, objective assessment of olfactory perception revealed no difference in the 
number of odours identified following four weeks supplementation (table 8.5). 
j 
Subjective assessment of gustatory and olfactory perception 
However, patients noted changes in their taste perception as described below. 
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Patient 01: 78year old Male, Stomach Cancer with Bone metastases 
Prior to baseline assessments, a change in taste perception was reported for several weeks. 
Gustatory changes encompassed a blunting of sweet perception coupled with a blunting of 
olfactory perception. No changes in taste and smell perception were reported following 
supplementation. 
Patient 02: 61 year old Male, Prostate callcer 
Both a heightened bitter taste coupled with a blunting of taste perception was reported at 
baseline. Following supplementation, subjective experiences of bitter taste were less 
noticeable. This is in contrast to the objective measurement of bitter perception in which 
detection thresholds were lowered following supplementation, indicating a heightened 
bitter taste perception. 
Patient 03: 67 year old Male, liver cancer with Bone metastases 
At baseline, a blunting of taste perception was reported. This was not specific to any taste 
modality but was reported as a reduction of the pleasurable aspect of a variety of food 
items such as sweet foods and fruit. Following 4 weeks supplementation of omega 3 fatty 
acids, improvements in the blunting of taste was reported. No changes in olfactory 
perception were objectively and subjectively measured throughout the intervention period. 
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Patient 04: 78 year old Female, Meningioma 
A loss of taste perception, reported at baseline, was unchanged following supplementation. 
No changes of olfactory perception were noted throughout the study. 
Patient 05: 84 year old Female, Cervical cancer 
A slight blunting of taste perception reported at baseline remained following 4 weeks 
supplementation. This was coupled with a blunting of olfactory perception throughout the 
study period. 
Patient 06: 58 year Male, Lung cancer 
A blunting of taste perception and an increased sweet perception, first noticed at diagnosis 
was reported throughout the study period. 
In addition to alterations in taste perception, other symptoms experienced by subjects are 
summarised in the table 8. 
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Figure 8.1 Comparison of bitter perception profiles of cancer patients and control subjects 
Table 8.4 Taste perception profiles before and after 4 weeks supplementation 
with omega 3 fatty acids 
Taste Assessment Period Patient 
01 02 03 04 05 06 
Thresholds Value 
Sweet Detection Baseline 4 5 3 5 5 2 
Post Supplementation 1 4 1 5 5 2 
Change in threshold .l, .l, .l, N N N 
Sweet Recognition Baseline 4 5 4 5 5 3 
Post Supplementation 3 4 2 5 5 2 
Change in threshold .l, .l, .l, N N .l, 
Sour Detection Baseline 1 1 1 2 1 1 
Post Supplementation 4 3 2 1 2 2 
Change in threshold t t t .l, t t 
Sour Recognition Baseline 5 1 2 4 2 2 
Post Supplementation 5 3 3 2 4 3 
Change in threshold N t t -L. t t 
Salt Detection Baseline 1 2 4 1 4 3 
Post Supplementation 3 4 1 3 1 3 
Change in threshold t t .l, t .l, N 
Salt Recognition Baseline 4 2 4 4 4 4 
Post Supplementation 5 4 5 5 4 4 
Change in threshold t t t t N N 
Bitter Detection Baseline 3 1 4 4 5 3 
Post Supplementation 4 5 2 2 3 4 
Change in threshold t t .l, .l, .l, t 
Bitter Recognition Baseline 5 1 4 5 5 3 
Post Supplementation 4 5 4 5 5 4 
Change in threshold 
-L. t N N N t 
N= No Change in threshold following supplementation 
t = Increase in threshold following supplementation (decreased taste sensitivity) 
-L. = Decrease in threshold following supplementation (increased taste sensitivity) 
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Table 8.5 Olfactory perception at baseline and post-supplementation 
Patient Number of Odours Recognised (Total no. assessed - 10) 
Baseline Post-Supplementation 
01 5 5 
02 6 5 
03 5 4 
04 6 5 
05 7 6 
06 6 7 
230 
Table 8.6 Symptoms reported by subjects at baseline and post supplementation 
Oral and Gastrointestinal symptoms reported by patients 
Patient Baseline Post Supplementation 
01 Appetite loss Nausea 
Nausea Diarrhoea 
Constipation Dry Mouth 1 
Diarrhoea 
Dry mouth 
02 Appetite loss Appetite loss 
Nausea Dry Mouth 1 
Dry Mouth 
Pain 
03 Diarrhoea Diarrhoea 1 
Dry Mouth Dry Mouth I 
Nausea 
:~ ;. 
04 Dry Mouth Dry Mouth 2 
Pain 
Constipation 
05 Pain Dry Mouth 
06 Nausea Less Nausea 
Constipation Constipation 2 
Dry Mouth 
Increased intensity of symptom from baseline 
2 Decreased intensity of symptom from baseline 
,',-
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8.3.3 Impact of altered taste perception on QO~ 
Baseline assessment ofQOL 
A baseline assessment of the impact of altered taste perception on the QOL of patients was 
made in all patients who reported a change in chemosensory perception (n 18, 82%). The 
following responses mirror those obtained from the previous group of patients with 
advanced cancer reported in chapter 4. 
Of these 18 patients, one half of the group first observed altered taste perception at 
diagnosis and the remainder during the months before questioning. With regards to the 
impact on eating habits, sixteen patients (89%) reported that taste changes reduced the 
amount of food they consumed and five patients (27%) reported that the presence of 
altered taste perception, altered their selection of food ite~,s. Individual responses are 
."" 
highlighted below: 
"I eat because I know I must and that I need to .... /ike I take a walk because I know it is 
good for me " 
(Male, 78 years, Myeloma) 
The question 'Have the taste changes affected your general enjoyment of life?' was asked. 
Half of respondents (n 8) reported that taste changes had no effect on their enjoyment of 
life: 
"I have lost my taste and that is that ..... ! get enough enjoyment still out of my food". 
(Female, 85 yeru;s, Ovarian Cancer) 
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However, for the remaining patients, taste changes had a negative effect on everyday life. 
This was related to family concerns about a poor appetite and a general enjoyment of food. 
More than half of the respondents (n 15) reported that their taste changes affected those 
close to them. Nine patients associated weight loss with a lack of interest in their 
appearance. 
Impact a/taste changes on QOLfollowing intervention 
,. 
,.'. 
Patient 01: During the semi-structured interview, a reduced appetite was directly 
attributed to a change in taste perception. Despite feeling frequently hungry, the taste of 
food reduced the desire to eat. This phenomenon appeared to have an impact on the choice 
of food but no impact on the general enjoyment of life. Other aspects of everyday life 
remained unchanged as the patient continued to enjoy certain hobbies. However, a loss of 
appetite and a change in taste perception had become a major worry for the patients main 
carer who was involved in food preparation. 
Patient 02: Altered taste perception was reported as a symptom continuously 
I, 
experienced. From analysis of the semi-structured interview, altered taste perception 
affected food selection and was reported as having a negative impact on his enjoyment of 
life. Moreover, weight loss was reported as a negative impact on everyday life. 
Patient 03: Positive responses towards aspects of everyday life that included enjoying 
socialising and hobbies were noted. This did not change throughout the study period. 
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Patient 04: In general, positive responses to questions tegarding everyday life were 
noted at baseline and following intervention. 
Patient 05: Changes in taste perception were reported as a predominant symptom. A 
significant amount of weight loss during the illness had a distinct impact on everyday life: 
'I get a fright when I look in the mirror cause I've lost so much weight' 
Patient 06: A change in taste perception at baseline was reported as an important cause 
of reduced food intake and influencing food selection. This was reported as impinging on 
QOL. 
"They (family) ask if I am eating ... They worry that I don't eat and that I'm losing weight" 
(Female, 78year, Lung Cancer) 
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8.3.4. Anthropometric parameters 
Anthropometric changes following supplementation 
Anthropometric status was assessed at baseline and following the supplementation period 
using indices of upper arm anthropometry (TSF, AMC). Following supplementation, 
comparison with baseline measurements are shown in table 8.7. 
All six patients at baseline were weight losing which was present for at least several weeks 
during the later stages of their illness. However, following 4 weeks supplementation, an 
increased weight was noted in four patients (1-4kg) and one patient continued to lose 
weight but at a reduced rate (Figure 8.2). No measurement of weight was made in one 
bed-bound patient. In addition, changes in triceps skinfold thickness are shown in Figure 
8.3. 
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Table 8.7 Anthropometric changes following 4 weeks supplementation with 
omega 3 fatty acids 
Anthropometric Parameter Mean +sem Range 
Weight (kg) Baseline 63.4 7.3 46-88 
Post 64.8 7.3 47-90 
Supplementation 
Hand Grip Baseline 11.3 1.9 6-20 
(kg) 
Post 13.7 1.6 10-20 
Supplementation 
TSF(mm) Baseline 13.8 2.2 4.8-18.8 
Post 13.2 1.9 4.4-17.6 
Supplementation 
TSF* Baseline 88.8 15.5 68.6-109 
Post 79.3 15.3 63-103 
Supplementation 
AMC(mm) Baseline 22.0 0.8 18.7-24.2 
Post 21.8 1.5 16.9-26.9 
Supplementation 
AMC* Baseline 91.1 3.4 92.7-106.0 
Post 88.8 6.1 84-118 
Supplementation 
AMA(cm2) Baseline 386.5 27.7 279.2-464.7 
Post 388.6 52.7 228.4-573.9 
Supplementation 
AMA* Baseline 81.3 7.0 84.7-13.3 
Post 81.3 13.5 69-15.1 
Supplementation 
-. Expressed as a percentage of reference values (Lehmann et ai, 1991; Burr and Phillips, 
1993) 
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8.3.5 Impact of altered taste perception on food selection 
Patients were asked to describe their current dietary intake. The following question was 
asked 'How would you describe your usual food intake?'. Responses were categorised by 
patients into one of five categories (very little, little, normal, nothing, a lot; Table 8.8). 
Patient 01: At baseline, the negative impact of altered taste perception on appetite and 
food selection was reported. A loss of sweet perception noted at baseline was reflected in 
the avoidance of certain sweet tasting foods. Food intake was reported as less than usual 
throughout the study period. 
Patient 02: Dietary intake was, at baseline, described as less than usual but further 
decreased during the intervention period. At baseline, foods items such as potatoes and 
red meat were reported to have a bitter taste. This was coupled with a heightened bitter 
taste perception at baseline. 
Patient 03: A reduced appetite and altered food preferences were attributed to 
alterations in taste perception. At baseline, although little solid food was consumed, this 
was reported as more than usual intake. Dietary intake was reduced further following 
supplementation. 
Patient 04: No change in dietary intake was reported throughout the supplementation 
period. Altered taste perception appeared to have a greater impact on food selection 
although no foods were reported (table 8.8). 
238 
Patient 05: Altered taste perception appeared to have no impact on food selection. At 
baseline, dietary intake was described as less than usual which increased to more than 
usual following the supplementation period. This did not influence appetite or the 
enjoyment of food. 
Patient 06: Altered taste perception was reported as an important cause of a reduced 
appetite and influencing food selection. In the latter stages of the illness, patient 
experienced early satiety . 
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Table 8.8 Subjective description of dietary intake at baseline and post 
supplementation 
Patient Baseline Post Supplementation 
01 Less than usual Further Decrease 
Little solid food 
02 Less than usual Further Decrease 
Very Little of Anything 
03 More than usual Less than usual 
Little solid food Very little of anything 
04 Less than usual Unchanged 
05 Less than usual More than usual 
06 Less than usual Unchanged 
Little solid food 
.:1.' 
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8.3.6 Biochemical parameters " '. ~ 
The cytokines, ILl~, TNFa and IL-6 were measured in six patients at baseline and 
following four weeks supplementation with omega 3 fatty acids. Plasma levels ofTNFa in 
all six patients were found to be less than 15.6 pg/ml. The changes in IL1~ and IL-6 are 
shown in the table 8.9. Levels of IL-lP increased in three patients and decreased in the 
remaining three. Likewise, levels of IL-6 had decreased in only one patient but only 
slightly increased in four patients. 
Table 8.9 Changes in cytokine levels following supplementation 
Plasma IL-l ~ pglml Plasma IL-6 pglml 
Patient Baseline Post- Baseline Post-
Supplementation Supplementation 
01 41 43 11 32 
02 41 42 26 29.4 
03 80 46 27.5 27.5 
04 46 43 1.0 1.0 
05 56 53 26 ,.15.0 
06 46 48 20 33 
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8.3.7 Compliance 
Compliance was assessed by the plasma uptake and incorporation in the cell membrane. 
Following a four week supplementation period, plasma levels of EPA and DHA had 
increased and no pattern of change is noted with arachidonic acid in all patients (Table 
8.10). 
Table 8.10 Plasma fatty acid concentrations pre and post supplementation 
Plasma Concentrations % 
Patient Arachidonic Acid EPA DHA 
Pre Post Pre Post . Pre Post 
01 6.75 6.9 1.13 8.5 2.95 4.5 
02 5.94 6.98 0.58 4.67 1.3 3.58 
03 7.64 3.92 0.24 0.65 1.71 1.35 
04 2.43 3.39 0.74 2.62 0.91 2.57 
05 4.62 5.1 0.83 7.66 1.36 3.89 
06 5.96 5.91 0.38 2.84 1.6 2.84 
Pre = Baseline assessment 
Post = Post-Supplementation assessment 
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8.3.8 Medications taken by patients in the intervention group 
None of the medication regimens outlined below were known to influence taste perception. 
Medication regimens remained consistent throughout the patients participation in the 
study. .:; 
Patient Indication Medication 
1 Sedative Temazepam 
Diazepam 
Analgesic Morphine 
Naproxen 
Steroid Prednisolone 
2 Analgesic Morphine 
Sedative Temazepan 
Laxative Co-danthramer 
3 Analgesic Morphine 
Dic10fenac 
Anti-emetic , Metochlopramide 
Anti-diarrhoea Lomotil 
Sedative Temazepam 
Steroid Dexamethasone 
4 Analgesic Paracetamol 
Asthma Voltarol® (A&H) 
Becotide® (A&H) 
5 Diuretic Frusemide 
Anti-emetic Domperidone 
Analgesic Aspirin 
Ulcer-healing Ranitidine 
6 Analgesic Diamorphine 
Anti-depressant Amitryptilline 
Laxative Co-danthramer 
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8.3.9 Recruitment 
During the recruitment period, reasons for exclusion of patients were noted. 169 patients 
were admitted to the ward during the 5 month recruitment period. The mean length of stay 
was 21 days (range 1-123 days). More than one third of these patients were admitted for 
continuing care (37%), symptom control (30%), pain control (17%) and 16% for respite 
care. Within the Day Hospice, 30 patients attended during the recruitment period. 
The majority (96%) of the sample population (n 155) in-patients and 75% (n 24) Day 
Hospice attendees were excluded from the study. For in-patients, this represented a mean 
hospice stay of 18 days. The main reasons for exclusion from the study are highlighted in 
tables 8.11 and 8.12. 
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Table 8.11 Reasons for exclusion of in-patients from the intervention study 
Reason For Exclusion n % 
Poor prognosis 51 33 
Uncontrolled symptoms 32 21 
Swallowing problems 13 8 
Dementia / Confusion 9 6 
Distressed patients 9 6 
Not eating 7 4 
Nystatin treatment 6 4 
Short admission (no study follow up possible: not Day 6 4 
Hospice or Home Care) 
Hepatitis B / C positive 6 4 
Recent chemotherapy / radiotherapy 5 3 
Previous subject in first stage 5 3 
Non malignancy 3 2 
Receiving nutritional support (gastrostomy) 2 1 
Language barrier 1 1 
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Table 8.12 Reasons for exclusion of Day Hospice patients from the 
intervention study 
Reasons For Exclusion Number of Patients Percentage 
Distressed patient 9 38 
Recent treatment 6 25 
Poor prognosis 5 21 
Colostomy 3 12 
Hepatitis B positive 1 4 
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8.4. Discussion 
8.4.1 Baseline measurement of taste perception 
The results obtained at baseline of 22 patients with advanced cancer support the evidence 
that heightened bitter taste perceptions are experienced by patients with advanced cancer. 
This is consistent with the results of the cross-sectional study that suggested that the 
changes are not related to treatment. Differences in bitter detection perception were noted 
in which patients with cancer had heightened bitter detection perception compared to 
control subjects. No other differences in the detection and recognition of the other 
thresholds were noted. 
Of these 22 patients, 82% of respondents reported an alteration in their taste perception. 
This group of patients may have a higher prevalence of altered taste perception as they 
consented to participating in a research study that had the potential to provide benefit for a 
symptom that they were experiencing. 
Subjective information regarding the impact of altered taste perception on QOL and food 
choice reflected results of the first stage of investigation where patients with altered bitter 
taste perception reported the avoidance of bitter tasting foods such as coffee and red meat. 
A change in taste perception of a certain food item resulted in the reduced intake that was 
not substituted by another item. Although dietary intake was not quantified, this would 
have a negative impact on overall dietary intake and hence nutritional status. The results of 
this current study emphases the need to develop individualised approaches to the dietary 
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management of patients who experience alterations in their taste perception. For example, 
the meal menu of patients may be tailored to suit alterations in taste perception. 
No consistent pattern with medication regimens and taste perception profiles were noted. 
Concerning nutritional symptoms, the severity and duration of these symptoms varied 
throughout the study period. The exact impact of pharmaceutical regimens on taste 
perception may be difficult to control that highlights inherent difficulty of conducting 
research within a dynamic group of patients in a longitudinal study. 
8.4.2 Effects of omega 3 fatty acid intervention 
In this current study, patients acted as their own controls, as comparisons were made 
between baseline and post supplementation parameters. Changes in reported taste 
perception were noted following intervention where two of six patients reported an 
improvement in their taste perception. One patient reported a heightened bitter taste at 
baseline that was less noticeable following supplementation. This was reflected in the 
objective measurement of bitter thresholds in which bitter perception was detected and 
recognised at a lower concentration at baseline compared to following intervention. This 
suggests that objectively measured profiles reflected actual changes in this patient's 
perception of bitter. 
Following 4 weeks supplementation, the most remarkable change in nutritional status was 
that four out of five patients gained weight and only 1 patient lost weight. These results 
are very encouraging, considering all patients were weight losing at baseline and warrants 
further investigations. Although oedema was not evident in the group of patients, a change 
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in weight may reflect a shift in fluid balance that would disrupt weight patterns. Looking 
more closely at this weight maintenance, no changes in upper arm anthropometry were 
noted. Similar results have been demonstrated by Wigmore and colleagues (1996) in a 
group of patients whose weight was maintained over a 3 month period following omega 3 
fatty acid supplementation. Likewise, patients studied by Wigmore and colleagues were 
weight losing (2.9kglmonth) at baseline. Our current results support the evidence that 
omega 3 fatty acids play an important role in the attenuation of weight loss associated with 
an acute phase response. 
In healthy human studies the consumption of dietary fat supplements constitutes only a 
small amount of total energy intake. Whereas, in patients with reduced dietary intakes 
associated with advanced cancer, dietary fat supplements may contribute significantly to 
the total energy intake. However, this contribution to dietary intake may not attenuate the 
weight loss in patients with an acute phase response and an elevation of pro-inflammatory 
cytokines. 
8.4.3 Intervention: compliance and effects 
The analysis of plasma cytokines highlights interesting findings where following 
intervention, no changes in plasma TNFa levels were found. In only one patient, plasma 
levels of IL-l and 11-6 were lowered following supplementation and remained elevated in 
other patients. It must be considered that continuous changes in cytokine levels attributed 
to an advanced stage of disease, may be masked by changes attributed to the effects of the 
intervention study. Measures could not be taken to control for these possible changes. It 
249 
would be interesting to examine the cytokine levels over a longer period. This would 
provide an indication of the changes in cytokine levels reflective of a dynamic disease 
process. 
The analysis of plasma cytokines raises two important questions, firstly, whether 
compliance to the omega 3 fatty acid supplements was adhered to. Secondly, these 
findings prompt us to examine the mechanisms of fatty:' acid uptake in the plasma 
membrane of patients with advanced cancer. 
With regard to compliance, procedures were taken to ensure patient compliance was 
maximised without compromising QOL. The number of fish oil capsules taken was 
assessed on a weekly basis and Day Hospice patients completed a diary of supplements 
consumed. For in-patients, capsules were prescribed during routine drug rounds and 
monitored by staff on drug prescription forms. This approach proved non-invasive in 
checking compliance. In addition, compliance was measured by the plasma lipid profiles. 
This also serves as an indicator of the mechanism of fatty acid uptake in cancer patients. 
, , ~ 
Results of fatty acid profiles indicated an alteration in plasma fatty acid profiles following 
4 weeks intervention. Unfortunately, a wash-out period to allow plasma levels to return to 
baseline was not feasible due to changing medical condition of patients. However, in 
future studies, the inclusion of a wash-out period would be an area of interest, measurable 
in patients with greater prognosis. In addition, these results suggest that the mechanisms of 
fatty acid uptake appeared to be unaltered in this group of patients. 
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The mechanism underlying the suppression of the synthesis of IL-IP and TNFa after 
dietary supplementation of omega 3 fatty acids remains inconclusive. A change in 
arachidonic acid metabolites may explain in part the reduced production of these cytokines 
(Endres, 1989). Endres and colleagues (1995) noted that after six weeks supplementation 
of I8g fish oil, ILIP was reduced by 43%. This was indeed a larger supplementation dose 
and for a longer period compared to in this current study. In addition, cytokine levels were 
measured by the production of mononuclear cells stimulated with endotoxin. It was 
beyond the scope of this study to measure the in vivo cytokine production and to 
implement such large doses of fish oil. 
8.4.4 Recruitment 
It should be emphasised that this was the first nutritional intervention study to be 
undertaken in the hospice. Although recruitment in the first stage was on target, the 
expected numbers of patients recruited was not achieved. The reasons for this include that 
some patients withdrew due to the number of capsules and this group of patients were 
characterised by multiple symptoms associated with their progressive disease. Within the 
period of four weeks, subjects condition deteriorated or changed and hence excluded 
patients from continuing in the study~ The difficulties in predicting prognosis resulted in 
fewer patients completing the assessments. In addition, inherent symptoms associated with 
certain tumour types such as strictures or dysphasia in oral or oesophageal cancers, or 
symptoms associated with metastatic disease such as· confusion excluded patients from 
participating in an intervention study. Constraints in this longitudinal study were 
highlighted from the tracking of reasons for exclusion throughout the study. 
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Concerning the recruitment of patients, D~y Hospice patients had fewer symptoms such as 
nausea and diarrhoea that would exclude them from the study.: However, these patients had 
often received recent palliative chemotherapy or radiotherapy that was an exclusion 
criteria. The longitudinal nature of the study itself posed greater problems as compared to 
the previous cross-sectional study. These findings themselves are most interesting in 
relation to conducting research in the terminally ill. Recruitment and retention of subjects 
was highlighted as a frustrating and demanding aspect in palliative care research. 
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9.1 Summary 
To summarise, the current findings provide substantive evidence to suggest that changes in 
taste perception occur in patients with advanced cancer who have not received any recent 
palliative chemotherapy or radiotherapy. These findings indicate a specific change in bitter 
perception rather than a general alteration in taste perception and is important firstly for 
meal production and product development. Moreover, changes in olfactory perception 
appear to accompany changes in taste perception. Perhaps bitter taste perception, 
associated with changes in dietary intake and nutritional status, may be used as a marker 
for nutritional assessment in patients with advanced cancer. Despite the heterogeneous 
nature of this group, patients with cancer had a lower threshold for the detection of salt and 
sour. In particular the recognition and detection thresholds of bitter was lower, indicating 
heightened bitter perception compared to control subjects. This suggests that the changes in 
taste sensitivity may be a natural phenomenon of the progression of the disease. 
These results have important clinical implications that contribute to the understanding of 
the role that taste perception plays in the QOL of the terminally ill. The psycho-social 
relationship between taste perception, dietary intake and weight loss highlights altered taste 
perception as an important dimension in QOL of patients with advanced cancer. QOL is 
therefore an important outcome measurement in any intervention aiming to improve taste 
perception. 
In this study, patients with advanced cancer illustrated a group nutritionally 'at risk'. This 
is clearly demonstrated by inadequate energy and macronutrient intakes and low body 
composition parameters found in the study population. The results highlight the impact 
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that altered taste perception plays in the food selection and subsequent dietary intake of 
these patients. 
More importantly, these results suggest that cytokines may be implicated in the alteration 
of bitter taste perception. The association between plasma cytokine (TNFa) production, 
serum CRP concentration and altered bitter taste perception has been demonstrated. TNFa 
, 
and ILl P are known to act on the hypothalamus pituitary adrenal axis in addition to 
peripheral action (Sherry and Cerami, 1988). Intervention aimed at altering the production 
of TNFa and the associated CRP production may have an impact on taste perception. 
However, intervention using omega 3 fatty acids, in this study did not demonstrate any 
alteration in cytokines TNPa and JL-I f3 concentration. However, in light of the changes in 
weight following the 4 weeks intervention period, the use of omega 3 fatty acids is very 
encouraging. In addition, the uptake of fatty acids in this group of patients highlight that 
the approach adopted successfully achieved compliance in patients receiving palliative 
care. 
It is important to note that, the study procedures proved to be acceptable to patients and 
staff. This is the first study of its kind within the hospice setting and highlights the non-
invasive approach taken to maintain the QOL of patients with terminal disease whilst 
obtaining accurate and reliable information. Patients, when asked at the end of the study, 
expressed an interest in contributing to this research. The feasibility of involving patients 
with advanced cancer in research without compromising patient autonomy is highlighted in 
this study. 
9.2 Conclusions 
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The overall picture emerging is that independent of chemotherapy and radiotherapy, 
alterations in taste perception occur due to mechanisms associated with the disease process. 
More importantly, the results highlight the impact that altered taste perception have on 
QOL, dietary intake and food selection of patients with terminal malignant disease. Within 
this group, the clinical impact in terms of food choice, dietary intake and QOL has been 
established. 
For the appropriate management of changes in taste perception, these results suggest that 
attention must also be paid to the heightened olfactory perception that patients experience. 
This may have implications in the selection of foods to minimise any negative impact that 
foods odours have on taste perception. 
9.3 Further Considerations 
This study specifically considered the influence of taste perception in a group of patients 
with advanced stage of malignant disease. However, due to time and financial constraints 
it was beyond the scope of this current study to examine the influence of specific tumour 
types on the degree of taste aberrations and associated weight loss. This would perhaps 
require a longer assessment period and the possibility of a multi-centered study. 
Concerning this cancer group, the onset of taste changes were reported throughout all 
stages of the illness. This suggests that further investigations into the prevalence of altered 
taste perception may be conducted at an earlier stage of disease to increase retention of 
patients in the study. Such investigations may be appropriate in patients following 
diagnosis. However, when conducting an assessment of taste perception, periods of active 
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treatment may impinge on findings and not therefore facilitate such investigations. 
Many lessons in conducting clinical research within the hospice setting are derived from 
this study. Changes in patients medical condition during the study period and the mode of 
intervention used in this study limited the recruitment and retention of patients. The way 
forward for a study of this nature are clearly twofold: firstly, in order to allow adequate 
recruitment of subjects, a multi-centre trial is required. Secondly the mode of intervention 
needs to be modified to ease compliance of the consumption of the required amount of 
omega 3 fatty acids. Patients were excluded due to swallowing problems and in addition, 
some patients were unwiIIing to consume the required number of capsules daily. One 
possible alternative is to use fish oil supplementation incorporated into food items. 
Alternatively, a pure source of EPA may necessitate a reduced number of capsules and may 
therefore constitute a more suitable mode of intervention. 
In view of the paucity of the data during the intervention study, further studies are required. 
The findings from this current study may be used in the pJanning and design of future 
studies in this area. This intervention study is considered as a pilot study highlighting 
important considerations concerning the implementation of such intervention in the 
terminally ill patients. 
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13 March 1995 
Miss R Pattison 
Department of Dietetics and Nutrition 
Queen Margaret College 
Clerwood Terrace 
EDINBURGH 
EH12 8TS 
Dear Miss Pattison 
RESEARCH APPLICATION - ALTERATION IN TASTE SENSITIVITY AND ITS 
RELATIONSHIP WITH NUTRITIONAL STATUS IN MALIGNANT DISEASE 
Further to your application, I have great pleasure informing 
you that ethical approval for the above project has been 
granted. 
As in accordance with all research projects, a yearly progress 
report is required. 
I would like to wish you success in your study. 
Yours faithfully 
Linda Semple 
Secretary, Medicine and Clinical Oncology, 
Research Ethics Sub-Committee 
DEACONESS HOUSE !l306 9307 
148 PLEASANce EDINBURGH EHS 9RS 
'ACH"Il[: OUl 536 
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20 February 1997 
Miss R Pattison 
Department of Dietetics and Nutrition 
Queen Margaret College 
Clerwood Terrace 
EDINBURGH 
EH12 BTS 
Dear :Miss Pattison. 
RESEARCH APPLICATION - ALTERATION IN TASTE SENSITIVITY AND 
ITS RELATIONSHIP WITH NUTRITIONAL STATUS IN MALIGNANT 
DISEASE 
I have been asked to comment and give management approval on your proposed 
research with regard to the impact on current primary care services. 
Having read your research application I am writing to . confirm that I have no 
reservations. This management approval is given subject also to ethical approval 
haviIig been granted. 
I hope your research will ultimately improve the outcome for the care of patients with 
malignant disease. 
Yours sincerely 
.~. 
12 DR PHILIP RU~LEDGE 
Senior Medical Adviser 
cc Linda Semple, Secretary, Medicine and Clinical Oncology, 
Research Ethics Sub-Committee 
DEACON ESS HOUSE 
!l306 9307 
148 PLEASANCE EDINBURGH EH8 'RS 
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Deparlmenl of IlcalLh 
NIEDICINES CO.NTROL AGENCY 
. Markel Towers 1 Nine Elms L:uw Lonuon SWK 5NQ· 
Telep/zolle 0171-273 0328 
Facsimile 0171-273 0443 
Dr T F. Benton 
Medical Director 
St Columba's Hospice 
Boswell Road 
Edinburgh EH53RW 
Dear Dr Benton 
OUf Ref: MF 800017256 
20 December 1996 
THE MEDICINES (EXEMPTION FROM LICENCES) (SPECIAL CASES AND 
MISCELLANEOUS PROVISIONS) ORDER 1972 . 
PRODUCT: Pikasol 
I am writing in connection \vith your notification under the Medicines (Exemption irom 
Licences) (Special Cases and ~v'lisceJlaneous Provisions) Order J 972 which relates to a 
proposed trial using Pikasol supplied by Lube AlS. . 
The Licensing AUlhority does not propose to issue a direction under Article 4(2)(v) of the 
above order in this case. The above named supplier may therefore supply the product for 
the purpose outlined in your notification without a marketing authorisation or clinical trial 
certificate being required. 
This exemption is conditional on your agreement that all serious or unexpected adverse 
reactions occurring during the course of the trial will be notified to the Licensing 
Authority at the earliest opportunity. 
Your attention is drawn to the fact that your notification to the Licensing Authority under . 
the above Order (ie 1972/1200) was not accompanied by the detailed and extensive data 
which is required to support a marketing authorisation or a clinical trial certificate. lL must 
. therefore he emphasised that the Licensing Authority has not positively assessed the 
product for s:.~fety, quality or efficacy. 
You may wish to ensure that the hospital, or other appropriate, Ethics COllunittee is aware 
of the limitations of the Licensing Authority'S approval of this trial. 
We shall be pleased to see a copy of allY report which is produced as a result of this trial. 
Yours sincerely 
-hitLlt4A 
Tina Hankin 
Clinical Trials Unit 
APPENDIX 3 
DEPARTMENT OF DIETETICS AND NUTRITION 
PATIENT INFORMATION 
We are examining the how taste can influence what you eat and how it affects 
your everyday life. In order to carry out this study we will need to find out some 
information about yourself. The study will be in 3 parts: 
• Questions about you usual food intake, your appetite and any recent changes in 
your weight 
• The following measurement will be carried: 
Height and Weight 
Measurement of the thickness of your skin and muscle using calipers 
A small painless measurement of your body composition 
Blood and urine measurement of various proteins (this will involve taking 
any extra blood) 
• Tasting 
You will be asked to taste several samples of solutions which are mildly sweet, 
sour. Salty and bitter and to identify 10 well known odours. All the samples are 
perfectly safe and are components of what you would consume in your everyday 
diet. The time taken assessing taste and smell is likely to be about 30 minutes each 
day for 5 days. 
If you agree to take part in this study, you are under no obligation to complete 
tests or the questions. You are therefore free to withdraw from the study at any 
time. This study will on no way effect your other medical treatment. Your help is 
much appreciated. 
For Further Information: 
Ruth Pattison 
Research Dietitian 
St.Columba's Hospice 
Edinburgh 
Queen Margaret College 
Edinburgh 
Nutrition and Taste Study 
Patient Information 
You may have recently noticed changes in the taste of food. We 
are hoping to look at taste changes, how this may affect your food 
choice and also to investigate how well-nourished people are when 
they come into St. Columba's. 
What will you be expected to do? 
In order to carry out this study we will need to find out some 
information about yourself. This study will be conducted over a 
period of 6 weeks. The time taken will be kept to a minimum to 
prevent you becoming overtired. 
1. Questions about the changes in the taste of food that you have 
noticed and other factors that may affect your appetite (15-20 
minutes). 
2. The following simple measurements, which take a few minutes 
will be performed: 
• Measurement of the thickness of your skin and muscle using 
calipers 
• Blood and urine measurement of various proteins (this will 
involve taking extra blood) . 
• He!ght and Weight 
3. Tasting - You will be asked to taste several samples of solutions 
which are mildly sweet, sour, salty and bitter and to identify 10 
well known odours. All the samples are perfectly safe. The time 
taken assessing taste and smell is likely to take about 30 minutes. 
You will then be asked to take 6g fish oil capsules per day for a 
period of 4 weeks. This will be in the form of 12 capsules (0.5g). 
The above measurements will then be repeated once again. 
If you agree to take part in this study, you are under no obligation 
to complete tests or questions. You are therefore free to withdraw 
from the study at any time. This study will in no way effect your 
other medical treatment. Your help is much appreciated. 
APPENDIX 4 
CONSENT FORM 
ASSESSMENT OF TASTE AND NUTRITIONAL STATUS 
* If you agree to take part in this study, you are under no obligation to complete 
either the tests or the questions. You are therefore free to withdraw from the 
study at any time. This study will in no way affect your other medical treatments. 
* All information is confidential. I would like to thank you very much for your co-
operation with this study. Please do not hesitate to contact me if you have any 
queries at any stage. 
* As a matter of routine, I must ask you to sign this consent form. 
* I ....................................................... agree to take part in this nutritional study and I 
understand that I may withdraw my consent at any time. 
* The researcher, Ruth Pattison, has explained the procedures for taste detection 
and nutritional assessment. I understand the procedures and have had an 
opportunity to ask questions about my participation. 
* I agree for notice to be sent to my General Practitioner and my Hospital 
Consultant about my participation in this study. 
* I agree to the provision of any clinically significant information to my General 
Practitioner and Hospital Consultant. 
* I understand that this is non-therapeutic research from which I cannot expect to 
derive any benefit. 
Signature of Patient ............................................... . 
Signature of Investigator ......................................... . 
Date ...................................... . 
APPENDIX 5 
Abbreviated Mental Test 
1. Can you tell me your age? Correct / Incorrect 
2. Can you tell me what time of the day it is? Correct / Incorrect 
Address Recall: 42 West Street 
3. Can you tell me what year this is? Correct / Incorrect 
4. Can you tell me your address? Correct / Incorrect 
5. Can you recognise these two people? Correct / Incorrect 
6. Can you tell me your date of birth? Correct / Incorrect 
7. Can you tell me the name of our present monarch Correct / Incorrect 
B. Can you tell me when the first world war began Correct / Incorrect 
9. Can you count backward from 20 to 1? Correct / Incorrect 
10. Can you remember the address given earlier Correct / Incorrect 
APPENDIX 6 
Quality of Life Questionnaire 
Date ............................... .. 
This questionnaire must only be used by the researcher, it is not suitable for the 
subjects to complete independently. 
Name ................................................. . Project Number ........................... . 
D· . lagnosls ............................................. . 
Have you noticed any changes in the taste of food or drink? Yes / No 
Have you noticed any changes in the smell of food or drink? Yes / No 
When did you first notice taste changes? 
At Diagnosis Chemotherap Radiotherapy Sore Mouth 
y 
1 2 3 4 
Are your taste changes consistent? 
Weeks ago 
5 
At time more At times less Continuous Getting better Getting worse 
noticeable noticeable 
1 2 345 
Before your illness, how would you have described your appetite? 
Enjoyed 
eating 
everything 
1 
Enjoyed 
eating most 
things 
2 
Ate because 
you had to 
3 
Fussy eater Ate very little 
4 5 
Have the taste changes affected your eating habits? 
Eat More Eat less Eat different Eat at different 
foods times of the 
day 
1 2 3 4 
Do you sometimes feel hungry but the taste puts you off? 
All of the time Frequently Occasionally No 
1 2 3 4 
Have the taste changes affected your general enjoyment of life? 
Had a Quiet alot A little No change 
significant 
negative effect 
1 2 3 4 
Do you ever feel too tired to eat? 
All of the time Often Occasionally Never 
1 2 3 4 
Has your illness affected the interest you take in your appearance? 
Yes, I don't Yes, I rarely No, but I No, just the 
want to see take an should try same 
myself interest harder 
1 2 3 4 
No Change 
5 
Never feel 
hungry 
5 
Improved 
5 
Less tired than 
before 
5 
Take more 
care then 
before 
5 
Have the taste changes affected those close to you? 
Yes, it has Yes, it has Occasionnally No No close 
become a caused friction it has been relationships 
major worry noticed 
1 2 3 4 5 
Now some more general questions about your present quality of life. 
How often nowadays do you sacialise with friends and / or family? 
Frequently Rarel, I am not Rarely, I am nt Never, I have 
up to it a very saciable lost interest in 
person being sociable 
1 2 3 4 
Never, sadly I 
find it too 
exhausting 
5 
How often have you spoken on the phone recently with friends and / or family? 
Frequently Rarely, I am Rarely, I never Never, I sadly Never, don't 
not up to it did use the have lost have a phone 
phone much interest 
1 2 3 4 5 
Do you enjoy watching TV, or reading a newspaper? 
Frequently Some days I Rarely, I Rarely, I never No 
do and some cannot did 
days I don't concentrate 
1 2 3 4 5 
Do you have a hobby? Yes / No Do you still enjoy it? 
Yes, this has Some days I Rarely, I No, I have not No hobby 
notcahnged do and some cannot the energy 
days I don't concentrate 
1 2 3 4 5 
Do you ever feel tense and nervous? 
Most of the Quite often Only when I Very rarely Never 
time go to the 
doctors or the 
hospital 
1 2 3 4 5 
APPENDIX 7 
PATIENT NO. ......... ..................... DATE ............................. . 
NAME 
SEX M (1) F (2) 
D.O.B. 
AGE 
ADMISSION DATE 
REASON FOR ADMISSION 
DIAGNOSIS 
METASTATIC DISEASE 
RELEVANT DRUG TREATMENT 
REGULAR AS REQUIRED 
PATIENT NO. ••••••••••••••••••••.••••••••• I>~1r~ •••••••••••••••••••••••••••••• 
DEMISP AN (cm) HEIGHT(m) 
WEIGHT (kg) DEMIQUET (M) 
MINDEX(F) 
RECENT WEIGHT HANDGRIP (kg) 
LOSS (kg) 
AC (cm) 
TSF(mm) %TSF 
AMC(mm) %AMC 
AMA(mm) %AMA 
Resistance LBM (kg) 
Reactance TBF (kg) 
TBW (1) 
BCM(kg) 
PATIENT NO. .............................. DATE 
Have you noticed that food / drink tastes different since you became ill? 
If yes, do you find that food tastes more sweet 
less sweet 
more salty 
less salty 
more sour 
less sour 
more bitter 
less bitter 
just tasteless 
Name any foods that in particular you either: 
enjoy more: 
enjoy less: 
Do you take any supplements eg Complan, Build-up, Vitamins? 
How would you describe your appetite recently? 
PATIENT NO. .............................. DATE 
Food Intake 
As compared to your normal intake during the past month, food intake has: 
Unchanged, 
More than usual 
Less than usual 
Food intake now: 
Symptoms 
Little solid food 
Only liquid 
Very little of anything 
Normal 
Any of the following problems that have kept you from eating: 
No problems eating 
No appetite, just do not feel like eating 
Nausea 
Constipation 
Mouth sores 
Vomiting 
Diarrhoea 
Dry mouth 
Pain 
APPENDIX 8 
PATIENT NO. ••••••.••••.•.•.•..•••.•..•••• IJ~1r~ ••••••••.•••••.•••..••••••••.• 
SOLUTIONS r t 2nd 
SOLUTION CODE At A2 
ANSWER 
SOLUTION CODE Bl B2 
ANSWER 
SOLUTION CODE Ct C2 
ANSWER 
SOLUTION CODE Dl D2 
ANSWER 
Last Meal/Snack ........................................... 
o = TASTELESS 
X = TASTELESS DETECTED 
XX= TASTE RECOGNISED 
3rd 
A3 
B3 
C3 
D3 
XXX = DIFFERENCES OF CONCENTRATION RECOGNITION 
4th 
A4 
B4 
C4 
D4 
PATIENT NO. .............................. DATE . ............................ . 
BOTTLE NO. ODOUR IDENTITY 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
APPENDIX 9 
PIKASOL CLINICAL TRIAL 
PRESCRIPTION 
Patient Name: ••••••••••••••••••••••••••••••••••••••••••••••••••••••• e 
Address: ........................................................ 
Please Dispense: 
Pikasol Capsules ............. Capsules ........... times a day for 4 weeks 
Prescribers Signature ........................................................ 
Date 
APPENDIX 10 
NUTRITION AND TASTE STUDY 
We would be grateful if you would complete this daily diary to record the 
number of capsules taken daily and any side-effects. 
PATIENT NAME ............................................................. . 
WEEK BEGINNING .......•......................•..............•...... 
For information, please contact: 
Ruth Pattison 
Research Dietitian 
St.Columba's Hospice 
DAY NO. CAPSULES TO BE TAKEN NO. CAPSULES TAKEN TO-DAY ANY SIDE -EFFECTS 
MONDAY 
TUESDAY 
WEDNESDAY 
THURSDAY 
IRIDAY I 
I 
SATURDAY 
SUNDAY 
